Identification and analysis of genes involved in skeletal dysplasias affecting growth and bone homeostasis by HELLEMANS, JAN
Jan Hellemans
Identification and analysis of 
genes involved in skeletal 
dysplasias affecting growth 
and bone homeostasis

III
This thesis is dedicated to my family:
Petra, my wife
Lode and Lisa, my children
and my parents
Thesis submitted to fulfill the requirements for the degree of Doctor in Medical Sciences
November 2006
Promotor
Prof. Dr. Geert Mortier
Ghent University, Belgium
Co-promotor
Prof. Dr. Paul Coucke
Ghent University, Belgium
Members of the examination committee
Prof. Dr. Anne De Paepe
Ghent University, Belgium
Dr. Jo Vandesompele
Ghent University, Belgium
Prof. Dr. August Verbruggen
Ghent University, Belgium
Prof. Dr. Jean Kaufman
Ghent University, Belgium
Prof. Dr. Wim Van Hul
University of Antwerp, Belgium
Prof. Dr. Kristin Verschueren
Katholieke Universiteit Leuven, Belgium
Prof. Dr. Stephan Mundlos
Institut für Medizinische Genetik am Campus Charité Mitte, Germany
Max Planck Institute for Molecular Genetics, Germany
Prof. Dr. Valérie Cormier-Daire
Department of Genetics, Hôpital Necker Enfants Malades, France
The research described in this thesis was conducted in the Center for Medical Genetics, Ghent 
University Hospital, Ghent, Belgium.
From 01-04-2001 to 31-12-2002, Jan Hellemans was supported by the Fifth Framework of the 
specific research and technological development program “Quality of Life and Management of 
Living Resources” of the European Commission, Contract QLG1-CT-2001-02188
From 01-01-2003 to  31-12-2006,  Jan Hellemans  was  an aspirant  of  the  Institute  for  the 
Promotion of Innovation through Science and Technology in Flanders (IWT-Vlaanderen) with 
grants no. IWT-SB/21476 and IWT-SB/23476.
IV
Acknowledgment – Dankwoord
A PhD thesis is not a one day nor a one mans 
work,  but  a  project  in  which  the  help  and 
support  of  many  needs  to  be  appreciated. 
My gratitude to these people has not always 
been apparent, but in this acknowledgment I 
would  like  to  thank  all  those  who  have 
contributed  directly  or  indirectly  to  the 
completion of this thesis.
I wish to express my sincere gratitude to my 
promoter  Prof.  Dr.  Geert  Mortier  and  co-
promoter Prof. Dr. Paul Coucke.
Geert,  in  2001  you  introduced  me  to  the 
fields  of  medical  genetics  and  skeletal 
dysplasias.   Although  my  education  as  a 
molecular biologist sometimes didn't seem to 
fit  my job, I  am grateful  you gave me the 
opportunity  to  work  on  these  fascinating 
research topics.  I very much appreciate your 
qualities  as  a  supportive  promoter  who 
guided  me  through  this  thesis  without 
restricting personal initiatives.  Also, without 
your help and understanding for my lack of 
medical  knowledge,  this  thesis  might  not 
have  been  possible.   Your  enthusiastic 
appreciation of the progress in my research 
always made me feel good in my work.
Paul, it was a pleasure to work in your lab. 
Without  the  equipment,  organization  and 
atmosphere of this lab, research would have 
been  much  harder.   I  also  appreciate  the 
chance  you  gave  me  to  help  organize  a 
sequencing  and  genotyping  facility  because 
tasks like this prevented me from becoming a 
blinkered specialist.
Geert  and  Paul,  thank  you  for  being  kind 
(co-) promoters always open for a discussion 
or  conversation,  and  not  merely  there  for 
orders and complaints.
Prof.  Dr.  Anne  De  Paepe,  the  Center  for 
Medical Genetics Ghent has become a highly 
regarded institute, in great part, because of 
you and I am grateful  having been able to 
work in such a center.
I would also like to express my appreciation 
for all the people who have invested time in 
teaching me new methods and techniques.
Jo,  thank  you  for  teaching  me  how  to 
perform correct real-time PCR quantification. 
Your  qPCR  expertise  allowed  us  to  swiftly 
complete our functional analyses and lies at 
the basis of a complete chapter of this thesis. 
Our long, and sometimes chaotic, discussions 
on the correct way to analyze qPCR data will 
long be remembered.
Prof.  Dr.  Stephan Mundlos,  Petra  Seemann 
and  colleagues,  working  amongst  you  in  a 
foreign  lab  was  a  nice  and  inspiring 
experience  to me.   Thank you for  showing 
me a different kind of research and for the 
effort put into my training.  Thanks for the 
good times.
Many thanks to all  the colleagues from the 
Center  of  Medical  Genetics.   Chantal,  Els, 
Ilse,  Inge,  Jozefien,  Karen,  Leen,  Nilgul, 
Petra, Renée and Sofie, it was a real pleasure 
working with you.  I really have appreciated 
the nice atmosphere in the lab and all  the 
help  you  have  provided,  as  well  as  your 
patience with me as a PhD student who often 
wanted to do things in another way.  Chantal 
and Jozefien, thank you for all the help with 
LEMD3 screenings.  Renée, working with you 
to get the sequencing facility up and rolling 
was a pleasure.
Andy, Sofie and Sophie, it was nice sharing a 
bureau with you.   Thank you for  the  good 
times,  interesting  discussions  and, 
sometimes loud, conversations.  Andy, when 
you  joined  us  in  the  Center  for  Medical 
Genetics  Ghent,  you  also  freed  me  from 
isolation in my 'Nijntje' bureau in K5.  Sofie 
and Sophie, thank you for all the help with 
vector  construction  and  patient 
administration.
Piet and Joris, I remember the times without 
ICT professionals.  Having your help allowed 
me  to  focus  on  my  research  in  stead  of 
solving PC problems.  Thank you for that.
Veerle, it was a nice experience having you 
as a thesis student.  I appreciate your work 
for the construction of an RNAi system which 
will be beneficial for future research.
A number of people from outside the Center 
for  Medical  Genetics  Ghent  have  also 
contributed to the results  presented in this 
thesis.  I would like to thank all collaborating 
clinicians for providing us with the invaluable 
samples  and  clinical  information,  and  all 
V
patients  for  their  willing  participation, 
especially  those  having  given  us  biopsy 
material.
I also appreciate the nice collaboration with 
the  research  groups  of  Prof.  Dr.  Kristin 
Verschueren  and  Prof.  Dr.  Wim  Van  Hul. 
They  have  provide  us  with  beautiful  data 
when faced with serious time pressure.
Mira, thank you for helping me out with the 
French  translation  of  the  summary  of  this 
thesis.
Een heleboel mensen in mijn werkomgeving 
hebben bijgedragen tot  het  volbrengen van 
mijn doctoraatsthesis.  Zonder de steun van 
mijn  familie  zou  dit  werk  echter  nooit 
afgeraakt  zijn,  en  misschien  zelfs  nooit 
gestart  zijn.   Liefste  ouders,  bedankt  voor 
alle steun en de kansen die jullie mij gegeven 
hebben.  Jullie interesse en aanmoedigingen 
hebben me gebracht tot waar ik nu sta.
Petra,  liefste,  al  van  tijdens  mijn  studies 
biotechnologie  sta  je  naast  mij.   Bedankt 
voor de morele steun en de leuke tijden die 
we  samen  beleefd  hebben.   Lode  en  Lisa, 
jullie  brachten  niet  enkel  een  hoop  extra 
verantwoordelijkheden  in  mijn  leven,  maar 
vooral veel  vreugde en het besef dat leven 
meer  is  dan  werken  alleen.   Jullie 
vriendschap en gulle lach hebben me steeds 
veel plezier gedaan.
VI
Table of Contents
Acknowledgment – Dankwoord............................................................. V
List of abbreviations........................................................................... IX
Chapter 1 Introduction 1
Outline.............................................................................................. 2
Skeletal development, growth and homeostasis....................................... 4
1 The human skeleton.............................................................................................4
2 Patterning...........................................................................................................5
3 Differentiation into bone.......................................................................................7
4 Growth...............................................................................................................9
5 Homeostasis......................................................................................................11
Skeletal dysplasias............................................................................ 18
1 Introduction......................................................................................................18
2 Classification.....................................................................................................18
3 Diagnosis..........................................................................................................19
Chapter 2 The IHH gene in acrocapitofemoral dysplasia 23
Paper 1............................................................................................ 24
Hellemans et al. Am J Hum Genet. 2003
Paper 2............................................................................................ 32
Hellemans and Mortier.  Book chapter in Inborn Errors of Development
Chapter 3 The LEMD3 gene in osteopoikilosis, BOS and 
melorheostosis 45
Paper 3............................................................................................ 46
Hellemans et al. Nat Genet 2004
Paper 4............................................................................................ 53
Hellemans et al. Hum Mutat 2006
Paper 5............................................................................................ 61
Hellemans and Mortier.  Book chapter in Inborn Errors of Development
Chapter 4 qBase framework and software for qPCR data analysis 75
Introduction to qPCR and qBase........................................................... 76
1 Introduction to qPCR..........................................................................................76
2 qPCR based quantification...................................................................................77
3 qBase...............................................................................................................78
Paper 6............................................................................................ 80
Hellemans et al. Genome Biology 2007
Chapter 5 Discussion 97
General discussion and future perspectives........................................... 98
1 Background.......................................................................................................98
2 The indian hedgehog gene..................................................................................99
3 The LEM domain containing 3 gene.....................................................................101
4 qBase.............................................................................................................103
References...................................................................................... 106
VII
Summary....................................................................................... 112
Samenvatting.................................................................................. 114
Résumé.......................................................................................... 116
Curriculum Vitae.............................................................................. 118
VIII
List of abbreviations
A-P anterior-posterior
ACFD acrocapitofemoral dysplasia
AER apical ectodermal ridge
ALK anaplastic lymphoma kinase
ATF4 activating transcription factor 4
BAF barrier to autointegration factor
BDA1 brachydactyly type A1
BMP bone morphogenetic protein
BOS Buschke-Ollendorff syndrome
bp basepair
CCD cleidocranial dysplasia
CED Camurati-Engelmann disease
CIZ Cas-interacting zinc finger protein
cM centi Morgan
CLS Coffin-Lowry syndrome
COL collagen
Cq quantification cycle
CSF colony stimulating factor
Ct threshold cycle
D-V dorsal-ventral
DNA deoxyribonucleic acid
E amplification efficiency
FGF fibroblast growth factor
FGFR fibroblast growth factor receptor
GCL germ cell less
GDF growth and differentiation factor
gDNA genomic DNA
GH growth hormone
goi gene of interest
HHIP hedgehog interacting protein
IGF insulin-like growth factor
IHH indian hedgehog
IRC inter-run calibrator
kDa kilo Dalton
LEMD3 LEM (LAP2, emerin, MAN1) domain 
containing 3
LHRH luteinizing hormone-releasing 
hormone
LMN lamin
LOD logarithm of odds
Mb mega bases = 1.000.000 bases
MH2 MAD homology 2
MIM mendelian inheritance in man
MM-C micromass cultures
MOS melorheostosis
MRI magnetic resonance imaging
NOG noggin
NRQ normalized relative quantity
NTC no template control
OPG osteoprotegerin
OPOI osteopoikilosis
OSX osterix
PCR polymerase chain reaction
Pr-D proximal-distal
PTHLH parathyroid hormone like hormone
PTHR parathyroid hormone receptor
qPCR real-time quantitative PCR
R-SMADreceptor activated SMAD
RANK receptor activator of nuclear factor 
kappa B
RANKL receptor activator of nuclear factor 
kappa B ligand
RDML Real-time PCR Data Markup 
Language
ref reference gene
RFLP restriction fragment length 
polymorphism
RHYNS retinitis pigmentosa, 
hypopituitarism, nephronophthisis, 
and mild skeletal dysplasia
RNA ribonucleic acid
RNAi RNA interference
ROR receptor tyrosine kinase-like orphan 
receptor
RQ relative quantity
RRM RNA recognition motif
RUNX runt-related transcription factor
SANE Smad antagonistic effector
SHH sonic hedgehog
SMAD MAD (mothers against 
decapentaplegic) homolog
SOX SRY (sex determining region Y) box
TGF transforming growth factor
TM trans membrane
TNF tumor necrosis factor
WNT9A wingless-type MMTV integration site 
family, member 9A 
XML Extensible Markup Language
ZPA zone of polarizing activity
Depending  on  the  species,  different  gene  nomenclature  rules  apply.   The  HUGO  Gene 
Nomenclature Committee (HGNC, http://www.gene.ucl.ac.uk/nomenclature/) sets the rules for 
human genes.   Human gene symbols are designated by upper-case Latin  letters and it  is 
recommended  that  they  are  italicized  in  print.   Mouse  gene  symbols 
(http://www.informatics.jax.org/mgihome/nomen/), on the other hand, should begin with an 
uppercase letter, followed by all lowercase letters.
IX
XChapter title pictures taken from:
De humani corporis fabrica
(On the fabric of the human body)
Andreas Vesalius 1543
Chapter 1
Introduction
Outline
Genetic disorders of the skeleton comprise a 
large  group  of  clinically  diverse  and 
genetically  heterogeneous disorders.   These 
disorders include both dysostoses, defined as 
malformations of individual bones or groups 
of  bones,  and  osteochondrodysplasias, 
defined  as  developmental  disorders  of 
chondro-osseous  tissue  (McKusick  1971). 
They  are  usually  monogenic  and  are 
characterized  by  defects  in  the  formation, 
growth  or  homeostasis  of  the  bone.   The 
severity  of  this  group  of  disorders  ranges 
from  asymptomatic,  over  mild  growth 
retardation  to  neonatal  lethality.   Short 
stature is a very common feature. In its last 
published  revision,  the  International 
Nosology and Classification of Constitutional 
Disorders  of  Bone  lists  a  total  of  294 
osteochondrodysplasias and dysostoses (Hall 
2002).  Although  they  are  individually  rare, 
they are of clinical relevance because of their 
overall prevalence of 1 in 2000 (Rasmussen 
1996).  
The  genetic  defect  of  a  growing  list  of 
disorders  is  being  discovered.   Causal 
mutations have now been identified in almost 
half  of  the  disorders  listed  in  the  2001 
nosology (Hall  2002).   These  findings  have 
both  clinical  and  scientific  implications. 
Identification  of  the  causal  genetic  defect 
allows  molecular  confirmation  of  the 
diagnosis  and  helps  in  genetic  counseling. 
From  a  scientific  point  of  view,  the 
identification  of  gene  defects  leading  to 
skeletal dysplasias provides new insights into 
the genetic and molecular regulation of bone 
development, growth and homeostasis.
In this thesis, two (groups of) disorders were 
investigated:  1) acrocapitofemoral  dysplasia 
(ACFD)  (Chapter  2)  and  2)  osteopoikilosis 
and its related dysplasias Buschke-Ollendorff 
syndrome  (BOS)  and  melorheostosis 
(Chapter 3).
Acrocapitofemoral  dysplasia,  abbreviated  to 
ACFD,  is  a  rare  autosomal  recessive 
dysplasia  that  only  recently  has  been 
described.   Radiographically,  it  is 
characterized  by  a  premature 
epimetaphyseal fusion in the tubular bones of 
the hand and proximal femur, resulting in a 
short  stature  with  brachydactyly  (Mortier 
2003).
Osteopoikilosis  is  a  benign,  autosomal 
dominant  disorder  that  is  usually  detected 
incidentally.   It  is  characterized  by  a 
symmetric  but  unequal  distribution  of 
multiple, small hyperostotic spots in different 
parts  of  the  skeleton  (Stieda  1905,  Benli 
1992).   Osteopoikilosis  can  occur  as  an 
isolated anomaly or in association with other 
skin or bone manifestations.  Osteopoikilosis 
often co-occurs with connective tissue nevi, 
and is then known as the Buschke-Ollendorff 
syndrome  (BOS)  (Buschke  1928). 
Melorheostosis  is  characterized  by  an 
asymmetric,  flowing  hyperostosis  of  the 
cortex of the tubular bones, that resembles 
wax dripping down the side of a candle (Léri 
1922, Green 1962).  It usually occurs as an 
isolated anomaly, but can co-occur with BOS 
in the same family (Debeer 2003).
The  first  objective  of  this  thesis,  the 
identification of the genetic defect underlying 
these disorders, was achieved by means of a 
classical genetic approach.  This strategy is 
used to identify the gene by mapping it to a 
specific  genomic  locus  and  involves,  for 
human genetics, the following steps:
1. Identification  of  a  large  family  affected 
by  the  disorder  of  interest  and 
establishment of a detailed phenotypical 
description of all family members.
2. Collection of genomic DNA from as much 
relatives as possible.
3. Genotyping  of  large  numbers  of 
informative markers spread all over the 
genome.   In  this  thesis,  Applied 
Biosystems  Linkage  Mapping  set  v2 
consisting of 400 microsatellite markers 
was used to genotype patients and their 
relatives.
4. Analysis  of  genotypic  data  in  order  to 
detect linkage between the investigated 
phenotype  (skeletal  dysplasia)  and  a 
genetic marker with known location.  For 
recessive  phenotypes  in  inbred  families 
an  efficient  homozygosity  mapping  can 
be  performed.   The  basic  idea  in  this 
approach is  that all  affected individuals 
have  to  be  homozygous  for  a  linked 
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marker.  More generally, the genotypes 
are added to a pedigree and LOD-scores 
are calculated for every marker (Lathrop 
1984).  Markers with a LOD-score of at 
least 3 are considered to show significant 
linkage with the investigated phenotype.
5. Fine  mapping  of  the  candidate  region. 
The  boundaries  of  the  linkage  interval 
are  determined  by  analyzing  additional 
markers around the linked locus.
6. Identification  of  the  causal  mutation. 
Since complete sequencing of  all  genes 
in  the  candidate  region  is  neither 
achievable  nor  an  efficient  strategy,  a 
selection of genes is made based on their 
known function or involvement in related 
disorders  (candidate  gene  approach). 
Mutation  analysis  is  subsequently 
performed  on  this  restricted  set  of 
candidate  genes  to  pinpoint  the  causal 
mutation.
The second objective of this thesis, analysis 
of  the  identified  genes,  has  two  facets:  a 
genetic and a functional.  Genetic analysis is 
performed  on  a  larger  set  of  patients  to 
verify  whether  the  condition  shows  locus 
heterogeneity and to investigate what kind of 
mutations are responsible for the phenotype. 
Larger  numbers  of  mutations  also  allow  to 
investigate genotype-phenotype correlations. 
Functional  analysis  aims  to  investigate  the 
normal function of the gene product  or the 
effects  of  mutations on this  function.   This 
type  of  analysis  often  involves  the 
determination  of  the  expression  levels  of  a 
selection  of  genes  for  which  real-time 
quantitative  PCR  (qPCR)  has  become  the 
method of choice.
Advancements in instruments and detection 
chemistry,  and  improved  assay  design 
guidelines  have  made  the  practical 
performance of qPCR measurements feasible 
for  most  users.  However,  accurate  and 
straightforward processing of the raw data as 
well  as the management of large data sets 
remain  the  major  hurdles.   The  qBase 
framework was developed to improve these 
issues (Chapter  4).   It  consists  of  a set of 
guidelines  and  formulas  for  the  correct 
conversion of raw Cq values into normalized 
and  calibrated  relative  quantities,  and  is 
implemented  in  the  qBase  software.   This 
freely  available  tool 
(http://medgen.ugent.be/qBase)  is 
compatible  with  most  qPCR  data  formats 
without  imposing  limits  to  the  number  or 
layout  of  data  points,  automates  all 
calculations,  and  visualizes  results  in  table 
and graph format.  Together,  the improved 
formulas  and  the  automation  of  the 
numerous  calculations  solve  some  of  the 
largest  remaining  problems  in  qPCR  based 
expression analysis.
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Skeletal development, growth and homeostasis
1 The human skeleton
The  human  skeleton  (from  the  Greek 
σκελετοσ,  dried  up)  is  a  complex  organ 
consisting  of  206  bones  (126 appendicular, 
74  axial,  6  ossicles).  It  has  multiple 
embryonic  origins  and  serves  many  key 
functions  including  mechanical  support  for 
movement,  protection  of  vital  organs,  and 
acting as a blood and mineral reservoir. The 
skeleton  consists  of  2  tissues:  bone  and 
cartilage,  and  3  cell  lineages:  those  of 
osteoblasts,  osteoclasts,  and  chondrocytes. 
Osteoblasts  and  osteoclasts  cells  are 
responsible  for  bone  formation  and  bone 
resorption  respectively,  while  chondrocytes 
make up the cartilage.
Only a small part of the bone is made up by 
cells,  the  remainder  is  filled  with  matrix 
which  has  both  organic  and  inorganic 
components.   Type  I  collagen  is  the  most 
predominant peptide in bone and comprises 
90-95% of the organic matrix.  The collagen 
secreted by osteoblasts is typically deposited 
in  parallel  or  concentric  layers  to  produce 
mature (lamellar) bone.  But when bone is 
rapidly formed, as in the fetus, the collagen 
is not deposited in a parallel array but in a 
basket-like  weave  and  is  called  woven, 
immature,  or  primitive  bone.   The  lamellar 
form confers more strength to the bone than 
the  woven  form.  Osteocalcin  is  the  most 
abundant  non-collagenous  protein  of  bone 
matrix.   The  main  mineral  component  of 
bone  is  an  imperfectly  crystalline 
hydroxyapatite  [Ca10(PO4)6(OH)2]  which 
comprises  about  ¼ the volume and ½ the 
mass of normal adult bone.  About 99% of 
the  1000g  of  calcium  in  an  adult  human 
resides  in  the  skeleton  in  the  form  of 
hydroxyapatite.   These  calcium  salts  are 
responsible  for  the compressive strength of 
bone and provide the structural  integrity of 
the  skeleton.   While  bone  is  essentially 
brittle,  it  does have a degree of  significant 
elasticity  contributed  by  its  organic 
components (Fig. 1).
Anatomically,  four  types  of  bones  can  be 
distinguished:  long  bones  (e.g.  tibia  and 
femur),  short  bones  (e.g.  carpals  and 
tarsals), flat bones (e.g. skull and ribs) and 
irregular  bones  (e.g.  vertebrae)  (Shier, 
Hole's  Human  Anatomy  &  Physiology – 
McGraw-Hill).
Long bones
Long bones are tubular in structure and have 
expanded ends. The central  shaft of a long 
bone is called the diaphysis, and has a hollow 
middle, the medullar cavity, filled with bone 
marrow. Surrounding the medullar cavity is a 
thin layer  of  cancellous  bone and an outer 
layer of compact cortical bone (Fig.2 ).  The 
cancellous or spongy bone is trabecular and 
has  an open,  meshwork  or  honeycomb-like 
structure that  helps reducing the weight  of 
the bone.  The spaces of the spongy bone are 
continuous with the medullary cavity and are 
filled with marrow.  A thin layer of squamous 
epithelial  cells,  called  endosteum,  lines  the 
cancellous bone.  The ends of the bone are 
called  the  epiphyses  and  are  mostly 
cancellous bone covered by a relatively thin 
layer  of  compact  bone.  Except  for  the 
articular  cartilage,  the  bone  is  completely 
enclosed  by  a  tough,  vascular  covering  of 
fibrous  tissue  called  the  periosteum.   In 
children,  long  bones  are  filled  with  red 
marrow,  which  is  gradually  replaced  with 
yellow marrow as the child ages.
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Figure 1: Contributions of mineral and collagen to 
bone strength (taken from Seeley, Anatomy and 
Physiology - McGraw-Hill)
Short bones
Short bones have a similar structure to long 
bones,  except  that  they  have  no  medullar 
cavity.  They have no shaft, as they do not 
increase  dramatically  in  size  during  linear 
growth.  They tend to be cuboidal in shape.
Flat bones
Flat bones consist of two layers of compact 
bone  with  a  zone  of  cancellous  bone  in 
between them (Fig. 3).
Irregular bones
Bones  which  don't  fit  any  of  the  previous 
forms are referred to as irregular.  They have 
a  variety  of  shapes  and  are  usually 
connected to several other bones.
Despite the common misconception that the 
skeleton is made up of dead tissue, it does, 
in  fact,  contain  cells,  nerves,  blood vessels 
and  pain  receptors.   Bone  is  also  not 
immutable  but  an  ever-changing  organ  in 
which mass and shape are regulated by the 
remodeling  activities  of  osteoblasts  and 
osteoclasts.
The final state of the skeleton is determined 
by  processes  in  different  stages  of 
development.  Firstly, patterning determines 
the  sites  at  which  bone  will  be  formed. 
Secondly, condensation of mesenchymal cells 
followed  by  their  differentiation  results  in 
bone formation.  Thirdly, growth affects the 
size  of  individual  bones  and,  finally, 
homeostasis  is  responsible  for  the 
maintenance of the skeleton.  Abnormalities 
in  any  of  these  steps  can give  rise  to  the 
many and varied forms of skeletal dysplasias 
or osteochondrodysplasias (Kornak 2003).
2 Patterning
The  first  step  in  skeletal  formation  is  the 
determination  of  the  position,  number  and 
shape of the elements that will develop into 
the bones that make up the skeleton.  Many 
of the crucial genes that regulate growth and 
patterning  of  the  limb  in  three  dimensions 
are now well defined.  This knowledge comes 
primarily from studies of limb development in 
chicken and mouse embryos.  The developing 
limb has served as a model for studying the 
signal transduction pathways and cell biology 
that  control  pattern  formation  because  the 
limbs  are  not  necessary  for  embryonic 
survival, allowing them to be experimentally 
and  molecularly  manipulated  (Niswander 
2003).
In  the  human  embryo,  the  appendicular 
skeleton  develops  from  limb  buds,  first 
visible at around 4 weeks of gestation.  By 
week 8, these buds have formed much of the 
mature limb structures (O'Rahilly 1975).  The 
skeletal tissues in the limb are produced by 
cells  derived  from  the  lateral  plate 
mesoderm.   The  patterning  of  the 
mesenchyme  in  the  limb  and  the  ultimate 
shaping of the limb bones are due to a series 
of interactions between the mesenchyme and 
the  overlying  epithelium.   Vertebrate  limbs 
display three axes of asymmetry referred to 
as  proximal-distal  (Pr-D;  shoulder  to  digit 
tips), anterior-posterior (A-P; thumb to little 
finger),  and  dorsal-ventral  (D-V;  back  of 
hand to palm).  Patterning along these three 
axes of the embryonic limb is regulated by 
three  key  organizing  centers  (Fig.  4). 
Integration  of  three-dimensional  patterning 
occurs as a result  of the complex interplay 
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Figure 2: Structure of an adult long bone (taken 
from Seeley, Anatomy and Physiology - McGraw-
Hill)
Figure 3: Structure of a flat bone (taken from 
Seeley, Anatomy and Physiology - McGraw-Hill)
amongst  these  three  signaling  centers 
(Niswander 2002).
Proximal-distal
A strip of specialized epithelium at the distal 
tip  of  the  limb  bud,  called  the  apical 
ectodermal  ridge (AER, Fig. 4 light blue) is 
needed  for  Pr-D  growth  and  for  the 
realization of Pr-D patterning.  Microsurgical 
removal of the AER from an early developing 
limb bud results in the loss of almost all limb 
structures,  whereas  its  removal  at 
progressively  later  stages  results  in 
progressively more distal loss, with proximal 
structures being unaffected.  These findings 
are  traditionally  explained  by  the  progress 
model  (Summerbell  1974),  but  recent  data 
now  suggest  an  attractive  alternative 
(Dudley  2002).   Fibroblast  growth  factors 
(FGF) are essential to perform the functions 
of  the  AER:  they  induce  or  maintain  the 
expression  of  many  genes  in  the  limb bud 
mesenchyme,  control  the  initial  size  of  the 
limb  bud  and  influence  cell  survival  and 
proliferation (Sun 2002).
Anterior-posterior
A population of cells in the posterior aspect 
of the limb mesenchyme, called the zone of 
polarizing  activity  (ZPA,  Fig.  4  orange) 
controls A-P patterning.  Grafting of ZPA cells 
to the anterior distal  margin of  a limb bud 
causes mirror-image duplications of skeletal 
elements (Tickle 1981).  The finding that a 
similar  digit  duplication  is  obtained  by 
anterior  addition  of  sonic  hedgehog  (SHH), 
and  other  experiments  in  Shh-/- limbs, 
indicate that SHH is the key signal originating 
from the ZPA (Riddle 1993).
Dorsal-ventral
D-V patterning in the limb bud is regulated 
by the overlying ectoderm.  When the limb 
ectoderm  is  rotated  180°  relative  to  the 
mesenchyme,  the  mesenchymal  structures 
(including  the  skeleton)  become  inverted 
such that they correspond to the polarity of 
the  ectoderm  (MacCabe  1974).   Wnt7a 
expression  in  the  dorsal  limb  ectoderm 
induces  the  production  of  the  transcription 
factor  Lmx1b  which  is  responsible  for  the 
dorsal character of the mesenchyme.  In the 
absence of Wnt7a, the dorsal pattern of the 
autopod  is  not  established  and  the  limbs 
appear  bi-ventral.   Bone  morphogenetic 
protein  (BMP)  induced  expression  of 
engrailed1  (En1)  in  the  ventral  ectoderm 
restricts  the  expression  of  Wnt7a  to  the 
dorsal ectoderm.  Consequently, loss of BMP 
signaling or En1 expression will result in bi-
dorsal limbs (Chen 1999).
The mesenchymal cells of the growing limb 
bud differentiate to form the various tissues 
of the limb in a proximodistal sequence.  The 
positional  identity  imposed  by  the  three-
dimensional  coordinate  system  described 
above  controls  differentiation  of  these  limb 
bud mesenchymal cells.  The aggregation of 
mesenchymal cells to form prechondrogenic 
condensations triggers cellular differentiation 
and  is  arguably  the  most  critical  event  in 
skeletal patterning.
Another crucial process for patterning is joint 
formation.   It  can  occur  either  at  the 
boundary  between  two  adjacent 
condensations  or  within  a  single 
condensation.   Two  genes,  growth 
differentiation  factor  5  (GDF5)  and  noggin 
(NOG), which encodes a BMP antagonist, are 
required for normal joint formation.  GDF5 is 
necessary for both cartilage development and 
the  restriction  of  joint  formation  to  the 
appropriate location (Storm 1999).  Loss of 
Nog function causes complete failure of joint 
formation  in  the  autopod,  partly  due  to  a 
failure to upregulate Gdf5 expression in the 
presumptive joint regions (Brunet 1998).  In 
spite of the requirement of these factors in 
the  formation  of  specific  joints,  GDF5  and 
NOG  are  not  sufficient  to  induce  joint 
formation.   In  contrast,  WNT9A,  which  is 
expressed  in  joint  forming  regions  prior  to 
segmentation of the cartilage elements, was 
found to actively direct prechondrogenic cells 
into  the  joint  forming  pathway  (Hartmann 
2001).
Much of the patterning process is complete 
by  the  time  that  condensations  have 
differentiated  into  cartilaginous  templates 
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Figure 4: Molecular interactions that coordinate 
limb growth and patterning along the three limb 
axes.  (Taken from Niswander 2003)
(see next section).  However, the remaining 
steps  in  endochondral  bone  formation  do 
influence final skeletal pattern.
The  proteins  described  above  (FGF,  SHH, 
BMP-EN1)  determine  the  major  regulatory 
pathways in bone morphogenesis, but many 
genes regulating these signaling cascades or 
other pathways are are required for normal 
bone development.  Mutations in these genes 
mainly  cause  dysostoses,  disorders  that 
affect  specific   embryologically  defined 
skeletal  elements  while  the  rest  of  the 
skeleton remains unaffected.   For example, 
many  types  of  polydactyly  are  caused  by 
defects in the hedgehog pathway.  Mutations 
in  GLI3,  the  downstream  effector  of  SHH, 
give  rise  to  postaxial  polydactyly  type  I, 
preaxial  polydactyly  type  IV,  Greig 
cephalopolysyndactyly  and  Pallister-Hall 
syndrome  (Vortkamp  1991,  Kang  1997). 
Another  example,  with  disturbed patterning 
involving the dorsoventral axis, is Nail-patella 
syndrome.   This  dysostosis  is  caused  by 
haploinsufficiency of LMX1B (Dreyer 1998).
3 Differentiation into bone
The mesenchymal condensations, as defined 
by the patterning process  described above, 
develop  into  bone  either  directly  through 
intramembranous  ossification  or  indirectly 
through  endochondral  ossification.   In  the 
human skeleton, only the membrane bones 
of  the  skull  and  part  of  the  clavicle  are 
completely  formed  by  direct  ossification  of 
condensed  mesenchyme  (intramembranous 
ossification). For the large majority of bones, 
bone  formation  and  linear  growth  proceed 
through  an  intermediate  cartilaginous 
template  or  anlage  in  a  process  called 
endochondral  ossification.   In  these  bones 
intramembranous  ossification  is  responsible 
for  appositional  growth  which results  in  an 
increase in diameter.
Intramembranous ossification is initiated by 
the invasion of condensed mesenchyme with 
a dense network of blood vessels.  Some of 
the  connective  tissue  cells  arrange  around 
these vessels, enlarge and differentiate into 
bone  forming  cells.   These  cells,  called 
osteoblasts,  deposit  bone  matrix  around 
themselves.  As a result, spongy bone forms 
in  all  directions  along  blood  vessels  within 
the  layers  of  primitive  connective  tissue 
(Shier,  Hole's  Human  Anatomy  –  McGraw-
Hill).   The  genes  involved  in  osteoblast 
differentiation and activity play an important 
role in this process and will be discussed in 
the homeostasis section.
Endochondral  ossification  is  the  process  by 
which  long  bones  are  formed  from 
mesenchymal  cells  through an intermediate 
cartilaginous model.  This multistage process 
starts with the formation of a mesenchymal 
condensation,  the  basic  anlage,  at  the  site 
where  the  future  bone  will  be  formed. 
Further  differentiation  of  condensed 
mesenchymal  cells  into  chondrocytes  that 
produce  hyaline  cartilage  instead  of 
mesenchymal matrix, creates a cartilaginous 
model with shapes similar to the future bone. 
This model grows rapidly for a time and then 
begins to change extensively.  Starting in the 
center,  chondrocytes  enlarge  and 
differentiate  to  become  hypertrophic 
chondrocytes,  producing  type  X  collagen. 
The  matrix  surrounding  these  cells  will 
subsequently  calcify,  and  the  hypertrophic 
chondrocytes  will  undergo  apoptosis. 
Concomitantly,  a  primary  bone  collar  with 
associated  periosteum  and  rudimentary 
vascular  supply   is  formed  at  the 
presumptive diaphysis.
The newly formed spaces within the calcified 
cartilage  are  invaded  by  periosteal  blood 
vessels  and  osteogenic  cells,  that  soon 
differentiate  into  osteoblasts.  The  latter 
deposit  a  bony  matrix  on  the  calcified 
cartilage,  resulting  in  the  formation  of  the 
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Figure 5. Schematic presentation of endochondral cones with left: growth of the cones, middle: filling in 
by membranous ossification, and right: creation of the marrow cavity (Adapted from Rockwood, 
Fractures in Children – Lippincott).
primary center of ossification.  The first bone 
formed  is  a  loose  trabecular  network 
connected to the adjacent periosteal shell of 
bone,  which is  the product  of  membranous 
ossification.   Both  processes  of  cartilage 
replacement  by  bone  and  bone  collar 
formation  subsequently  spread  towards  the 
ends of the developing bone.  Spreading of 
increased  matrix  formation,  chondrocyte 
hypertrophy,  cartilage  calcification  and 
replacement by bone results in the creation 
of endochondral cones.  The apices of these 
cones  juxtapose  at  the  site  of  the  original 
primary  ossification  center,  whereas  the 
bases  are  located  towards  the  physeal 
region.  Endochondral cones grow away from 
the  apex,  resulting  in  longitudinal  growth, 
but  also  grow diametrically  to  increase  the 
area  of  the  cone  base  (Fig.  5,  left).   The 
surrounding  bone  collar  expands  by 
membranous  ossification  to  fill  in  the  gaps 
produced by the endochondral cones (Fig. 5, 
middle).   Therefore,  the  periosteum  is  the 
primary  contributor  to  latitudinal  growth  of 
the  diaphysis  and  metaphysis  of  tubular 
bones.   As  the  endochondral  cones  grow, 
bone  tissue  is  resorbed from the  center  to 
create  the  marrow  cavity  (Fig.  5,  right). 
Elaborate  remodeling  and  tubulation  in 
children's  bones  mask  many  of  the  steps 
described above.  The concept of juxtaposed 
patterns  of  endochondral  and  membranous 
ossification  is  however  apparent  in  most 
marine  mammals  who  lack  extensive 
remodeling (Rockwood, Fractures in Children 
– Lippincott; Urist, Fundamental and Clinical 
Bone Physiology – Lippincott).
At birth, the primary ossification center has 
expanded to replace the entire cartilaginous 
diaphysis with bone.  The epiphyses of most 
long bones, with the exception of the distal 
femoral  epiphysis,  do  however  remain 
cartilaginous  until  after  birth.   At  a  time 
characteristic  for  each  chondroepiphysis,  a 
secondary  center  of  ossification  forms  and 
gradually enlarges.  As a result, the majority 
of the cartilaginous anlage will be replaced by 
bone,  except  for  the  physis,  that  closes 
around puberty,  and the articular  cartilage, 
that builds up the joint.  Also postnatally, the 
membranous  woven  bone  is  remodeled  to 
create  a  more  rigid  cortical  bone  (Fig.  5, 
middle: dark gray zone).
An  overview  of  the  complete  process  of 
endochondral  ossification is  depicted in Fig. 
6.
A number of key regulatory elements in early 
bone formation have already been identified. 
SOX9 is an important transcription factor in 
the early steps of endochondral ossification. 
It is required for mesenchymal condensation 
and subsequent chondroblast differentiation, 
and  controls  the  production  of  the  major 
collagen  of  cartilage:  type  II  collagen 
(Lefebvre  1998,  Bi  1999).   Inactivation  of 
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Figure 6. Overview of the process of endochondral ossification (Taken from Seeley, Anatomy and 
Physiology – McGraw-Hill)
Sox9  in  mouse  limb  buds  before 
mesenchymal  condensation  results  in  the 
complete absence of both cartilage and bone. 
The expression of Sox5 and Sox6, two other 
Sox genes involved in chondrogenesis, is no 
longer  detected  in  these  animals  and 
expression  of  Runx2,  a  transcription  factor 
required  for  osteoblast  differentiation,  is 
abolished.  Sox9 is needed for the formation 
of  mesenchymal  condensations,  whereas 
Sox5  and  Sox6  are  required  for  the 
differentiation  of  condensed  cells  into 
chondrocytes  (Akiyama  2002).   The 
TGFβ/BMP/GDF5  pathways  also  play  an 
important  role  in  the  regulation  of 
condensation  and  differentiation  of 
condensed  cells  into  chondrocytes  (Kornak 
2003).
The  next  step  in  endochondral  ossification, 
osteoblast differentiation, is rather similar to 
the  differentiation  process  in 
intramembranous ossification.   The function 
of  genes  like  RUNX2 and  osterix which 
regulate  osteoblast  differentiation  are 
discussed in the homeostasis section.
Genetic defects that result in the disturbance 
of  mesenchymal  condensation  and/or 
differentiation  can  be  expected  to  have  a 
patterning-like  phenotype  (loss  or 
underdevelopment of certain bones) together 
with a growth defect.  Such conditions have 
been termed “dysostoplasias”, indicating that 
aspects  of  dysostosis  occur  together  with 
those  of  dysplasias  (Kornak  2003).   Two 
examples  are  campomelic  dysplasia  and 
cleidocranial dysplasia, the former caused by 
haploinsufficiency of  SOX9 (sex determining 
region Y box 9) (Foster 1994, Wagner 1994), 
and the latter by mutations in RUNX2 (runt-
related  transcription  factor  2)  (Mundlos 
1997).
4 Growth
Postnatal growth of long bones involves two 
different  processes.   Endochondral 
ossification  is  responsible  for  integrated 
longitudinal  and  latitudinal  growth  at  the 
epiphyseal  plate,  while  intramembranous 
ossification results in appositional growth at 
the diaphysis (Fig. 7).  The growth plate is a 
highly organized structure localized between 
the  epiphysis  (the  secondary  center  of 
ossification)  and the  metaphysis  (the distal 
end of  the primary  ossification  center).   It 
generates all of the longitudinal growth and 
remains active until the end of puberty when 
primary  and  secondary  ossification  centers 
fuse.
A developing bone thickens as compact bone 
is deposited on the outside, just beneath the 
periosteum.   While  this  compact  bone  is 
formed on the surface, the bone tissue at the 
inside is eroded by osteoclasts.  The resulting 
space becomes the medullary cavity (Shier, 
Hole's  Human  Anatomy  &  Physiology  – 
McGraw-Hill).
During  longitudinal  growth,  all  the 
differentiation stages of  initial  endochondral 
bone  formation  are  recapitulated.   These 
stages  are  reflected  by  the  different 
consecutive zones that make up the growth 
plate.   From  epiphysis  to  metaphysis  the 
following zones can be distinguished: zone of 
resting cartilage, zone of proliferation, zone 
of  hypertrophy,  zone  of  calcification  and 
finally bone formation (Fig. 8).  The resting 
zone contains  a pool  of  slowly  proliferating 
chondrocytes that do not actively participate 
in growth, but act as the stem-like cells that 
replenish  the  pool  of  proliferative 
chondrocytes  (Abad  2002).   This  layer 
anchors  the  epiphyseal  disk  to  the  bony 
tissue  of  the  epiphysis.   Cells  leaving  the 
resting zone start to multiply at a high rate 
and  form  columns  of  stacked,  proliferating 
chondrocytes.   The  alignment  of  these 
columns,  parallel  to  the  axis  of  growth,  is 
directed  by  a  morphogen  produced  by  the 
resting chondrocytes (Abad 2002).   After a 
period of clonal expansion, chondrocytes stop 
dividing  and  terminally  differentiate  into 
hypertrophic  chondrocytes.    During  the 
hypertrophic process, chondrocytes increase 
their  height  about 6  to  10-fold.   Therefore 
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Figure 7. Longitudinal and latitudinal growth of 
long bones (Taken from Marieb, Human Anatomy 
& Physiology – Benjamin Cummings)
hypertrophic  differentiation,  in  concert  with 
cellular  proliferation  and  increased  matrix 
volume, makes an important contribution to 
longitudinal  growth  (Hunziker  1994). 
Calcium salts accumulate in the intercellular 
matrix  adjacent  to  the  oldest  cartilaginous 
cells,  and  as  the  matrix  calcifies,  the 
hypertrophic cells begin to die.  This calcified 
cartilage  is  subsequently  invaded  by  blood 
vessels  and  bone  cells  that  change  the 
cartilage  into  bone  tissue,  which  then 
becomes part of the metaphysis.
A  very  complex  interplay  of  different 
signaling  pathways  (both  endocrine  and 
paracrine) regulates the rate of proliferation 
and the conversion of proliferating cells into 
hypertrophic  chondrocytes.   Most  of  these 
endocrine  signals  regulate  growth  plate 
function  by  acting  locally  on  chondrocytes 
but  also  by  modulating  other  endocrine 
signals  in  the  network.   Some of  the  local 
effects of hormones are mediated by changes 
in paracrine factors that control chondrocyte 
proliferation  and  differentiation  (Nilsson 
2005).   An overview of  the local  effects of 
endocrine signals is shown in table 1.
Growth  hormone  (GH)  and  insulin-like 
growth factors (IGFs) are potent stimulators 
of longitudinal bone growth.  GH excess, due 
to pituitary adenomas in childhood, results in 
gigantism.   Conversely,  GH  deficiency  or 
insensitivity due to GH-receptor mutations or 
defects  in  GH-signaling  pathways  markedly 
impairs  postnatal  growth  and  will  result  in 
proportionate  short  stature.   The  original 
somatedin  hypothesis  stipulates  that  the 
effect of GH on linear growth is mediated by 
the liver derived IGF-1.    More recently, the 
dual effector hypothesis states that GH acts 
locally at the growth plate to recruit resting 
chondrocytes  into  a  proliferative  state,  as 
well  as  to  stimulate  local  IGF-1  production 
which  then  stimulates  proliferation  of 
chondrocytes  in  the  proliferative  zone 
(Nilsson 2005).  The vast majority of other 
short-stature  disorders,  however,  result  in 
disproportionate  dwarfism,  presumably 
because they affect not only proliferation but 
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Figure 8. Epiphyseal plate: differentiation zones and growth process (Taken from Seeley, Anatomy and 
Physiology – McGraw-Hill)
GH Proliferation of resting chondrocytes
Stimulates local IGF-1 expression
IGF-1 Increses proliferation of resting and 
proliferative chondrocytes
Increases hypertrophic cell size
Glucocorticoid Inhibits chondrocyte proliferation
Delays growth plate senescence
Induces chondrocyte apoptosis
Thyroid hormone Permissive for proliferation and 
differentiation
Estrogen Inhibits proliferation in the 
proliferative zone
Accelerates growth plate senescence
Androgen Stimulates proliferation and matrix 
production
Increases IGF-1 expression
Vitamin D Permissive for normal differentiation 
and apoptosis of hypertrophic 
chondrocytes
Leptin Stimulates proliferation and 
differentiation
Table 1: Effects of endocrine factors on growth 
plate chondrocytes
also differentiation of chondrocytes (Kornak 
2003).
A number of  growth factors,  in conjunction 
with the macromolecules of the extracellular 
matrix, are essential for proper development 
and functioning of cartilage and bone.  The 
major  signaling  pathways  that  control 
proliferation  and  differentiation  of 
chondrocytes  include  the  indian  hedghog  – 
parathyroid hormone related hormone (IHH-
PTHLH)  loop  and  signals  from  fibroblast 
growth  factors  (FGF)  and  bone 
morphogenetic  proteins (BMP).  The effects 
of  these  paracrine  factors  are  more 
extensively  described  in  Chapter  2: 
Overview.   Briefly,  IHH  produced  by 
prehypertrophic  chondrocytes  induces  the 
expression  of  parathyroid  hormone  like 
hormone (PTHLH) which in turn suppresses 
the  differentiation  of  columnar  proliferating 
cells  into  hypertrophic  chondrocytes 
(Vortkamp  1996).   IHH  also  directly 
stimulates  proliferation  of  chondrocytes  in 
the  growth  plate  (Karp  2000).   Growth 
factors  of  the  FGF  and  BMP  families  work 
next to IHH and have antagonistic effects on 
chondrocyte proliferation and differentiation. 
BMPs  stimulate  chondrocyte  proliferation, 
induce  IHH  secretion  and  inhibit  terminal 
chondrocyte  differentiation  whereas  FGFs 
have the opposite effect (Minina 2002).
The  importance  of  these  pathways  is 
exemplified  by  a  number  of  skeletal 
dysplasias  resulting  from  mutations  in  the 
genes encoding proteins of the IHH, FGF or 
BMP family.  
Homozygous  and  heterozygous  missense 
mutations  in  IHH can  result  in 
acrocapitofemoral  dysplasia  (ACFD)  or 
brachydactyly  type  A1 (BDA1),  respectively 
(Gao  2001,  Paper  1:  Hellemans  2003). 
ACFD is a more generalized skeletal dysplasia 
whereas  BDA1  is  mainly  characterized  by 
brachydactyly.
Homozygous  loss-of-function  mutations  and 
dominant  activating  mutations  in  the 
parathyroid hormone receptor (PTHR1) result 
in,  respectively,  Blomstrand 
chondrodysplasia  and  metaphyseal 
chondrodysplasia Jansen-type (Jobert 1998, 
Schipani 1995).  The former is characterized 
by  a  short-limb-dwarfism  with  accelerated 
bone maturation  whereas  patients  with  the 
latter chondrodysplasia suffer from a severe 
growth retardation and bone deformations.
The  importance  of  FGF  signaling  became 
apparent  with  the  discovery  of  fibroblast 
growth factor receptor 3 (FGFR3) mutations 
in  patients  with  achondroplasia,  the  most 
frequent  form  of  dwarfism  (Shiang  1994). 
Two  allelic  disorders  exist: 
hypochondroplasia  with  less  growth  deficit 
and  thanatophoric  dysplasia  which  is 
characterized  by  severe  disproportionate 
dwarfism and death in early infancy.  All the 
FGFR3 mutations  involved  in  the  three 
conditions have a receptor-activating effect, 
and a clear  genotype-phenotype correlation 
has been described.
5 Homeostasis
Despite the common misconception that the 
skeleton is immutable, it is, in fact, an ever-
changing organ in which mass and shape are 
regulated by the activities of osteoblasts and 
osteoclasts.   Remodeling,  the  coordinated 
action of bone resorption by osteoclasts and 
bone  formation  by  osteoblasts,  is  essential 
for  the  maintenance  of  the  structural 
integrity of bone and for the regulation of the 
circulating Ca2+ concentration.  If remodeling 
is  out  of  balance,  either  a  loss  or  an 
accumulation  of  bone  occurs,  resulting  in 
osteoporotic  or  osteopetrotic  phenotypes, 
respectively.
Bone formation by osteoblasts
Osteoblasts, responsible for bone formation, 
arise  from  cells  in  the  condensing 
mesenchyme.  Three forms of the osteoblast 
cell  lineage  are  recognized:  progenitor 
osteoblasts  (pre-osteoblasts),  mature 
osteoblasts and osteocytes.  Pre-osteoblasts 
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Figure 9: Interaction of FGFs and BMPs with the 
IHH-PTHLH loop (Taken from Minina 2002)
have the capacity to divide, but have not yet 
acquired  many  of  the  protein-synthesizing 
characteristics  of  mature  osteoblasts.   As 
they  mature,  osteoblasts  stop  dividing  and 
become  highly  metabolically  active.   They 
synthesize  the  collagenous  constituents  of 
the  bone  matrix  and  also  regulate  its 
mineralization.
During  the  process  of  bone  formation,  the 
osteoblast  determines  its  own  fate  by 
calcifying itself into a lacuna.  At the point of 
total  encasement,  the  metabolic  activity  of 
the cell dramatically decreases as a result of 
the lack of nutrient diffusion.  Approximately 
15%  of  osteoblasts  eventually  survive  as 
osteocytes.
Several factors, including RUNX2, ATF4, OSX 
and CIZ, have been found to be essential for 
the development, maturation and function of 
osteoblasts (Fig. 10).
RUNX2
In  1997,  four  independent  papers  in  the 
same  issue  of  Cell  demonstrated  the 
importance  of   Runx2  (runt  related 
transcription  factor  2)  in  osteoblast 
differentiation  and  development  of  calcified 
bone.  Two groups created Runx2 knock-out 
mice that, when homozygous, died soon after 
birth  due  to  respiratory  insufficiency  (Otto 
1997,  Komori  1997).   The  most  striking 
feature  of  these  mice  was  a  total  lack  of 
bone,  and  retention  of  a  partially  calcified 
cartilaginous  skeleton.   Histochemical  and 
gene expression analyses showed absence of 
osteoblastic  cells.   Heterozygous  Runx2+/- 
mice were found to have a phenotype very 
similar to cleidocranial dysplasia (CCD).  The 
identification  of  heterozygous  inactivating 
RUNX2 mutations  in  CCD  patients  is  fully 
consistent  with  these  findings  (Mundlos 
1997).   Also,  in  a  search  for  osteocalcin 
specific  transcription  factors,  Runx2  was 
identified  as  a  regulator  of  osteoblast 
differentiation  (Ducy  1997).   In  vivo 
expression  analysis  of  Runx2 suggests  that 
this  transcription  factor  may  regulate 
expression  of  early  markers  for  osteoblast 
differentiation,  as  well  as  expression  of 
osteocalcin,  a  marker  for  differentiated 
osteoblasts.   Runx2 overexpression induced 
the expression of type I collagen, osteopontin 
and osteocalcin  in nonosteoblastic  and pre-
osteoblastic  cells.   Together  these  data 
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Figure 10: Signaling pathways regulating maturation and activity of osteoblasts and osteoclasts (Adapted 
from Krane 2005).
provide  compelling  evidence  that  Runx2  is 
indispensable  for  normal  osteoblast 
differentiation.
OSX
Osterix (OSX) is another transcription factor 
that is essential for osteoblast differentiation 
(Nakashima  2002).   Similarly  to  Runx2-/- 
mice, in the absence of Osx, no cortical bone 
and  no  bone  trabeculae  are  formed. 
However,  in  contrast  to  Runx2-/- mice, 
absence  of  Osx  does  not  deregulate 
chondrocyte differentiation.  Nakashima et al. 
therefore  concluded  that  Osterix  acts 
downstream of Runx2 to regulate a later step 
in osteoblast differentiation.  Runx2 was later 
shown to directly bind and transactivate the 
promoter of Osx (Nishio 2006).
ATF4
ATF4 (activating transcription factor 4) is the 
target transcription factor of RSK2 (RPS6KA3 
=  ribosomal  protein  S6  kinase,  90kDa, 
polypeptide 3).   Mice deficient  for  the Atf4 
gene show a delayed bone formation during 
embryonic development and a low bone mass 
characterized by a severe reduction in bone 
volume and in the number and thickness of 
trabeculae.   This  phenotype  is  due  to  a 
failure  to  achieve  terminal  osteoblast 
differentiation,  to  defects  in  osteoblast 
function and to a posttranscriptional decrease 
in type I collagen synthesis.  These findings 
identify  Atf4  as  a  critical  regulator  of 
osteoblast differentiation and function (Yang 
2004).   Also,  Rsk2  deficient  mice  have  a 
delayed  mineralization  of  the  skull  and  a 
significant  reduction in long bone length at 
one month of age.  These abnormalities are 
similar  to  those  reported  in  patients  with 
Coffin-Lowry  syndrome  (CLS),  a  condition 
with  mental  retardation  and  skeletal 
abnormalities  caused  by  RSK2 mutations 
(Trivier 1996), confirming the importance of 
the  RSK2-ATF4  pathway  in  bone 
development.
CIZ
The recent  identification  of  CIZ (ZNF384 = 
zinc finger protein 384) as a suppressor of 
adult bone mass is an interesting finding in 
view  of  the  impact  of  osteoporosis  on  our 
aging  population  (Morinobu  2005).   In  Ciz 
deficient mice, bone volume and the rate of 
bone formation are increased whereas bone 
resorption  is  not  altered.   The  absence  of 
major  alterations  in skeletal  morphogenesis 
during  embryonic  stages  suggests  that  CIZ 
action is more important in bone metabolism 
in adulthood than in embryonic life.  CIZ was 
found  to  reduce  osteoblast  activity  by 
inhibition of SMAD mediated BMP signaling.
Bone resorption by osteoclasts
Osteoclasts  are  the  highly  specialized  bone 
lining  cells  responsible  for  bone  resorption. 
Before  1980,  the  origin  of  multinucleated 
osteoclasts  was  controversial.   Experiments 
with  radiation  chimeras  did,  however, 
provide  strong  evidence  for  the 
haematopoietic  origin  of  osteoclasts  (Ash 
1980).   They  differentiate  in  a  late  phase 
from the monocyte/macrophage cell lineage. 
At  endosteal  bone  surfaces,  the  precursors 
proliferate  and  fuse  to  form  giant, 
multinucleated  cells  containing  4  to  20 
nuclei.   Osteoclasts  are  usually  found  in 
contact  with  a  calcified  bone  surface  and 
within  a  lacuna  (Howship's  lacunae  or 
resorption pit).  Osteoclast are motile cells. 
They resorb bone to form a lacuna and then 
move  across  the  bone  surface  to  resorb  a 
separate area of bone.  Periods of locomotion 
are not associated with resorption.
In order for resorption to occur, osteoclasts 
need to attach to the bone surface.  The zone 
of contact with the bone (the sealing zone) is 
characterized  by  the  presence  of  a  ruffled 
border with dense patches on each side.  The 
plasma membrane in the ruffled border area 
contains  proteins  that  are  also  found  in 
lysosomal membranes, and a specific type of 
electrogenic  proton  ATPase  necessary  for 
acidification  of  the  extracellular 
compartment.   Lysosomal  enzymes  are 
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Figure 11: Resorption by osteoclast (Taken from 
Teitelbaum 2003).
actively  synthesized  by  the  osteoclast  and 
secreted,  via  the  ruffled  border,  into  the 
extracellular  bone-resorbing  compartment 
where  they  reach  a  sufficiently  high 
extracellular  concentration  because  this 
compartment  is  sealed  off  (Fig.  11).   The 
extracellular bone-resorbing compartment is 
therefore  the  functional  equivalent  of  a 
secondary  lysosome.   The  low  pH  in  the 
sealing  zone  dissolves  the  hydroxyapatite 
crystals,  thus  exposing  the  matrix  to 
lysosomal enzymes.  These enzymes, now at 
optimal pH, subsequently degrade the matrix 
components.   At  the  end  of  the  resorbing 
phase,  the  osteoclasts  undergo  apoptosis 
(Teitelbaum 2003).
In  vitro  experiments  revealed  that  a  direct 
cell-to-cell  contact  with  osteoblastic  cells  is 
required for the differentiation of osteoclast 
progenitors  into  multinucleated  osteoclasts 
(Takahashi  1988).   CSF1  and  the  RANK-
RANKL-OPG  system  were  found  to  be  the 
essential osteoblast derived elements for the 
differentiation  of  haematopoietic  progenitor 
cells into osteoclasts (Fig. 10).
CSF1
Macrophage colony stimulating factor (CSF1 
=  colony stimulating factor 1) is expressed 
by  osteoblasts  and  their  precursors  as  a 
soluble and membrane-bound protein.   The 
finding  that  osteoclast  deficiency  in 
osteopetrotic  (op/op)  mice  is  due  to  an 
inability  to  produce  functionally  active  Csf1 
strongly indicates a critical role for this factor 
in osteoclast development (Felix 1990a, Felix 
1990b, Yoshida 1990).  CSF1 was shown to 
promote  both  proliferation  and  survival  of 
osteoclast precursors.
RANK-RANKL-OPG
Osteoprotegerin  (OPG  or  TNFRSF11B)  is  a 
soluble member of the tumor necrosis factor 
(TNF)  receptor  family  secreted  by  the 
preosteoblastic/stromal  cells.   Studies  of 
transgenic  mice  overexpressing 
osteoprotegerin  (i.e.  to  protect  bone)  and 
animals  injected  with  OPG  have 
demonstrated  that  this  protein  inhibits 
osteoclastogenesis  and  suppresses  bone 
resorption (Simonet 1997, Yasuda 1998a).
In  1998,  the  long  sought  ligand  mediating 
the  essential  signal  of  osteoblastic  cells  to 
osteoclast progenitors for their differentiation 
into osteoclasts was identified: a soluble form 
of  the  membrane  associated  receptor 
activator  of  NF-κB  ligand  (RANKL  or 
TNFSF11)  was  found  to  induce  osteoclast 
formation from spleen cells in the absence of 
osteoblast/stromal  cells  (Yasuda  1998b). 
Addition  of  osteoprotegerin  abolished  this 
effect of RANKL indicating that OPG acts as a 
decoy receptor that binds directly to RANKL 
on  osteoblasts/stromal  cells.   As  such  it 
interrupts  RANKL-mediated  signaling  from 
osteoblasts/stromal  cells  to  osteoclast 
progenitors,  and inhibits  osteoclastogenesis. 
In combination with CSF1, RANKL was found 
to be sufficient for osteoclast formation from 
monocytes or spleen cells (Quinn 1998).
The  final  piece  of  the  puzzle  of  osteoclast 
formation  fell  into  place  with  the  the 
identification  and  characterization  of  the 
receptor  for  RANKL:  RANK  (TNFRSF11A). 
Rank knockout mice were found to develop a 
severe osteopetrosis  due to the absence of 
osteoclasts  (Li  2000).   This  confirms  the 
requirement of RANK signaling to osteoclast 
precursors  for  the  formation  of  mature 
osteoclasts.   Thus,  in  conjunction  with 
macrophage  colony-stimulating  factor,  the 
RANK-RANKL-OPG  system  regulates 
osteoclast differentiation.
Coupling  of  bone  formation  and 
resorption
Under  normal  conditions,  bone  remodeling 
renews 5-10% of bone volume per year.  In 
early  life  bone  formation  by  osteoblasts 
predominates  over  bone  resorption  by 
osteoclasts.   The highest  velocities  of  bone 
mineral addition are achieved by the ages of 
13  and  14.5  years  for  girls  and  boys, 
respectively.   This  gain  in  bone  mass  is 
mainly  related  to increasing bone  volumes. 
About 90% of peak bone mass is acquired by 
age  18,  with  only  minimal  further  bone 
acquisition  until  age  30  (Heaney  2000). 
Later in life, the rate of bone formation may 
not  fully  compensate  for  the  bone  lost  by 
resorption,  resulting  in  a  net  loss  of  bone 
tissue.  When the process of bone remodeling 
becomes  unbalanced  then  either 
osteopetrosis or osteoporosis may develop.
Bone formation and bone resorption do not 
occur along the bone surface at random, but 
in  a  coordinated  fashion.   In  the  adult 
skeleton, bone formation occurs only where 
bone resorption has previously taken place. 
Together,  these  processes  constitute  the 
turnover  mechanism  by  which  old  bone  is 
replaced  by  new bone.     Osteoblasts  and 
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osteoclasts,  coupled  together  via  paracrine 
cell  signaling,  are  referred  to  as  bone 
remodeling units.  The complete remodeling 
cycle (Fig. 12) takes about 3 to 6 months to 
complete  and  consists  of  the  following 
phases:
Quiescence phase:
Bone is at rest and no active remodeling is 
taking place.
Activation phase
The  bone  surface  is  activated  by  the 
retraction  of  bone  lining  cells  and  the 
digestion  of  the  endosteal  membrane  by 
collagenase  action.   Once  activated,  the 
mineralized  surface  attracts  the  circulating 
osteoclast  precursors  supplied  by  nearby 
vessels.
Resorption phase
Multinucleated  osteoclasts  dissolve  the 
mineral  matrix  and  decompose  the  osteoid 
matrix.
Formation phase
Attracted by the growth factors released from 
the  matrix,  preosteoblasts  migrate  into  the 
resorbed  areas.   Differentiated  osteoblasts 
then  synthesize  the  osteoid  material  which 
fills the resorbed areas.
Mineralization phase
Mineralization begins approximately 1 month 
after deposition of the osteoid (organic bone 
matrix),  ending  at  about  90  days  in  the 
trabecular and at 130 days on the average in 
the cortical bone.  The quiescent phase then 
begins again.
In  general,  bone  remodeling  is   regulated 
and  influenced  by  genetic  constitution, 
systemic hormones, nutrition and mechanical 
factors  (Fig.  13).   A  number  of 
epidemiological, family and twin studies have 
revealed an important role for genetic factors 
in  bone  remodeling.   Overall  these  studies 
suggest  that  60-80%  of  variance  in  bone 
phenotypes (e.g. maximum bone density) at 
any age or group is  genetically  determined 
(Eisman  1999).   On  the  other  hand, 
environmental  factors such as nutrition and 
physical  loading  (gravity  and  exercise)  are 
known  to  be  important  as  well.   Physical 
activity  is  essential  for  the  correct 
development of bone.  In athletes, increased 
loading  has  been  shown  to  be  associated 
with increased bone mass,  often located to 
the sites of loading.  On the other hand, the 
absence  of  muscular  activity,  rest  or 
weightlessness  has  an  adverse  effect  on 
bone,  by  accelerating  resorption.   Nutrition 
can influence bone density in both ways: a 
minimum amount  of  calcium is  needed  for 
mineralization  while  toxic  substances  like 
alcohol or smoking constitute a risk factor for 
osteopenia.
Bone remodeling is regulated by a number of 
hormones (thyroid and parathyroid hormone, 
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Figure 12: Bone remodeling process (Taken from 
http://www.umich.edu/news/Releases/2005/Feb05/bone.html)
Figure 13: Regulation of bone mass
sex  steroids,  insulin,  glucocorticoids  and 
growth  hormone)  and  local  factors.   An 
overview of  the effect  of  these local  acting 
growth  factors  and  cytokines  is  shown  in 
table  2.   At  the  molecular  level  bone 
remodeling appears to be mainly controlled 
by  the  balance  between  RANKL  (osteoclast 
inductive)  and  OPG  (osteoclast  inhibitive). 
Preosteoblasts express a high level of RANKL 
relative to osteoprotegerin  which stimulates 
osteoclast  differentiation  and  function,  and 
allows  resorption  to  start.   More  mature 
osteoblasts, by contrast, express high levels 
of osteoprotegerin relative to RANKL, which 
inhibits osteoclast differentiation and function 
(Gori  2000).   This  prevents  further  bone 
resorption and allows the mature osteoblasts 
to fill the resorption pits with fresh bone.  It 
makes sense that the critical, initial step in 
bone  remodeling,  the  development  of 
osteoclasts,  should  be under  the control  of 
preosteoblastic/stromal  cells.   This  ensures 
that  the  processes  of  bone  resorption  and 
formation will be tightly coupled, allowing for 
a wave of bone formation to follow each cycle 
of  bone  resorption.   Further  coupling 
between  osteoblastogenesis  and 
osteoclastogenesis is ensured by the fact that 
the osteoclast differentiation factor,  RUNX2, 
is necessary for adequate expression of the 
osteoclast  differentiation  factor,  RANKL,  on 
the  surface  of  preosteoblastic/stromal  cells 
(Gao 1998).
Two of the growth factors listed in table 2, 
BMP and TGFβ, are of special importance in 
this thesis:
TGFβ
Strong evidence for a positive effect of TGFβ 
on  bone  formation  in  humans  comes  from 
the  rare  skeletal  dysplasia,  Camurati-
Engelmann disease  (CED).   This  autosomal 
dominant  disorder  is  characterized  by  a 
progressive  cortical  thickening  of  the 
diaphyses of the long bones.  Hyperostosis is 
bilateral and symmetrical, and usually starts 
during  childhood.   A  total  of  10  different 
mutations  in  the  TGFB1  gene  have  been 
found  in  CED  patients,  all  leading  to 
increased  TGFβ  activity  (Janssens  et  al. 
2006).   The  identification  of  activating 
mutations  in  TGFB1  in  patients  with  CED 
demonstrates that  increased TGFβ signaling 
can lead to hyperostosis.
BMP
The positive effect of BMP signaling on bone 
formation was demonstrated in a number of 
transgene  mice.   Mice  with  a  dominant-
negative BMP receptor (BMPR-IB) mutation in 
osteoblasts  suffer  from  impaired  postnatal 
bone formation as the result of reduced BMP 
signaling.   Bone  mineral  density,  bone 
volume  and  bone  formation  rates  in  these 
mutant animals are severely reduced without 
changes  in  osteoblast  and  osteoclast 
numbers  (Zhao  et  al.  2002).   Also, 
transgenic  mice  overexpressing  noggin,  an 
extracellular BMP antagonist, have a reduced 
bone  mineral  density  and  decreased 
trabecular bone volume (Devlin et al. 2003).
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Stimulate
bone formation
Stimulate
bone resorption
Inhibit
bone resorption
Growth factors
BMP-2
BMP-4
BMP-6
BMP-7
IGF-I
IGF-II
TGF-β
FGF
PDGF
TNF
EGF
PDGF
FGF
M-CSF
GM-CSF
Cytokines
IL-1
IL-6
IL-8
IL-11
PGE2
PGE1
PGG2
PGI2
PGH2
IFN-γ
IL-4
Table 2: Regulatory local factors in bone remodeling (Taken from Fernandez-Tresguerres-Hernandez-
Gil 2006)
The  positive  effect  on  bone  formation  of 
these growth factors was confirmed by our 
finding  that  loss  of  function  mutations  in 
LEMD3,  encoding  an  inhibitor  of  SMAD 
mediated BMP and  TGFβ signaling, result in 
the  hyperostotic  disorders  osteopoikilosis, 
BOS and melorheostosis (Paper 2: Hellemans 
2004).
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Skeletal dysplasias
1 Introduction
As indicated in the previous section, the final 
state  of  the  skeleton  is  determined  by  the 
processes  of  patterning,  endochondral  and 
intramembranous  ossification,  growth  and 
bone homeostasis.   Abnormalities in any of 
these components can give rise to disorders 
of  the  heterogeneous  group  of  skeletal 
dysplasias  or  osteochondrodysplasias.   The 
phenotypic  spectrum  of  these  disorders 
ranges  from  asymptomatic  over  various 
degrees  of  short  stature  to  death  in  the 
neonatal period.  Secondary complications of 
skeletal  deformity  and  manifestations  in 
extraskeletal  organs  add  to  the  burden  of 
this group of disorders. 
Skeletal dysplasias are individually rare, but 
collectively  quite  common.  Because of  the 
rarity of some of these conditions, they can 
be difficult to diagnose.  The prevalence has 
been assessed by a number of investigators 
and ranges from 0.95 to 7.6 depending on 
the cited source (Table 3, Rasmussen 1996). 
Prevalence rates of about 1 in 10,000 have 
been found by three groups that  only took 
lethal cases into account.  Five papers report 
a  prevalence  between  2 and  5  per  10,000 
newborns.  This rate increases to about 7.6 
when  dysplasias  noted  at  older  ages  are 
taken into account as well.
2 Classification
At  the  end  of  the  19th century  the  term 
“achondroplasia”  was  introduced  to 
distinguish  patients  with  disproportionate 
short  stature  from  persons  with 
proportionate  short  stature  (Parrot  1886). 
Subsequently,  the  diagnosis  of 
achondroplasia  was  retained  for  those  with 
short-limb  dwarfism  and  the  term  Morquio 
syndrome  for  those  with  short-trunk 
dwarfism.  Further heterogeneity within the 
group of skeletal  dysplasias was recognized 
by  the  middle  of  last  century.   The 
description  of  many  new chondrodysplasias 
required the development of a uniform and 
consistent  nomenclature  and  classification 
system  for  these  conditions.    The 
'International  Working  Group  on 
Constitutional  Diseases  of  Bone'  formulated 
the  first  'International  Nomenclature  of 
Constitutional  Diseases  of  Bone'  in 1970 in 
Paris.  They classified genetic disorders of the 
skeleton in a few classes.  Dysostoses were 
defined as 'malformations of individual bone, 
singly  or  in  combination'  whereas 
osteochondrodysplasias were  described  as 
'abnormalities  of  cartilage  and/or  bone 
growth  and  development'.  (McKuscik  1971) 
In  his  book  'Bone  Dysplasias'  Jürgen 
Spranger defined the constitutional errors of 
bone development as follows: dysostoses are 
malformations  of  single  bones,  alone  or  in 
combination,  disruptions are  secondary 
malformations  of  bones  and  skeletal 
dysplasias are  developmental  disorders  of 
chondro-osseous  tissue  (Spranger,   Bone 
Dysplasia – Oxford University Press).
Dysostoses
Dysostoses  are  manifestations  of  transient 
signaling defects in the first 6 weeks of fetal 
life resulting in abnormal organogenesis and 
defective bone formation.    Because of  the 
transient nature of the defective process, the 
malformations  do  not  spread  to  involve 
previously  normal  bones  and  joints. 
Therefore, the dysostotic phenotype is static 
throughout life.  Since dysostoses are finite 
disorders caused by a past, closed process, 
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Population Rate per 10,000 Reference
Lethal neonatal 0.95 Rasmussen 1996
Lethal neonatal 1.1 Connor 1985
Lethal 1.5 Andersen 1989
Not specified 1.6 Källén 1993
Newborn 2.1 Rasmussen 1996
Newborn 2.3 Orioli 1986
Newborn 2.4 Camera 1982
Newborn 3.2 Stoll 1989
Newborn 4.7 Gustavson 1975
All dysplasias 7.6 Andersen 1989
Table  3:  Prevalence  of  osteochondrodysplasias 
(Adjusted from Rasmussen 1996)
there  is  no  danger  of  malignant 
degeneration.   The  lesions  may  be 
asymmetrically  distributed  and,  although 
they are malformations of  individual  bones, 
several  bones  may  be  affected  in 
combination.   Dwarfism  is  not  a  primary 
manifestation of dysostoses (unless bones of 
the  vertical  body  axis  are  defective  or 
missing) and the chondro-osseous histology 
is normal.
Disruptions
Toxic  substances  or  infectious  agents  to 
which  an  embryo  may  be  exposed  act  for 
limited  periods  of  time,  as  do  transiently 
expressed  signaling  genes.   They  may 
produce secondary malformations, but do, by 
definition,  not  result  in  dysplasias. 
Thalidomide  and  rubella  embryopathy  are 
prime examples of, respectively, a chemical 
and  a  viral  insult  resulting  in  skeletal 
disruptions.
Dysplasias
Defects of  prenatally  expressing genes that 
continue  to  be  expressed  in  postnatal  life 
lead to dysplasias.  In contrast to dysostoses, 
however,  most  dysplasia  genes  are  not 
expressed  during  organogenesis  in  a  way 
that their defects would manifest.  Mutations 
lead  to  postnatally  ongoing  errors  of  cell 
proliferation,  differentiation  and 
degeneration, and thus to defective skeletal 
growth  and  development.    Malignant 
degeneration is possible but rare in skeletal 
dysplasias. Primary skeletal dysplasias result 
from mutated  genes  that  are  expressed  in 
chondro-osseous  tissue  while  secondary 
dysplasias  are  caused  by  abnormalities  of 
extraosseus factors with secondary effects on 
the  skeletal  system  (e.g.  metabolic 
disorders).   Since  skeletal  dysplasias  are 
disorders  of  bone  as  tissue,  mutations  of 
dysplasia  genes  affect  all  anatomic  sites  in 
which  a  mutated  gene  is  expressed. 
Homologous  sites  are  affected  and  the 
resulting  disorders  are  mostly  symmetric. 
Eventual development of asymmetric lesions 
usually  results  from  the  influence  of  local 
mechanical factors or somatic mutations.  In 
contrast  to  dysostoses,  dwarfism  is  a 
common  feature  of  skeletal  dysplasias 
(Spranger,   Bone  Dysplasia  –  Oxford 
University Press).
Since  its  first  description  in  1970,  the 
International  Nomenclature of Constitutional 
Diseases of Bone has been officially revised 
and  updated  on  6  occasions:  1977,  1983, 
1991,  1997,  2001  (Hall  2002)  and  2005 
(Superti-Furga  2007).   The  initial 
categorizations  were  purely  descriptive  and 
consisted  of  a  mixture  of  the  key  clinical, 
radiographic, and histologic features of each 
condition. The recent advances in molecular 
biology  and  technology  in  conjunction  with 
the progress  of  the human genome project 
have  allowed  the  concept  of  groups  of 
disorders  to  evolve,  where  conditions  with 
similar genetic defects are put together.
The  last  published  classification  of 
constitutional  disorders  of  bone is  a  hybrid 
that  incorporates  clinical  (e.g.  mesomelic 
dysplasia  group),  radiographic  (e.g. 
metaphyseal dysplasia group), and molecular 
descriptors  (e.g.  type  II  collagenopathies 
group), as well  as using various descriptive 
Greek  terms  to  name  conditions  (e.g. 
atelosteogenesis  omodysplasia  group).   The 
need for separate but parallel classifications, 
one based on clinical features and the other 
on molecular defects, was clearly identified at 
the 2001 meeting.  Superti-Furga suggested 
a  molecular  and  pathogenetic  classification 
into 7 groups (Superti-Furga 2001):
1. defects  in  extracellular  structural 
proteins
2. defects in metabolic pathways (including 
enzymes, ion channels, transporters)
3. defects  in  folding,  processing  and 
degradation of macromolecules
4. defects  in  hormones  and  signal 
transduction mechanisms
5. defects  in  oncogenes  and  tumor-
suppressor genes
6. defects in RNA and DNA processing and 
metabolism
3 Diagnosis
The  latest  nosology  and  classification  of 
genetic  skeletal  disorders  (2006  revision) 
lists 372 distinct conditions, of which 215 are 
associated with one or more of 140 different 
genes  (Superti-Furga  2007).   The  diversity 
together  with  the  rarity  of  each  individual 
disorder,  makes  a  correct  diagnosis  often 
difficult for the clinician.  The establishment 
of a correct diagnosis is however important 
for a number of reasons.  It allows accurate 
genetic ounseling and is the cornerstone for 
proper clinical management.
The  diagnosis  usually  requires  a  careful 
clinical  examination  of  the  patient  and 
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thorough  radiographic  evaluation  of  the 
skeleton.  Morphologic studies of the growth 
plate,  cartilage and bone can be  helpful  in 
further  narrowing  the  differential  diagnosis, 
certainly in the lethal conditions where tissue 
specimens are easily available.   Biochemical 
or molecular analysis can be used to confirm 
the diagnosis, provided that the causal gene 
is known (Mortier 2001).
A  complete  history,  pedigree  analysis  and 
physical examination should be the first step 
in  the  diagnostic  assessment  of  a  patient 
suspected  for  having  a  skeletal  dysplasia. 
Knowledge  of  birth  length  and  postnatal 
growth  curves  are  very  important.   The 
recognition of congenital  malformations and 
other connective tissue abnormalities can be 
very helpful in the diagnostic work-up.  The 
diagnosis of a skeletal dysplasia however still 
mainly  relies  on  a  careful  radiographic 
evaluation  of  the  skeleton.   Because 
epiphyseal  closure  after  puberty  makes 
evaluation of the epiphyses and metaphyses 
difficult, if not impossible, a skeletal survey is 
preferably taken before puberty.  Offiah and 
Hall have provided a schematic approach that 
can be followed when evaluating a skeletal 
survey (Offiah 2003).  This scheme has been 
devised as an easy to remember mnemonic 
in which the A, B, C and D characteristics are 
to  be  investigated.   They  indicate 
respectively:
A – Anatomical localization
Some  conditions  are  broadly  named 
according  to  the  anatomical  sites  involved. 
The anatomic localization of skeletal defects 
may occasionally be sufficient, but certainly 
gives a radiologist a good starting point and 
is  usually  required  for  the  further 
classification of the condition.
B – Bones
The  following  is  an  aid  memoir  to  the 
radiological  analysis  of  bones  (the  five 
‘‘S’s’’):
Structure
This applies to the general appearance of 
the bones, including abnormalities of bone 
density  and  the  presence  of  tumorous 
lesions.  The distribution of abnormalities 
is also important.
Shape
Alterations in shape may affect the whole 
bone or  be restricted to part of  a bone, 
such as the metaphyses or the epiphyses. 
Some shapes are  very specific and can be 
used as a predictive marker.
Size
Abnormalities of size may be absolute or 
relative to the size of other bones.  When 
considering size, it is also relevant to take 
the bone age into account.
Sum
Bones  may  be  too  many,  too  few,  or 
fused.
Soft tissues
Abnormalities  of  soft  tissues  that  should 
be  looked  for  include  wasting,  excessive 
soft tissues, contractures and calcification. 
Soft  tissue involvement  may change not 
only the diagnosis, but also the patient's 
prognosis.
C – Complications
Although  recognition  of  complications  does 
not usually help in reaching a diagnosis, from 
the point of view of patient management it is 
important to exclude known complications of 
a  condition  once  a  diagnosis  has  been 
reached.
D – Dead/alive
The fact that a dysplasia is lethal can help to 
exclude or confirm a given diagnosis, or may 
affect the subtype of the condition.
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Role of IHH in skeletal development and dysplasias
Brachydactyly  type  A1  (BDA1)  and 
acrocapitofemoral  dysplasia (ACFD) are two 
rare skeletal dysplasias with brachydactyly as 
a  common  characteristic.   Whereas  hand 
abnormalities  are  the only  defects  in  BDA1 
patients,  individuals  with  ACFD  have  a 
disproportionate short stature resulting from 
premature  epimetaphyseal  fusion. 
Homozygous  and  heterozygous  missense 
mutations in the signaling domain of indian 
hedgehog  (IHH)  are  responsible  for  ACFD 
and BDA1,  respectively.   The heterozygous 
carriers  of  an ACFD mutation do, however, 
not show any sign of brachydactyly.  IHH is a 
secreted signaling molecule essential for the 
regulation  of  endochondral  ossification.   It 
controls  chondrocyte  proliferation  and 
differentiation,  and  determines  the  site  of 
bone collar formation.   It  is  not yet known 
how  the  different  IHH  missense  mutations 
affect  endochondral  ossification  to  result  in 
ACFD or BDA1.
Indian hedgehog (IHH) and the 
growth plate
The  first  steps  in  skeletal  morphogenesis 
involve  the  induction  of  undifferentiated 
mesenchyme  and  its  differentiation  into 
condensed  mesenchyme.  In  the  human 
skeleton,  only  the  membrane  bones  of  the 
skull and part of the clavicle are formed by 
direct ossification of condensed mesenchyme 
(intramembranous ossification). For the large 
majority  of  bones,  bone  formation  and 
growth  proceeds  through  an  intermediate 
cartilaginous template or anlage in a process 
called  endochondral  ossification  (Seeley, 
Anatomy  and  Physiology  –  McGraw-Hill). 
These  cartilaginous  models  are  formed  by 
further  differentiation  of  condensed 
mesenchymal  cells  into  chondrocytes  that 
produce  hyaline  cartilage  instead  of 
mesenchymal matrix. In the center of these 
cartilaginous  templates,  chondrocytes  will 
form  columns  of  proliferating  cells  and 
subsequently enlarge to become hypertrophic 
chondrocytes, producing type X collagen.  In 
parallel  with  the cellular  differentiation,  the 
extracellular  cartilage matrix will  be altered 
through  the  actions  of  carbonic  anhydrase 
and  alkaline  phosphatase.  Finally,  the 
hypertrophic  chondrocytes  disintegrate  and 
die  with  simultaneous  calcification  of  the 
modified  matrix.  The  newly  formed  spaces 
with  calcified  cartilage  are  invaded  by 
periosteal blood vessels and osteogenic cells, 
which  soon  differentiate  into  osteoblasts 
(Ballock  2003).  The  latter  deposit  a  bony 
matrix on the calcified cartilage, resulting in 
the  formation  of  the  primary  center  of 
ossification. This ossification center is formed 
within  the  central  portion  of  the  cartilage 
template and will expand both proximally and 
distally  toward the ends (epiphyses)  of  the 
developing bone. Also, secondary ossification 
centers  start  appearing  in  the  epiphyseal 
regions.  As  these  ossifications  centers 
enlarge, they replace almost all the cartilage 
by  bone  except,  firstly,  for  a  layer  of 
specialized  hyaline  cartilage  at  the  joint 
surfaces (articular cartilage) and, secondly, a 
thicker zone between the diaphysis and the 
epiphysis,  representing  the  growth  plate 
(Seeley, Anatomy and Physiology – McGraw-
Hill).
The growth plate is a specialized and highly 
organized  zone  of  hyaline  cartilage 
responsible for linear skeletal growth. It is a 
very dynamic tissue with a high cellular turn-
over.  It  forms  a  transition  region  between 
cartilage  and  bone  and  is  divided  into 
different zones, reflecting the several stages 
of chondrocyte differentiation (Fig. 22-1). In 
each  zone  a  different  pattern  of  gene 
expression  is  observed  (Provot  2005).  The 
reserve  zone,  containing  resting 
chondrocytes,  is  located  farthest  from  the 
center of the growing bone where it merges 
into  the  epiphyseal  cartilage.  In  the 
proliferative  zone,  clusters  or  columns  of 
proliferating  flattened  chondrocytes  are 
found. These columns are oriented parallel to 
the axis of growth and separated from each 
other by septa of interterritorial matrix. The 
hypertrophic zone can be divided into areas 
of  prehypertrophic,  hypertrophic  and 
terminally  differentiated  chondrocytes. 
Mineralization  of  the  cartilage  matrix 
(provisional  calcification)  starts  in  the 
hypertrophic zone. About every 24 hours, the 
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hypertrophic  zone  shows  complete  cellular 
turn-over.  At  the  lower  end  of  the  growth 
plate,  near  the  zone  of  primary  spongiosa, 
the terminal  hypertrophic  chondrocytes  and 
the  surrounding  matrix  become invaded by 
metaphyseal  blood  vessels.  This  invasion 
results  in  degradation  and  degeneration  of 
the  matrix  and  apoptosis  of  the  terminally 
differentiated  chondrocytes.  The  remaining 
cartilaginous cores will serve as templates for 
the  deposition  of  bone  matrix  (osteoid)  by 
osteoblasts.  This  process  of  endochondral 
ossification goes on until  the closure of the 
growth plate at the end of puberty which will 
result  in  a  stop  of  linear  growth  of  the 
involved bone.
A  well-controlled  balance  between 
chondrocyte  proliferation  and  differentiation 
is  important  for  proper  functioning  of  the 
growth  plate  (van  der  Eerden  2003, 
Kronenberg 2003). Several genes are playing 
an  important  role  in  regulating  and 
maintaining this balance. One of them is the 
gene coding for the Indian hedgehog (IHH) 
protein. IHH is one of the three mammalian 
homologues of the D. melanogaster segment 
polarity  gene,  Hedgehog.  The  Hedgehog 
gene  family  encodes  a  group  of  secreted 
signaling  molecules  that  are  essential  for 
growth  and  patterning  of  many  different 
body  parts  of  vertebrate  and  invertebrate 
embryos.  As  a  common  feature,  these 
proteins are processed by internal  cleavage 
to  generate  an  amino-terminal  fragment 
(HH-N) with all the known signaling activity, 
and  a  C-terminal  fragment  (HH-C)  that  is 
responsible for the autoproteolytic cleavage. 
The addition of cholesterol and palmitate to 
the  HH-N  fragment  affects  the  spatial 
distribution  and  signaling  activity  of 
hedgehog  proteins  (Porter  et  al.  1996; 
Chamoun et  al.  2001).   Processing  of  and 
signaling  by  these  hedgehog  proteins  have 
been  reviewed  comprehensively  by  Michael 
Cohen (Cohen 2003).
In the growth plate, IHH is mainly secreted 
by  the  prehypertrophic  chondrocytes 
(Vortkamp et al. 1996; Minina et al. 2002). A 
series  of  experiments  have  revealed  an 
important  regulatory  role  of  IHH  in  the 
process of endochondral ossification. Several 
lines of evidence indicate that IHH regulates 
chondrocyte  proliferation,  chondrocyte 
hypertrophic  differentiation  and  bone 
formation.
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Fig. 22-1 Schematic representation of the growth plate with indication of the 
different zones.  The effects of IHH, BMP and FGF signaling are shown by 
pointing arrows in case of stimulation and by blocking arrows in case of 
inhibition. Arrows directed to the horizontal lines (separating the different 
zones) indicate the effect on the transition from one zone to the other. The 
division rate of the chondrocytes in the proliferative zone is shown by the + 
sign.
Pioneering  work  by  Vortkamp  et  al. 
demonstrated  that  IHH  induces  the 
expression  of  PTHLH  (previously  known  as 
PTHrP) in the periarticular perichondrium and 
that this hormone inhibits the differentiation 
from  columnar  proliferating  into 
prehypertrophic chondrocytes (Lanske et al. 
1996; Vortkamp et al. 1996).  In this way, 
IHH and PTHLH function in a feedback loop 
that  regulates  the  rate  of  chondrocyte 
differentiation in the growth plate (Fig.  22-
1).   When  chondrocytes  become 
prehypertrophic  they  express  IHH  that 
upregulates the expression of PTHLH.  PTHLH 
diffuses  to  the  proliferative  zone  where  it 
limits  differentiation  of  additional 
proliferating  cells  into  prehypertrophic 
chondrocytes.  As  prehypertrophic 
chondrocytes  continue  to  differentiate  they 
cease to express IHH, resulting in decreased 
PTHLH production and a consequent increase 
in  chondrocyte  differentiation  (Vortkamp et 
al.  1996).   In  this  way a  constant  pool  of 
prehypertrophic  chondrocytes  is  maintained 
in the growth plate.
It has, however, not been resolved how the 
IHH  signal  is  propagated  from  the 
prehypertrophic  chondrocytes  to  the 
periarticular  region  to  upregulate  the 
expression of  PTHLH.  Both IHH dependent 
secondary signals and direct long range IHH 
signaling  have  been  proposed  to  activate 
PTHLH expression.   Alvarez  et  al.  provided 
evidence  for  TGFβ2  mediated  effects  of 
hedgehog  on  PTHLH  expression  and 
hypertrophic differentiation.  They found that 
IHH stimulates TGFβ2 and TGFβ3 expression 
in  the  perichondrium  and  that  the 
perichondrium  is  required  to  mediate  the 
effects  of  hedgehog  on  hypertrophic 
differentiation.  This effect was found to be 
dependent  on  TGFβ  signaling  in  the 
perichondrium, and more specifically on the 
production  of  TGFβ2 (Alvarez  et  al.  2002). 
On the other hand, several experiments have 
also  indicated  that  IHH  can  act  as  a  long 
range  morphogen,  directly  activating  the 
expression of PTHLH.  Although hydrophobic 
modification  by  cholesterol  and  palmitate 
suggested  tethering  of  hedgehog  to  the 
plasma membrane,  hedgehog was found to 
form  freely  diffusible  multimers  capable  of 
mediating long-range signaling (Zeng et al.  
2001).   Experiments  with  Ext1  gene  trap 
mice  indicated  that  the  signaling  range  of 
hedgehogs is regulated by heparin sulphate 
and  suggested  that  IHH  directly  activates 
PTHLH  expression  to  regulate  chondrocyte 
proliferation (Koziel et al. 2004).
In  addition  to  the  effects  of  IHH  via  the 
aforementioned feedback loop, IHH regulates 
endochondral  ossification  in  PTHLH 
independent ways as well.  As a direct effect, 
IHH stimulates chondrocyte proliferation (St-
Jacques et al. 1999; Karp et al. 2000) and 
induces the differentiation from periarticular 
chondrocytes into flat, columnar proliferating 
chondrocytes  (Kobayashi  et  al.  2005).   It 
also  interacts  with  a  number  of  additional 
signaling  molecules  and  growth  factors  to 
create  a  complex  regulatory  network  (Fig. 
22-1).  BMPs and FGFs were found to have 
antagonistic  effects  on  bone  development 
(Minina  et  al.  2002).   BMPs  stimulate 
chondrocyte  proliferation,  induce  IHH 
secretion  and  inhibit  terminal  chondrocyte 
differentiation  whereas  FGFs  reduce 
chondrocyte  proliferation,  inhibit  IHH 
secretion and stimulate terminal chondrocyte 
differentiation.
Finally, IHH is also important in determining 
the  site  of  bone  collar  formation  in  the 
adjacent perichondrium. Thus, by regulating 
chondrocyte  proliferation  and  differentiation 
as  well  as  bone  formation,  IHH  couples 
chondrogenesis  to  osteogenesis  in 
endochondral  bone  development  (Chung  et 
al. 2001).
Acrocapitofemoral dysplasia and 
brachydactyly type A1
Acrocapitofemoral  dysplasia  (ACFD,  MIM 
#607778) and brachydactyly type A1 (BDA1, 
MIM  #112500)  are  two  distinct  skeletal 
dysplasias  that  share  brachydactyly  as  a 
common feature.   BDA1 was first identified 
by Farabee in 1903, and has the distinction 
of  being  the  first  condition  in  man  to  be 
interpreted  as  a  mendelian  dominant  trait 
(Farabee 1903).  ACFD, on the other hand, 
was  described  exactly  hundred  years  later 
(Mortier  et  al.  2003).   The  Nosology  and 
Classification  of  Genetic  Skeletal  Disorders 
(2006 revision) classifies ACFD and BDA1 in 
groups  14  (acromelic  dysplasias)  and  34 
(brachydactylies),  respectively  (Superti-
Furga  2007).Acrocapitofemoral  dysplasia  is 
an  autosomal  recessive  skeletal  dysplasia 
characterized clinically by short stature with 
short  limbs  and  radiographically  by  cone-
shaped epiphyses, mainly in hands and hips. 
The  condition  was  for  the  first  time 
Paper 2 35
delineated in two consanguineous families of 
Belgian  and  Dutch  origin  (Mortier  et  al. 
2003).   The  phenotype  in  these  families 
showed some resemblance  to the  condition 
reported in a 12 year-old-boy by Hoeffel et 
al. (Hoeffel et al. 1987). The short stature in 
ACFD  is  usually  of  postnatal  onset  and  of 
variable  degree.  Only 5 affected individuals 
have  been  reported  so  far  with  heights 
ranging from 2.3 to 8.6 standard deviations 
below the mean (Paper 1: Hellemans et al. 
2003; Mortier et al. 2003). Shortening of the 
limbs  is  most  pronounced  in  the  acromelic 
segments (brachydactyly).  Affected subjects 
do  not  exhibit  associated  congenital 
anomalies and are of normal intelligence. The 
head  circumference  is  usually  above  the 
mean  and  severe  cases  show  genu  vara. 
Narrow thorax with a pectus deformity  can 
be  observed.  The  diagnosis  relies  on  the 
recognition  of  the  typical  radiographic 
abnormalities  in  the  hands  and  hips  that 
usually  disappear  in  late  childhood.  In  the 
hands,  cone-shaped  epiphyses  become 
apparent at an early age (around 2 years of 
age) and are mainly observed in the middle 
phalanges,  the  distal  phalanges  and  all 
tubular  bones  of  the  thumb (Fig.  22-2  A). 
They  can  also  be  present  in  the  proximal 
phalanges and metacarpals.  The process of 
coning  is  followed  by  a  complete 
epimetaphyseal fusion, the moment at which 
the  cone-shaped  epiphysis  disappears  and 
the  growth  plate  closes.  The  onset  of  this 
closure depends on the bone involved but is 
usually observed before the age of 10 years 
in case of the distal and middle phalanges. 
In  the  hips  a  similar  process  takes  place. 
Around  the  age  of  2  years  the  proximal 
femoral epiphysis starts to develop a small, 
thorn-like outgrowth pointing to the centre of 
the femoral neck, resembling a tear drop and 
to some extent reminiscent of a cone-shaped 
epiphysis (Fig. 22-2 B). This is followed by a 
premature  epimetaphyseal  fusion  of  the 
proximal femoral growth plate resulting in an 
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Fig. 22-2 Anteroposterior radiographs of hands and hips in acrocapitofemoral 
dysplasia.  (A) Image of the left hand at the age of 3y5m showing cone shaped 
epiphyses in all phalanges and metacarpals except for the proximal phalanx of 
digits III and IV.  (B) Image of the hips at the age of 22 months.  The proximal 
femoral epiphysis starts to develop a small, thorn-like, outgrowth pointing to the 
centre of the femoral neck, resembling a tear drop (most visible on the right side). 
(C) Image of the hips at the age of 3y8m showing premature epimetaphyseal fusion 
of the proximal femoral growth plate.  (D) Image of the hips at the age of 9y3m 
showing the abnormally shaped femoral head and hypoplastic femoral neck.
abnormal  (egg-shaped)  femoral  head 
attached to a very short femoral  neck (Fig. 
22-2 C and D). Cone-shaped epiphyses can 
also be observed in the shoulders, knees and 
ankles  but  are  less  characteristic  and  not 
always  present.  Because  the  most 
distinguishing  and  constant  radiographic 
anomalies  were  observed  in  the  hands 
(“acra”)  and  the  hips  (capital  femoral 
epiphyses),  this  skeletal  dysplasia  was 
named acrocapitofemoral dysplasia.
The brachydactylies are a group of heritable 
skeletal  disorders  mainly  affecting  the 
tubular  bones  of  the  hands.   They  were 
initially classified in 5 different classes (A-E), 
with  3  subtypes  (A1-A3)  in  the  first  class 
(Bell 1951).  Brachydactyly type A1 (BDA1), 
also  known  as  the  Farabee-subtype 
brachydactyly,  is  mainly  characterized  by 
short  middle  phalanges  of  most  digits  and 
short  proximal  phalanx  of  the  thumb  (Fig. 
22-3). In severe cases the middle phalanges 
may  be  absent  and  shortening  of  the 
metacarpals  can  also  be  present.  BDA1 
shows  autosomal  dominant  inheritance. 
Affected individuals are usually shorter than 
their  unaffected  relatives  (Armour  et  al. 
2000).  BDA1 is characterized by significant 
inter- and intra-familial phenotypic variability 
(McCready et al. 2005).
Mutations in Indian Hedgehog 
are the cause of 
acrocapitofemoral dysplasia and 
brachydactyly type A1
To unravel the genetic defect causing BDA1, 
a genome wide linkage study was performed 
in two large Chinese families.  This allowed 
mapping of  the disease gene to an 8.1 cM 
interval on chromosome 2q35-q36 (Yang et 
al.  2000).   After  having  excluded  the 
possibility  of  disease-causing  mutations  in 
the PAX3 gene, the investigators elected to 
sequence  IHH,  a  second  candidate  gene 
residing in the linkage interval.  They were 
successful  in  identifying  different 
heterozygous  IHH missense  mutations: 
c.283G>A  (p.Glu95Lys),  c.300C>A 
(p.Asp100Glu) and c.391G>A (p.Glu131Lys) 
in three unrelated families (Gao et al. 2001). 
Subsequently,  these  mutations  were  also 
found in other unrelated patients with BDA1 
confirming  that  heterozygous  missense 
mutations in IHH can cause BDA1 (McCready 
et al. 2002; Giordano et al. 2003; Kirkpatrick 
et  al.  2003;  McCready  et  al.  2005). 
Interestingly, McCready et al showed that a 
founder  mutation  was  responsible  for  the 
BDA1 phenotype in the original Farabee and 
Drinkwater families (McCready et al. 2005). 
The  same  c.298G>A  mutation  was  also 
identified in an Italian kindred and in families 
from the USA and New Zealand (Giordano et 
al.  2003;  McCready  et  al.  2005).   These 
studies  did  also  reveal  evidence  for  locus 
heterogeneity in BDA1.  This was confirmed 
by  the  identification  of  a  balanced 
translocation  between  chromosome  5 
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Fig. 22-3 Radiograph of both hands in an 
individual with brachydactyly type A1 caused by 
the p.Arg128Glu IHH mutation.  Note the short 
middle phalanges of digits II to V and short 
metacarpal of digit I.
Disease Mutation Reference
ACFD c.137C>T; p.Pro46Leu Hellemans et al. 2003
BDA1 c.283G>A; p.Glu95Lys Gao et al. 2001
BDA1 c.284A>G; p.Glu95Gly Kirkpatrick et al. 2003
BDA1 c.298G>A; p.Asp100Asn McCready et al. 2002; Giordano et al. 2003; McCready et al. 2005
BDA1 c.300C>A; p.Asp100Glu Gao et al. 2001
BDA1 c.383G>A; p.Arg128Glu Unpublished results
BDA1 c.391G>A; p.Glu131Lys Gao et al. 2001
ACFD c.569T>C; p.Val190Ala Hellemans et al. 2003
Table 1 Overview of IHH mutations in BDA1 and ACFD
(5q11.2) and chromosome 17 (17q23) in a 
girl with the Klippel-Feil anomaly and BDA1 
(Fukushima et  al.  1995)  and a  subsequent 
linkage study showing strong evidence for a 
second BDA1 locus on chromosome 5.  The 
identified  linkage  interval  on  5p13.2-p13.3 
was however not located in the neighborhood 
of  the  5q11.2  breakpoint  (Armour  et  al.  
2000).  Finally, exclusion of linkage to both 
IHH and  the  locus  on  chromosome  5  in 
another  family  with  BDA1  suggests  the 
existence  of  even  a  third  BDA1  locus 
(Kirkpatrick et al. 2003).
The  genetic  basis  of  ACFD  was  unraveled 
after a genome wide homozygosity mapping 
study  in  the  two  large  consanguineous 
families  in  whom  the  disorder  was  initially 
delineated (Paper 1: Hellemans et al. 2003). 
Linkage analysis revealed a 5 cM candidate 
region on chromosome 2q35-q36 with a high 
LOD-score of 8.02 and without evidence for a 
common  haplotype  between  both  families. 
Sequence  analysis  of  the  most  appealing 
candidate  gene  IHH in  the  linkage  interval 
resulted  in  the  identification  of  a  disease-
causing  mutation in  both families.  The two 
affected  individuals  in  the  Belgian  family 
were  homozygous  for  a  c.137C>T 
(p.Pro47Leu)  mutation  whereas  the  three 
affected individuals in the Dutch family were 
homozygous  for  a  c.569T>C  (p.Val190Ala) 
mutation.  Both  missense  mutations  are 
located in the N-terminal signaling domain of 
IHH  and  substitute  a  strongly  conserved 
amino acid  residue (Paper  1:  Hellemans et 
al.  2003).   Since  this  observation,  no 
additional ACFD patients have been reported 
to our knowledge.
Establishing the diagnosis
The diagnosis of both BDA1 and ACFD mainly 
relies  on  a  clinical  examination  and 
radiographic  evaluation,  and  can  be 
confirmed  by  mutation  analysis  of  the  IHH 
gene.  Patients  with  BDA1  mainly  show 
brachydactyly but can also be relatively short 
in  comparison  with  their  unaffected  first 
degree  relatives.  Radiographic  evaluation  is 
necessary  to  confirm  the  diagnosis  and  to 
distinguish  it  from  the  other  forms  of 
brachydactyly (Spranger et al. 2002). Short 
middle  phalanges  can  be  seen  in  many 
conditions but the presence of other clinical 
findings help to distinguish them from BDA1.
The diagnosis of ACFD should be considered 
in every patient  with disproportionate short 
stature  and  brachydactyly.  The  hands  are 
usually short with typically broad and small 
finger  nails.  Other  clinical  signs  that  favor 
this  diagnosis  are  a  relatively  large  head, 
narrow  thorax,  lumbar  lordosis  and  genu 
vara. Affected individuals do not have other 
congenital  anomalies  and  are  of  normal 
intelligence. The diagnosis can be confirmed 
when  radiographs  reveal  cone-shaped 
epiphyses  in  hands  (mainly  involving  the 
middle  and distal  phalanges)  in  association 
with an early closure of the proximal femoral 
physis.  The diagnosis  can be difficult  in an 
older child when the typical changes in hands 
and hips  have disappeared after  closure  of 
the  growth  plate.  Review  of  radiographs 
taken at an earlier age may be important in 
these  instances.  The  differential  diagnosis 
mainly  include  other  bone  dysplasias  with 
cone-shaped epiphyses (Mortier et al. 2003). 
However  the  association  of  cone-shaped 
epiphyses  in  the  hands  with  premature 
epimetaphyseal  fusion  of  the  proximal 
femoral  physis  is  to  our  knowledge  quite 
specific,  if  not  pathognomonic,  for  this 
disorder. ACFD should also not be confused 
with  hypochondroplasia.  In  both  conditions 
brachydactyly  and  short  femoral  necks  can 
be present. However, cone-shaped epiphyses 
are not observed in hypochondroplasia and in 
addition, normal shape of the femoral heads, 
interpedicular narrowing in the lumbar spine 
and  short  vertebral  pedicles  are  important 
findings  in  hypochondroplasia  that  are  not 
present in ACFD.
Treatment, management and 
counseling
BDA1  is  a  benign  condition  with  good 
prognosis that usually does not require any 
specific  treatment.  The  condition  shows 
autosomal  dominant  inheritance.  Affected 
individuals have a 50% chance of passing on 
the  abnormal  gene  to  their  offspring. 
Prenatal diagnosis is not indicated.
ACFD is a more generalized skeletal dysplasia 
affecting  linear  growth  and  resulting  in  a 
disproportionate  short  stature.  Since  the 
condition  has  only  been  described  in  5 
patients, not much data are available on the 
final adult height. One patient (patient 4 in 
Mortier  et  al.  2003)  has  already  reached 
adult  age  and  measures  114  cm.  The  two 
Belgian patients are now both 15 years age 
old and measure respectively 137.2 cm (girl) 
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and 147 cm (boy). Both children have been 
treated with LHRH analogs with the aim to 
delay the onset of puberty (and in this way 
postpone the  closure  of  the normal  growth 
plates allowing maximal growth). The effect 
of  this  treatment  on  growth  is  currently 
under  investigation.  ACFD  is  an  autosomal 
recessive  disorder.  The risk for  an affected 
child  when  both  parents  are  carrier  of  the 
mutated gene, is  25% for each pregnancy. 
Prenatal  diagnosis  is  only  possible  after 
identification of the genetic defect.
Animal models
The  effect  of  IHH  on  endochondral 
ossification has been examined in a number 
of animal models.  In experiments conducted 
by Vortkamp et al. viral vectors were used to 
misexpress IHH during cartilage formation in 
chicken embryos.  Using this model, IHH was 
shown to  regulate  the  rate  of  hypertrophic 
differentiation  of  chondrocytes  through  a 
negative  feedback  loop  involving  PTHLH 
produced  in  the  periarticular  perichondrium 
(Vortkamp  et  al.  1996).   The  first  mouse 
model,  an  Ihh  null  mouse  (Ihh-/-),  was 
created  in  1999  (St-Jacques  et  al.  1999). 
Almost  half  of  the  Ihh-/- embryos  died 
between  10.5  and  12.5  days  postcoitum. 
Most  of  the  remaining  Ihh-/- embryos 
developed to term but died at birth due to 
respiratory  failure.  At  birth  the  mutant 
animals  showed  short-limb  dwarfism.  Both 
the  axial  and  appendicular  skeleton  was 
affected with short ribs and short, somewhat 
misshapen  limb  bones.  Not  all  joints  were 
formed properly.  There  was  failure  of  digit 
segmentation  and  also  fusion  of  carpal 
bones. Endochondral ossification was clearly 
more  affected  than  intramembranous 
ossification. Striking was also the absence of 
bone formation in the mutant mice. Studies 
on these mice supported the existence of an 
IHH  feedback  loop  controlling  chondrocyte 
differentiation,  and  also  illustrated  the 
requirement  of  IHH for  normal  chondrocyte 
proliferation and osteoblast development (St-
Jacques  et  al.  1999).   The  short-limb 
dwarfism  observed  in  the  Ihh-/- mice  was 
more  severe  than  that  of  PTHLH  mutants, 
suggesting  that  IHH  also  regulates  growth 
independent  of  the  PTHLH-related  pathway 
(Karaplis  et  al.  1994;  St-Jacques  et  al.  
1999).
Various  combinations  of  Ihh-/-,  Pthlh-/- and 
constitutively  active  Pthr1  mouse  mutants 
have  been  created  to  investigate  the 
interactions between IHH and PTHLH.  These 
studies  suggest  that  the  molecular 
mechanisms  that  inhibit  chondrocyte 
hypertrophic differentiation are different from 
those  stimulating  chondrocyte  proliferation 
(Karp  et  al.  2000).   IHH  also  seems  to 
determine the site  of  bone collar  formation 
(Chung et al. 2001).  The experiments with 
Ihh knock-out mice were refined by creating 
conditional  Ihh-/- mice  that  lack  Ihh 
specifically  in  cartilage  (Col2a1  expressing 
cells).   The  phenotype  of  these  mice  was 
similar to that reported for the conventional 
Ihh knock-out mice, but with lesser severity. 
Mutant  animals  contained  no  cortical  or 
trabecular  bone  and  had  a  disorganized 
growth plate (Razzaque et al. 2005).
Although a number of model organisms have 
been used to investigate the effect of IHH on 
endochondral ossification, animal models for 
BDA1 or ACFD have not yet been created.
From mutation to phenotype
For several genes that play a role in skeletal 
development,  it  has  now  been  shown  that 
heterozygous mutations cause some form of 
brachydactyly  whereas  homozygous  or 
compound  heterozygous  mutations  in  the 
same gene cause a more generalized skeletal 
dysplasia affecting more than just the short 
tubular  bones  of  the  hands.  Heterozygous 
mutations  in  ROR2,  a  cell  surface  receptor 
tyrosine kinase, cause brachydactyly type B 
whereas homozygous mutations in the same 
gene result in the recessive form of Robinow 
syndrome, a condition characterized by short 
stature with acromesomelic shortening of the 
limbs,  dysmorphic  face  and  vertebral 
segmentation  defects  (Afzal  et  al.  2000; 
Schwabe et  al.  2000;  van Bokhoven et  al. 
2000). A second example involves the GDF5 
gene,  coding  for  the  growth/differentiation 
factor  5  that  belongs  to  the  TGF-beta 
superfamily of growth factors. Heterozygous 
mutations  in  GDF5  have  been  identified  in 
patients  with  brachydactyly  C  or 
brachydactyly  A2 (Polinkovsky  et  al.  1997; 
Seemann et al. 2005). Recessive mutations 
in  GDF5 can cause a more severe disorder 
such  as  the  Hunter-Thompson  and  Grebe 
types  of  acromesomelic  chondrodysplasia 
and Du Pan syndrome (Thomas et al. 1996; 
Thomas et al. 1997; Faiyaz-Ul-Haque et al. 
2002). The same observation holds for  IHH, 
where  heterozygous  mutations  cause  BDA1 
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and  homozygous  mutations  ACFD. 
Interestingly,  the  heterozygous  parents  of 
the ACFD patients do not show signs of BDA1 
(Paper 1: Hellemans et al. 2003). A similar 
situation  where  heterozygotes  of  the 
recessive  mutations  do  not  exhibit  the 
dominant phenotype has been observed for 
the ROR2 gene (Afzal et al. 2000).
Both BDA1 and ACFD mutations are missense 
mutations  that  replace  conserved  amino 
acids in the amino-terminal signaling domain 
of the protein. They are located in domains 
where  disease-causing  mutations  in  other 
Hedgehog  proteins  have  been  identified. 
When plotted on a tertiary structure of  the 
protein,  both  BDA1  and  ACFD  mutations 
seem to cluster on different sides of this part 
of  the  protein  (Paper  1:  Hellemans  et  al.  
2003).  These  data  suggest  that  the  ACFD 
and BDA1 mutations must  have a different 
effect  on  the  normal  function  of  the  IHH 
protein. Experiments in mice have indicated 
that  homozygous  loss  of  Ihh  results  in 
embryonic  or  neonatal  lethality  with  even 
absence of bone formation.  The phenotype 
of  these  Ihh  knock-out  mice  is  far  more 
severe than that seen in the human recessive 
counterpart, ACFD, suggesting that the ACFD 
mutations  most  likely  do  not  result  in  a 
complete loss of function of the IHH protein.
It  has  been  clearly  demonstrated  that  IHH 
plays  a  key  role  during  endochondral 
ossification in the growth plate.  It stimulates 
chondrocyte  proliferation  and  inhibits, 
through  the  action  of  PTHLH,  the  rate  of 
chondrocyte  differentiation.   It  is  therefore 
not  surprising  that  mutations  in  IHH can 
result  in  a  growth  plate  disorder  with 
shortening of the affected bones. The cone-
shaped epiphyses observed in ACFD patients 
may  represent  the  radiographic  sign  of  a 
disturbed  balance  between  chondrocyte 
proliferation and differentiation in the growth 
plate due to abnormal, probably reduced IHH 
signaling. To test this hypothesis, functional 
studies  addressing the effect  of  the human 
IHH mutations  on  skeletal  patterning, 
endochondral  ossification  and  growth  plate 
maintenance will be necessary.
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Inborn errors of development (2nd ed), Chapter 39
Role of LEMD3 in skeletal development and dysplasias
Osteopoikilosis,  the  Buschke-Ollendorff 
syndrome (BOS) and melorheostosis are rare 
sclerosing bone dysplasias that can co-occur 
within the same family.  Osteopoikilosis and 
BOS  are  benign  disorders  with  autosomal 
dominant  inheritance,  whereas 
melorheostosis is usually an isolated anomaly 
with symptoms like contractures, stiffness or 
chronic  pain.   These  dysplasias  can  be 
caused by loss of function mutations in the 
LEMD3 gene which encodes a protein of the 
inner  nuclear  membrane.  It  interacts  with 
receptor  activated  SMADs,  leading  to  a 
suppression  of  SMAD  mediated  BMP  and 
TGFβ signaling.  Loss of suppression of these 
signaling  pathways  is  suspected  to  be 
responsible  for  the  sclerosis  observed  in 
these disorders.
This  overview  has  been  submitted  as  a 
chapter  in  Inborn  Errors  of  Development, 
Chapter  39:  LEMD3  in  osteopoikilosis,  the 
Buschke-Ollendorff  syndrome  and 
melorheostosis.
LEMD3: an inner nuclear 
membrane protein inhibiting the 
BMP and TGFβ signaling 
pathways
LEMD3  is  an  integral  protein  of  the  inner 
nuclear membrane and has a molecular mass 
of  about  100  kDa.  It  is  composed  of  a 
nucleoplasmic  N-terminal  domain,  a  first 
transmembrane segment,  a  luminal  loop,  a 
second  transmembrane  segment  and  a 
nucleoplasmic  C-terminal  domain  (Fig.  39-
1)(Lin  et  al.  2000).  LEMD3 was  previously 
known as MAN1. It was initially identified as 
a  nuclear  envelope  protein  recognized  by 
autoantibodies from a patient (MAN refers to 
the initials of this patient) with an ill-defined 
collagen  vascular  disease  (Paulin-Levasseur 
et  al.  1996).  To  avoid  confusion  with  the 
abbreviations  of  the  different  mannosidase 
enzymes,  MAN1  was  recently  renamed  as 
LEMD3 (LEM domain containing 3), herewith 
referring to the LEM domain in the N-terminal 
portion of the protein. The LEM domain is a 
conserved globular motif of approximately 40 
amino  acids  found  in  several  inner  nuclear 
membrane  and  nucleoplasmic  proteins. 
“LEM” refers  to the three proteins in which 
the domain was initially characterized: LAP2, 
emerin and MAN1.
A subtractive proteomics study suggests that 
there are approximately 80 integral proteins 
of  the  inner  nuclear  membrane,  many  of 
which have been shown to  bind to  lamins, 
chromatin components or both. LEMD3 is no 
exception.  Like  all  LEM-domain  containing 
proteins tested, it binds directly to A- or B-
type  lamins  and  the  barrier-to-
autointegration factor (BAF) (Gruenbaum et 
al. 2005).  Binding to lamin A and lamin B1 is 
mediated  by  the  N-terminal  domain  of 
LEMD3 and is at least partially responsible for 
retainment  of  LEMD3  in  the  inner  nuclear 
membrane  (Fig.  39-2)  (Wu  et  al.  2002; 
Ostlund et al. 2006).  The importance of this 
interaction has been demonstrated for the C. 
elegans homologue of LEMD3, Ce-MAN1 that 
is undetectable at the nuclear envelope when 
lmn-1  expression  is  reduced  (Liu  et  al.  
2003).   The  N-terminal  domain  has  been 
found to interact with emerin as well.
Structural  analysis  of  the C-terminal  region 
of LEMD3 revealed the presence of a winged 
helix  motif,  required  for  DNA  binding  and 
located  outside  the  previously  delineated 
RNA recognition motif (RRM) (Caputo et al. 
2006).  An MH2 binding domain, responsible 
for  SMAD  interaction,  is  located  between 
both motifs (Fig. 39-1). This shows that the 
regions involved in DNA binding and SMAD 
interaction  are  essentially  different, 
suggesting that LEMD3 binds simultaneously 
to  R-SMADs  and  their  targeted  DNA 
sequences  (Caputo  et  al.  2006).   The  C-
terminal  domain  of  LEMD3  binds  to  the 
transcriptional regulator germ cell-less (GCL) 
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Fig. 39-1 Structure of the LEMD3 protein, with TM 
indicating the transmembrane domains
and  BAF,  a  protein  that  can  form  bridges 
between  the  LEM-domain  proteins  and  the 
chromatin (Mansharamani and Wilson 2005) 
(Fig. 39-2).
In C. elegans, Ce-MAN1 and Ce-emerin have 
overlapping  functions  in  chromosome 
segregation  and  cell  division  (Liu  et  al. 
2003).  In  addition,  the  Xenopus ortholog 
XMAN1  has  been  shown  to  play  a  role  in 
bone morphogenetic protein (BMP) signaling 
(Osada et al. 2003; Raju et al. 2003). In a 
functional  screening  for  neuralizing  factors, 
Osada  et  al.  identified  XMAN1 as  a  Smad-
interacting  protein  regulating  neural 
development by antagonizing BMP signaling. 
Using deletion mutant analysis, they showed 
that  the  BMP-antagonizing  activities  were 
located  in  the  C-terminal  portion  of  the 
protein  and  that  this  domain  strongly 
associated  with  BMP  responsive  Smads 
(Smad1,  Smad5  and  Smad8),  weakly  with 
the transforming growth factor beta (TGFβ) 
responsive Smads (Smad2 and Smad3) but 
not with the common mediator Smad4 or the 
inhibitory  Smads  (Smad6  and  Smad7) 
(Osada  et  al.  2003).  Using  a  yeast-two 
hybrid  screening  for  Smad1  interaction 
partners, Raju et al. identified SANE (Smad1 
antagonistic effector) as a novel protein with 
significant  sequence  similarity  to  nuclear 
envelop proteins. SANE is identical to XMAN1 
and  shows  55% overall  identity  to  human 
LEMD3, with greater similarity (up to 85%) in 
the  C-terminal  part.  Except  for  the  LEM 
domain,  much of  the N-terminal  domain of 
LEMD3  diverges  significantly  from  the 
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Fig. 39-2 Schematic presentation of SMAD mediated BMP and 
TGFβ signal transduction, and LEMD3 interaction partners in 
the nucleus.  “P” indicates phosphorylation of receptors or R-
SMADs.  The arrows at the bottom of the picture represent 
transcription of BMP and TGFβ target genes.
corresponding  region  of  SANE  or  XMAN1. 
Raju  et  al.  showed  that  SANE  co-
immunoprecipitates with Smad1 and strongly 
interacts  with  the  BMP-specific  Smads  but 
only  weakly  with  TGFβ-specific  Smads.   In 
addition,  the  BMP-specific  type  I  receptors 
(ALK3  and  ALK6)  strongly  associated  with 
SANE,  but  interaction  with  ALK2  and  ALK4 
was barely detectable.  BMP type I receptor 
interaction  was  mediated  through  the  N-
terminal  domain,  while  the  C-terminal 
domain  was  required  for  Smad1  binding. 
SANE  specifically  reduced  Smad-mediated 
BMP signaling but did not disrupt activin or 
TGFβ  signaling.   Inhibition  appeared  to  be 
mediated  by  reducing  BMP-induced  Smad 
phosphorylation and nuclear translocation in 
a dose dependent manner (Raju et al. 2003).
In contrast to its  Xenopus ortholog, human 
LEMD3 interacts  with  all  receptor  activated 
SMAD proteins (R-SMADs) (Fig. 39-2).  This 
interaction  is  mediated  by  the  C-terminal 
domain of LEMD3 and the MH2 domain of the 
R-SMADs  and  is  independent  of  the  SMAD 
phosphorylation  status.   LEMD3  does  not 
affect the expression or stability of R-SMADs, 
but  reduces  the  amount  of  phosphorylated 
SMADs  in  the  nucleus  and  blocks  hetero-
oligomerization  of  R-SMADs  with  SMAD4. 
Through  its  interaction  with  the  R-SMADs, 
LEMD3 acts as a specific repressor of TGFβ, 
activin  and  BMP  signaling  (Paper  2: 
Hellemans  et  al.  2004;  Pan  et  al.  2005). 
Decreasing  LEMD3 expression  results  in  an 
increase in transcriptional activation of TGFβ, 
activin  or  BMP  responsive  promotors.  The 
expression  level  of  LEMD3  appears  to  be 
important  for  cell  survival  since  both 
overexpression  and  attempts  to  reduce 
LEMD3 expression with antisense constructs 
result in cell death (Pan et al. 2005).
Osteopoikilosis, the Buschke-
Ollendorff syndrome and 
melorheostosis
Osteopoikilosis  (MIM  #166700),  Buschke-
Ollendorff  syndrome  (BOS,  MIM  #166700) 
and melorheostosis (MIM #155950) are rare 
sclerosing bone dysplasias that can co-occur 
within the same family.   The Nosology and 
Classification  of  Genetic  Skeletal  Disorders 
(2006 revision) has classified these disorders 
in  group  22  (increased  density  group, 
without  modification  of  bone  shape) 
(Superti-Furga  2007).   Osteopoikilosis  is  a 
benign  condition  with  autosomal  dominant 
inheritance and an estimated prevalence of 
1/20,000.   The  first  patient  found  to  have 
this disorder was described by the German 
surgeon Alfred Stieda in 1905 (Stieda 1905), 
but the term “osteopoikilie” (spotted bones) 
was not used until 1916 (Ledoux-Rebard et 
al.  1916).   Osteopoikilosis  is  characterized 
radiographically by a symmetric but unequal 
distribution of  multiple,  small  and round to 
oval hyperostotic lesions in different parts of 
the skeleton (Fig. 39-3A).  The number can 
vary  from a  few to  many lesions  involving 
nearly all bones.  This variable expression is 
not only observed between families but also 
within  the  same  family.   In  a  study  of  4 
families  including  53  affected  individuals, 
Benli et al. noted that the lesions are most 
common  in  the  epimetaphyseal  regions  of 
the long tubular bones and that their number 
and  bone  density  may  increase  with  age 
(Benli  et  al.  1992). Lesions are usually not 
found in the diaphysis of the tubular bones. 
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Occurrence of sclerotic lesions
(based on 53 patients in 4 families)
Hand phalanges 100%
Carpals 97.4%
Metacarpals 92.3%
Foot phalanges 87.2%
Metatarsals 84.4%
Tarsals 84.6%
Pelvis 74.4%
Femur 74.4%
Radius 66.7%
Ulna 66.7%
Sacrum 58.9%
Humerus 28.2%
Tibia 20.5%
Fibula 12.8%
General characteristics
Bilateral occurrence of lesions 94.8%
# foci per bone 1 - 1000
Size 1x1 mm – 12x16 mm
Shape Linear, ellipsoid or 
bullet shaped
Lesions are most common in the metaphyses of the 
long tubular bones
Number and radiodensity of lesions increased with age
Table 1 Distribution of bone lesions in 
osteopoikilosis patients (adapted from Benli et al. 
1992)
The  size  and  number  of  lesions  per  bone 
ranged from 1x1 mm to 12x16 mm and from 
1  to  1000,  respectively.   The  hyperostotic 
lesions  are  most  commonly  found  in  the 
bones  of  hands  and  feet  with  the  largest 
number usually detected in the pelvis (table 
1).   The  axial  skeleton  (skull,  ribs  and 
vertebrae) is rarely affected.
The  lesions  usually  become more  apparent 
during childhood but osteopoikilosis has been 
observed in neonates and even in a 4-month-
old  fetus  (Green  et  al.  1962).  Affected 
individuals  are  by  definition  asymptomatic. 
The lesions do not affect the structure and 
function  of  the  bone.  There  is  no 
predisposition  to  fractures.  Histopathologic 
studies show that the osteopoikilosis lesions 
are  foci  of  numerous  bone  trabeculae  that 
are  slightly  thicker  than  normal  but  still 
resemble the structure of spongy bone. They 
merge  into  the  surrounding  structures 
gradually,  disappearing  among  those  of 
normal  spongiosa.  The  thicker  trabeculae 
consist  of  lamellar  bone  with  a  parallel 
arrangement for the most part, but in a few 
instances  they  are  arranged  concentrically 
around blood vessels (Schmorl 1931).
Osteopoikilosis  has  been  associated  with 
various  other  anomalies,  usually  in  single 
case reports,  suggesting coincidental  rather 
than causal relationships (Green et al. 1962; 
Mindell et al. 1978; Weisz 1982; Ayling and 
Evans 1988; Gunal  et al.  1993; Gunal and 
Kiter 2003).  However, there is at least one 
well-defined  association,  the  Buschke-
Ollendorff  syndrome  (BOS),  that  is 
characterized  by  osteopoikilosis  and 
connective tissue nevi.  In 1928 Buschke and 
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Fig. 39-3 (A) Anteroposterior radiograph of the knee showing multiple osteopoikilosis lesions in the distal  
portion of the femur and the proximal portion of the tibia. A few lesions are also present in the fibular 
head. (B) Joint contractures of the middle finger in a female patient with melorheostosis. (C) 
Anteroposterior radiograph of the left lower leg in a patient with melorheostosis (patient with p.Val759fs 
mutation listed in table 2). An extensive melorheostosis lesion, resembling dripping candle grease, is 
present along the diaphysis of the fibula. A few osteopoikilosis lesions are also visible in the distal portion 
of the tibia. (D) Radiograph of both forearms in a patient with melorheostosis. The affected left forearm 
is shown on the right side of the picture. The right forearm (shown on the left) is normal. The 
melorheostosis lesions in the left forearm start at the base of the third and fourth metacarpals (shown at 
bottom of figure), extend over the carpal bones towards the ulna and finally cross the elbow joint 
towards the distal portion of the humerus.
Ollendorff  described  dermatofibrosis 
lenticularis  disseminata  as  the  skin 
manifestation of osteopoikilosis (Buschke and 
Ollendorff 1928).  The cutaneous lesions may 
be  present  at  birth  or  appear  later  in 
childhood or even adulthood (Morrison et al. 
1977). They are connective tissue nevi and 
appear  as  either  numerous,  widely 
disseminated,  skin-colored  to  yellow  small 
papules or more localized and asymmetrically 
distributed  larger  lesions  known  as  yellow 
plaques.  Histological  studies  of  these  skin 
lesions show variable degrees of connective 
tissue  abnormalities  affecting  the  collagen 
bundles  and  elastic  fibers.  The  collagen 
bundles  can  be  thickened  or  normal,   the 
elastic  fibers  can  be  increased,  broad  and 
interlacing,  diminished,  fragmented  or 
normal.   This  variability  has  been  seen  in 
patients  within  a  family  and  even  between 
different lesions in the same patient (Schorr 
et al. 1972).  Calcification is not observed in 
the BOS skin lesions,  distinguishing it  from 
pseudoxanthoma elasticum.
In  1922,  the  French  physicians,  Léri  and 
Joanny,  described  the  first  case  of 
melorheostosis  (Léri  and  Joanny  1922). 
They used the term “melorheostosis” for this 
sclerosing bone disorder because the cortical 
hyperostosis  of  affected  bones  resembles 
dripping candle grease (“melo” and “rhe(o)” 
are  referring  to  Greek  words  for  limb  and 
flow respectively) (Fig. 39-3C). In contrast to 
osteopoikilosis,  the  hyperostotic  lesions  in 
melorheostosis  usually  affect  the  diaphysis 
(cortex)  of  the  tubular  bones.  There  is  a 
tendency for monomelic distribution but also 
different, usually contiguous bones from the 
same  sclerotome,  can  be  affected.  The 
lesions have a linear pattern and can cross 
joints when involving neighboring bones (Fig. 
39-3D). The linear hyperostosis of the cortex 
can  extend  internally  into  the  medullary 
canal  or  externally  with  periosteal 
involvement  resulting  in  the  characteristic 
wavy outline of the affected bone. In some 
patients  with  melorheostosis  spotty  lesions 
reminiscent  of  osteopoikilosis  can  be 
observed  in  the  epiphyses  of  the  affected 
long bones (Green et al. 1962).  Small bone 
deposits in the surrounding soft tissues have 
also  been  reported  (Campbell  et  al.  1968; 
Greenspan 1991).  The hyperostosis is often 
accompanied  by  hyperplasia  and 
abnormalities  of  the  adjacent  connective 
tissues  (e.g.  scleroderma-like  lesions  or 
fibrosis) (Happle 2004).  Melorheostosis may 
be  asymptomatic  but  often  causes  joint 
contractures (Fig. 39-3B), stiffness or chronic 
pain.  Severe cases may even present with 
shortening  of  the  affected  bones. 
Histological examination reveals hyperostotic 
cortical  bone  formation  with  thickened 
trabeculae  and  fibrotic  changes  in  the 
marrow spaces.  The bone appears primitive 
and  consists  largely  of  primary  haversian 
systems that  are  almost  obliterated by the 
deposition  of  sclerotic,  thickened  and 
somewhat irregular lamellae (Greenspan and 
Azouz 1999).
Whereas  osteopoikilosis  and  BOS  are 
autosomal  dominant  conditions, 
melorheostosis  is  predominantly  a  sporadic 
disorder.  However,  individuals  with 
melorheostosis  have  been  observed  in 
families  with  osteopoikilosis  (Butkus  et  al. 
1997; Nevin et al. 1999; Debeer et al. 2003). 
We are aware of at least one family with two 
affected  cousins  with  melorheostosis.  Also, 
sporadic  patients  with  melorheostosis  in 
association  with  osteopoikilosis  and 
osteopathia  striata  have  been  described 
(Ghai and Sharma 2003).
Heterozygous LEMD3 mutations 
can cause osteopoikilosis, the 
Buschke-Ollendorff syndrome 
and melorheostosis
Using  a  genome  wide  linkage  analysis  and 
subsequent candidate gene approach in three 
families  with  the  variable  co-occurrence  of 
osteopoikilosis, BOS and melorheostosis, we 
were  able  to  identify  LEMD3 as  the  causal 
gene  in  this  group  of  disorders  (Paper  2: 
Hellemans et al. 2004). The LEMD3 gene is 
located on chromosome 12q14, contains 13 
exons and has a size of 4,744 bp. It encodes 
a 911 amino acid protein, LEMD3.
All  LEMD3 mutations  identified  so  far  are 
predicted to result in a loss of function of the 
protein (Paper 3: Hellemans et al. 2006). The 
spectrum  of  LEMD3 mutations  includes 
complete  gene  deletions,  nonsense 
mutations,  frameshift  mutations  and  splice 
site mutations that cause a frameshift with a 
premature stop codon as a consequence. The 
loss-of-function  effect  of  these  mutations 
results from either total deletion of the gene, 
nonsense  mediated  decay  of  the  mutant 
transcripts  or  formation  of  a  truncated 
protein  that  lacks  the  SMAD-interacting  C-
terminal domain (Paper 2: Hellemans et al. 
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2004).  Since all  mutations are predicted to 
result  in  haploinsufficiency  for  LEMD3,  the 
germline mutation alone can not account for 
the phenotypic variability. Other factors such 
as modifying genes, environmental influences 
and  perhaps  (but  yet  unidentified)  somatic 
defects at the other  LEMD3 allele or within 
the  signaling  pathways  must  influence  the 
ultimate phenotype.
Table  2  summarizes  the  genotypic  and 
phenotypic  data in  a  series  of  47 patients. 
The  patients  are  classified  in  4  groups 
depending on the phenotype and the familial 
occurrence of the disorder. Group A consists 
of  three  unrelated  patients  sharing 
osteopoikilosis,  proportionate  short  stature 
and  learning  problems  as  common  clinical 
features.  In  two  of  these  patients  a 
microdeletion of approximately 6 Mb in size 
and  encompassing  the  LEMD3  gene  on 
12q14,  was  identified.  The  third  patient 
reported by Jurenka et al. was not available 
for genetic testing. Group B contains sporadic 
and familial cases with osteopoikilosis and/or 
BOS skin lesions. A germline LEMD3 mutation 
was  identified  in  the  majority  of  these 
patients  (14/17).   In  one  osteopoikilosis 
patient, for whom the diagnosis could not be 
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phenotype nucleotide and residue changes reference
Group A
OPOI, MOS, short stature, MR not tested Jurenka et al. 1995
OPOI, short stature, MR, ectopic kidney microdeletion Hellemans et al. 2004
OPOI, short stature, MR microdeletion Unpublished
Group B
BOS c.2134dupT; p.Met712fs Hellemans et al. 2004
BOS c.1185dupT; p.Gly395fs Hellemans et al. 2004
OPOI c.1033_1035delGGGinsC; p.Gly345fs Hellemans et al. 2004
OPOI c.1921+5delG; exon skip - frameshift Hellemans et al. 2004
OPOI c.457C>T; p.Gln153X Hellemans et al. 2004
OPOI c.1801G>T;  p.Glu601X Hellemans et al. 2006
BOS c.1323C>A;  p.Tyr441X Hellemans et al. 2006
BOS c.1873C>T;  p.Arg625X Hellemans et al. 2006
BOS c.1914dupA;  p.Leu638fs Hellemans et al. 2006
OPOI c.2494-9A>G; splice site Hellemans et al. 2006
BOS c.1873C>T;  p.Arg625X Hellemans et al. 2006
BOS c.2245C>T;p.Gln749X Hellemans et al. 2006
BOS c.1707_1708delTG; p.Pro569fs Unpublished
OPOI c.1813delA; p.Ile605fs Unpublished
OPOI (1 patient) normal Hellemans et al. 2006
BOS (2 patients)* normal Unpublished
Group C
MOS in BOS family c.1609C>T; p.Arg537X Hellemans et al. 2004, 
Debeer et al. 2003
MOS in BOS family c.830dupA;  p.Lys277X Hellemans et al. 2006
MOS in BOS family [c.1963C>T,c.2488C>T];  p.Arg655X Hellemans et al. 2006, 
Butkus et al. 1997
MOS in BOS family c.2275_2278delGTTA ; p.Val759fs Unpublished
Group D
MOS c.1913T>A;  p.Leu638X Hellemans et al. 2006
MOS (22 patients) normal Hellemans et al. 2006
Table 2 Overview of LEMD3 mutations in 4 different patient groups (OPOI: osteopoikilosis, BOS: 
Buschke-Ollendorff syndrome, MOS: melorheostosis)
verified, and in 2 BOS patients, for whom the 
presence  of  bone  lesions  could  not  be 
demonstrated,  no  LEMD3 mutation  was 
found. Group C consists of 4 melorheostosis 
patients  who belong to a family  with other 
relatives affected with osteopoikilosis or BOS. 
Sporadic  patients  with  melorheostosis  are 
classified  in  group  D.  A  germline  LEMD3 
mutation  was  found  in  all  4  patients  from 
group C but in only 1 patient from group D. 
In the latter patient, besides melorheostosis 
also  remote  osteopoikilosis  lesions  were 
visible  on  skeletal  radiographs.  The  co-
occurrence  of  osteopoikilosis  and 
melorheostosis lesions in the same individual 
was also observed in patients from group C. 
On  the  other  hand,  osteopoikilosis  lesions 
were  not  found  in  the  22  patients  with 
normal LEMD3 results from group D (but not 
all  patients  had  an  extensive  radiographic 
evaluation).  The presence of  osteopoikilosis 
lesions  seems  therefore  to  be  a  good 
indicator  for  the  existence  of  a  germline 
LEMD3 mutation.
The cause of the sporadic and isolated form 
of melorheostosis still remains unknown. The 
possibility of somatic mosaicism for a LEMD3 
mutation  has  been  investigated  in  two 
patients  from  group  D  but  no  LEMD3 
mutations  were  found  when  analyzing 
affected  skin  and  bone  samples  (Paper  3: 
Hellemans  et  al.  2006).   In  addition,  a 
second  somatic  mutation  in  LEMD3 as 
explanation for the localized character of the 
skin  lesions  in  BOS  patients,  has  not  yet 
been  identified  (Paper  2:  Hellemans  et  al.  
2004).
The group of acromelic dysplasias contains 2 
conditions  which  share  the  characteristic 
cone-shaped  epiphyses  with 
acrocapitofemoral  dysplasia,  and  for  which 
the causal  genetic  defect  has not yet been 
discovered.   Screening  of  the  IHH gene  in 
two patients with acrodysostosis and in one 
patient  with  Saldino-Mainzer  dysplasia  did, 
however,  not  reveal  the  presence  of  IHH 
mutations (unpublished data).
Establishing the diagnosis
Osteopoikilosis is a benign condition, usually 
found by chance when radiographs are taken 
for  other  purposes.  The  diagnosis  of 
osteopoikilosis  mainly  relies  on  a  careful 
radiographic  evaluation.  In  our  experience, 
the lesions are most commonly found in the 
shoulders, hands, pelvis, knees and feet. The 
lesions  can  be  scarce  at  a  young  age  and 
therefore be missed early on in life.
The diagnosis of BOS requires the presence 
of both osteopoikilosis lesions and connective 
tissue  nevi,  the  latter  preferentially 
confirmed at the histological level after skin 
biopsy.  In  families  with  BOS,  affected 
individuals  can  either  have  both  bone  and 
skin  lesions  or  just  one  of  these 
manifestations.
The  diagnosis  of  melorheostosis  is  usually 
based on clinical evaluation and the finding of 
the characteristic radiographic abnormalities. 
Plain  radiographs  are  usually  sufficient  to 
confirm  the  diagnosis.  Scintigraphy  reveals 
increased tracer uptake in the affected bone 
and soft tissue areas. Computed tomography 
and magnetic  resonance imaging (MRI) are 
usually not needed for  diagnosis.  The bone 
and  soft  tissue  lesions  have  low  signal 
activities  on all  MRI  sequences  (Greenspan 
and Azouz 1999; Judkiewicz et al. 2001).
Management and genetic 
counseling
Osteopoikilosis  and  BOS  are  benign 
conditions that do not require any treatment. 
Both conditions are inherited in an autosomal 
dominant manner. Affected individuals have 
a 50% risk of passing on the mutant allele to 
each  offspring.  Prenatal  diagnosis  is 
theoretically possible when the mutation has 
been  identified  but  usually  not  indicated 
because  of  the  benign  nature  of  both 
disorders.
Melorheostosis is usually a sporadic condition 
with  no  increased  risk  for  the  offspring. 
However,  individuals  with  a  germline 
mutation in LEMD3 have an increased risk to 
develop the disorder. Melorheostosis can be 
asymptomatic  but  often  causes  pain,  joint 
contractures, deformity or even shortening of 
affected  bones.  The  disease  can  be 
progressive  with  periodic  exacerbations. 
There is currently no cure for the disorder. 
Surgery  is  possible  to  correct  bone 
deformities  and  asymmetric  bone  growth. 
However, bone healing after osteotomy can 
be  problematic  in  melorheostosis  patients. 
Soft tissue releases in children have a high 
failure  rate  and  are  often  complicated  by 
abnormal  scar  formation.  Contracture 
releases are more effective in adults and the 
outcome seems to improve with the use of 
rotation  flaps.  Prior  to  surgery,  the 
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application of external fixators spanning the 
contracture  area  should  be  considered  and 
this may even be the sole treatment.  More 
details on these management issues can be 
found on the website of  the Melorheostosis 
Association  (www.melorheostosis.com  – 
guidelines developed by Jeffrey C King, MD 
and James Dobyns,  MD),  a  patient  support 
group located in the USA. A second patient 
support  group  is  based  in  the  United 
Kingdom  (www.melo.eu.com).  Both 
organizations  are  important  resources  for 
both  professionals  and  patients  with 
melorheostosis.
Animal models
The  function  of  LEMD3 orthologs  has  been 
examined in at least two animal models. In 
Xenopus, XMAN1 was found to neuralize the 
ectoderm  and  dorsalize  the  ventral 
mesoderm  by  antagonizing  BMP  signaling. 
Embryos  injected  with  XMAN1  antisense 
morpholino  oligos  gastrulated  normally  but 
the  development  of  the  anterior  structures 
was  severely  reduced  and  the  eyes  were 
absent or poorly formed (Osada et al. 2003). 
Knock-down  experiments  in  C.  elegans 
revealed  that  RNAi  mediated  removal  of 
~90% of  Ce-Man1  was  lethal  to  ~15% of 
embryos.   However  in  the  absence  of  Ce-
emerin,  ~90%  reduction  of  Ce-Man1  was 
lethal  to  all  embryos  by the 100-cell  stage 
(Liu et al. 2003).  A Lemd3 knock-out mouse 
has  been  created  (Baygenomics,  California) 
but no data have yet been reported.
From mutation to phenotype
All  data  so  far  indicate  that  heterozygous 
inactivating germline mutations in LEMD3 can 
cause  osteopoikilosis  and  the  Buschke-
Ollendorff syndrome (Paper 2: Hellemans et 
al.  2004; Paper 3: Hellemans et al.  2006). 
The  presence  of  a  second,  somatic  LEMD3 
mutation as an explanation for the localized 
nature of the bone and skin lesions has not 
yet  been  shown.  The  situation  for 
melorheostosis is more complex. Despite the 
evidence  that  haploinsufficiency  for  LEMD3 
acts  as  a  predisposing  factor  for  the 
development  of  melorheostosis,  the  role  of 
LEMD3 in  the  pathogenesis  of  isolated  and 
sporadic  melorheostosis  is  not  yet  fully 
understood.  The  overwhelming  majority  of 
patients with melorheostosis do not seem to 
harbor  a  germline  mutation  in  LEMD3. 
Somatic mosaicism for a  LEMD3 mutation in 
these patients is a likely hypothesis but has 
not yet been shown when analyzing affected 
skin and/or bone tissues. 
Osteopoikilosis, Buschke-Ollendorff syndrome 
and  melorheostosis  are  characterized  by 
bone  lesions  with  increased  bone  density. 
This  suggests  that  LEMD3  must  play  an 
important role in bone homeostasis. Several 
experiments  have  demonstrated  the 
interaction  of  LEMD3  with  BMP  and  TGFβ 
receptor activated SMADs (R-SMADs).  This 
interaction  leads  to  a  decreased 
phosphorylation  and  nuclear  localization  of 
the  R-SMADs,  and  ultimately  in  a  reduced 
BMP and TGFβ signaling (Paper 2: Hellemans 
et al. 2004; Pan et al. 2005).  Both pathways 
have  been  shown  to  be  very  important  in 
bone homeostasis and the regulation of bone 
mineral density.
In-vitro  and  in-vivo  experiments,  analyzing 
the  effect  of  TGFβ signaling  on  osteoblasts 
and  osteoclasts,  have  revealed  seemingly 
conflicting data suggesting both positive and 
negative  effects  on  bone  formation.   For 
example,  osteoblast  proliferation,  matrix 
deposition and collagen maturity are severely 
diminished in Tgfb1 knock-out mice, whereas 
mice  with  an  increased  Tgfb2  production 
show a dramatic, age-dependent loss of bone 
mass  reminiscent  of  high-turnover 
osteoporosis (Erlebacher and Derynck 1996; 
Geiser et al. 1998).  Strong evidence for a 
positive effect of TGFβ on bone formation in 
humans  comes  from  the  rare  skeletal 
dysplasia,  Camurati-Engelmann  disease 
(CED).   Camurati-Engelmann  disease  or 
progressive  diaphyseal  dysplasia  is  an 
autosomal  dominant  disorder  characterized 
by  a  progressive  cortical  thickening  of  the 
diaphyses of the long bones.  Hyperostosis is 
bilateral and symmetrical, and usually starts 
during  childhood.   A  total  of  10  different 
mutations  in  the  TGFB1  gene  have  been 
found  in  CED  patients,  all  leading  to 
increased  TGFβ  activity  (Janssens  et  al. 
2006).   The  identification  of  activating 
mutations in  TGFB1 in  patients with a CED 
demonstrates that  increased TGFβ signaling 
can lead to hyperostosis.
Similarly,  the  effects  of  BMP  signaling  on 
bone  formation  have  been  studied. 
Reduction of BMP signaling, resulting from a 
dominant-negative  BMP  receptor  (BMPR-IB) 
mutation  in  mice  osteoblasts,  impairs 
postnatal  bone  formation.   Bone  mineral 
density,  bone  volume  and  bone  formation 
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rates in these mutant animals  are severely 
reduced  without  changes  in  osteoblast  and 
osteoclast  numbers  (Zhao  et  al.  2002). 
Transgenic  mice  overexpressing  noggin,  an 
extracellular BMP antagonist, have a reduced 
bone  mineral  density  and  decreased 
trabecular bone volume (Devlin et al. 2003). 
Both  experiments  demonstrate  the  positive 
effect of BMP signaling on bone formation.
In addition to its role in bone homeostasis, 
TGFβ signaling is also important for normal 
fibroblast activity. This may explain the skin 
involvement  in  BOS  and  melorheostosis. 
Patients  with  the  latter  disorder  can  show 
sclerodermatous  skin  lesions.  Interestingly, 
increased TGFβ signaling has been observed 
in fibroblasts from patients with scleroderma, 
an  autoimmune  disorder  characterized  by 
progressive  cutaneous  and  visceral  fibrosis 
(Mori  et  al.  2003;  Asano  et  al.  2004).   A 
reduction in the expression of the inhibitory 
SMAD7  and  upregulation  of  SMAD3 
expression  were  found  in  the  scleroderma 
skin lesions (Dong et al. 2002).  
In conclusion, both BMP and TGFβ signaling 
seem  to  have  a  stimulatory  effect  on 
osteoblast  and  fibroblast  function. 
Upregulation of BMP and TGFβ signaling as a 
consequence  of  LEMD3  haploinsufficiency 
may therefore explain both the skin and bone 
lesions  in  osteopoikilosis,  BOS  and 
melorheostosis patients.
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Chapter 4
qBase framework 
and software for qPCR data analysis
Introduction to qPCR and qBase
1 Introduction to qPCR
History
The  polymerase  chain  reaction  or  PCR 
technique is the technology by which small 
amounts of template DNA can be specifically 
and exponentially amplified in an enzymatic 
reaction.   For  the  invention  of  this 
technology,  Karry  B.  Mullis  received  the 
Nobel Prize in Chemistry in 1993.
At the time of the first demonstration of the 
polymerase chain reaction in 1985, thermo-
labile polymerase needed to be added to the 
reaction in each PCR cycle (Saiki 1985).  The 
usage of thermo-stable polymerases was first 
reported  in  1988,  and  unlocked  the  full 
potential of the PCR technology (Saiki 1988).
Since  amplification  products  of  a  PCR  are 
analyzed after the completion of the reaction, 
classical PCR is called an endpoint detection 
technology.   Endpoint  detection  is  usually 
used for qualitative analysis but is not very 
well suited for quantitative measurements. It 
can  at  best  be  used  semi-quantitatively. 
Real-time  quantitative  PCR  (qPCR),  on  the 
other hand, does not use endpoint detection 
but measures the increase in DNA during the 
reaction (Higuchi 1993).  The advantage of 
real  time  measurements  is  that  they  allow 
the determination of starting template copy 
number  with  high  accuracy  and  sensitivity 
over a wide dynamic range.  In addition they 
do not require any post PCR steps and can be 
analyzed  without  requiring  gel 
electrophoresis.   Therefore,  qPCR  is 
considered  the  method  of  choice  for 
quantification of a limited number of target 
sequences for multiple samples in parallel.
Principles
In a normal PCR, template DNA is mixed with 
specific complementary oligonucleotides, free 
nucleotides  and a  thermostable  polymerase 
in a suitable buffer.  This mix is then placed 
in  a  thermocycler  that  cycles  25-40  times 
between 3 different temperatures: 94°C for 
the denaturation of the DNA, 45-65°C for the 
annealing of the oligonucleotides, and 72°C 
for the elongation of the oligonucleotides.  In 
principle there is a doubling of the amount of 
target DNA after each cycle.
Real-time PCR is very similar but requires the 
addition of one extra component to the mix: 
a  fluorescent  reporter  to  monitor  the 
amplification  during  the  reaction.   Basically 
two different types of reporter can be used: 
DNA-binding  dyes  or  dye-labeled  sequence 
specific  oligonucleotide  primers  or  probes. 
DNA-binding  dyes  such  as  SYBR  Green  I 
exhibit  little  fluorescence  when  free  in 
solution but increase their fluorescence up to 
1,000  fold  on  binding  to  double  stranded 
DNA  (Fig.  14).   These  dyes  have  the 
advantage  of  being  easier  to  design  and 
faster to set up, and are initially more cost-
effective because of the high purchase cost 
of labeled probes.  In addition, creation of a 
melt-curve  plotting  the  vartiation  in 
fluorescence against the temperature allows 
the evaluation of  the specificity  of  the PCR 
reaction.   On  the  other  hand  DNA-binding 
dyes lack the added specificity of probes and 
do not allow multiplexing of PCRs.
Many  fluorescent  primer-  and  probe-based 
chemistries  have  been  devised  and  are 
available from different commercial vendors. 
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Figure 14: SYBR Green I detection principle
These  chemistries  are  often  based  on  the 
combined use of a reporter and a quencher. 
At  the  start  of  the  PCR  reaction  the 
fluorescent  signal  is  quenched by the close 
proximity of a quencher to the reporter.  DNA 
amplification  will  subsequently  result  in  the 
separation  of  quencher  and  reporter,  and 
lead to increased fluorescent signaling (Fig. 
15).
Specialized real-time PCR instruments allow 
the  monitoring  of  the  increase  in 
fluorescence  as  more  and  more  DNA  is 
formed  in  each  cycle.   The  intensity  of 
fluorescence is then plotted against the cycle 
number (Fig. 16).  Three different parts can 
be distinguished in this plot: in the beginning 
fluorescence does not exceed the background 
signal,  then  it  increases  exponentially,  and 
finally it  reaches the nonexponential  phase. 
The cycle at which the fluorescence exceeds 
a given threshold is called the quantification 
cycle  or  Cq value.   This  general  term was 
introduced  in  the  RDML  data  format  (real-
time  PCR  data  markup  language, 
http://medgen.ugent.be/rdml/) to  replace 
the  various  available  descriptions  (Ct  for 
threshold cycle, TOP for take off point, Cp for 
crossing  point).   The  Cq  value  is  directly 
related  to  the  amount  of  template  at  the 
start  of  the  reaction:  high  template 
concentrations  result  in  small  Cq  values 
whereas small amounts of template result in 
large Cq values.  This linear relation between 
Cq value and logarithm of the initial amount 
of  template  is  the  basis  for  quantification 
with real-time PCR.
2 qPCR based quantification
Quantification models
Two different types of quantification can be 
performed using real-time PCR: absolute and 
relative quantification.
Absolute quantification returns results  for  a 
single  sample,  independently  of  any  other 
sample and should be used when interested 
in the intrinsic properties of a sample such as 
the number of viral particles per ml of blood. 
The  absolute  quantity  of  template  in  a 
sample is obtained by plotting the Cq values 
for  a  number  of  samples  with  known 
quantities  and  interpolating  the  quantity  of 
the sample of interest (Fig. 17).
Relative quantification, on the other hand, is 
based  on  the  comparison  of  Cq  values 
between a number of samples.  It results in a 
ratio representing the relative amount (fold 
difference)  of  a  target  nucleic  acid  as 
compared to a reference sample.  It could for 
example be used for the comparison of gene 
expression  levels  between  patients  and 
healthy  individuals,  between cancerous  and 
normal  tissue,  or  between  treated  and 
untreated cells.
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Figure 17: Absolute quantification based on a 
standard curve for samples with known quantity
Figure 16: Amplification plot
Figure 15: TaqMan probe detection principle 
(R=reporter, Q=quencher)
Calculation of relative quantities
During the exponential phase of a PCR there 
is a linear relationship between the logarithm 
of  the  starting  template  copies  and  the 
number  of  amplification  cycles  required  for 
the  product  to  reach  a  threshold 
concentration.   As  a  consequence  the 
difference in Cq value between samples can 
be converted into the fold difference in their 
quantities.   Assuming  a  doubling  in  the 
amount  of  target  sequence  each  cycle, 
formula  1  describes  the  calculation  of  the 
relative quantity (RQ) of a given nucleic acid 
template  for  sample  1  as  compared  to 
sample 2.
This  approach  is,  however,  usually  not 
applicable for the analysis of copy numbers 
or  expression levels of a given gene because 
the results also depend on the total amount 
of  starting  material.   A  ten  fold  higher 
expression of  a gene could for  example be 
masked if ten times less cDNA was used as 
the  input  of  the  real-time  qPCR  reaction. 
One  can  try  to  minimize  the  difference  in 
total input RNA / DNA, but this is often not 
possible and can usually not be guaranteed. 
Therefore,  data  is  commonly  normalized  to 
correct for differences in the amount of input 
nucleic  acids.   Very  often  reference  genes, 
i.e. genes with the same expression level in 
all samples being compared, are used for this 
purpose.  The ΔΔCt or Livak method (formula 
2) improves formula 1 to take normalization 
against  a reference gene (ref)  into account 
and  allows  the  calculation  of  normalized 
relative quantities for a gene of interest (goi) 
(Livak 2001).
The  Livak  method  assumes  100% 
amplification  efficiency,  i.e.  a  doubling  of 
DNA each cycle, for both the gene of interest 
and the reference gene.  This assumption is, 
however,  not  always  valid  in  real  life 
experiments.   Amplification  efficiencies  are 
not always 100% and can differ between the 
gene  of  interest  and  the  reference  gene. 
Therefore,  Pfaffl  et  al.  developed formula 3 
that allows calculation of normalized relative 
quantities  taking  variable  amplification 
efficiencies (E) into account (Pfaffl 2001).
In theory reference genes should be able to 
correct  for  differences  in  DNA  quantity  or 
quality, but they rely on the assumption that 
they  are  stably  expressed  in  all  samples. 
Perfect  reference  genes  with  equal 
expression  levels  in  all   samples  are, 
however,  hard  to  find,  if  they  exist  at  all. 
Therefore,  it  was  suggested  to  use  the 
geometric mean of a set of reference genes 
for  the  normalization  of  the  relative 
quantities.   This  geometric  mean  should 
better reflect the differences in starting DNA 
amounts, and should therefore better correct 
these  differences  (Vandesompele  2002). 
Formula  4  is  an  adaptation  of  the  Pfaffl 
formula that allows normalization with a set 
of (n) reference genes.
This  formula  is  reduced  to  that  of  Pfaffl  if 
only  one  reference  gene  is  used.   If,  in 
addition,  100%  amplification  efficiency  is 
used for  both the gene of  interest and the 
reference  gene,  it  equals  the  formula 
published by Livak et al.
3 qBase
Nucleic  acid  quantification  in  general  and 
gene  expression  analysis  more  specifically 
are  becoming  increasingly  important  in 
biological  research  and  clinical  decision 
making,  with  real-time  quantitative  PCR 
(qPCR)  becoming  the  method  of  choice  for 
expression  profiling  of  selected  genes. 
Advancements in instruments and detection 
chemistry,  and  improved  assay  design 
guidelines  have  made  the  practical 
performance of qPCR measurements feasible 
for  most  users.  However,  accurate  and 
straightforward processing of the raw data as 
well  as  the  management  of  large  and 
growing data sets remain the major hurdles 
in  this  type of  PCR based  gene  expression 
analysis.
Therefore  we  created  the  qBase  software 
that automates the elaborate process of the 
correct calculation of relative quantities from 
qPCR data (paper 4).   This program allows 
data to be imported from the numerous data 
formats  currently  being  used.   The  qBase 
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Browser module allows data to be managed 
by  organizing  them  into  experiments  and 
projects,  and  by  providing  a  means  for 
annotating data.  A second part of qBase, the 
Analysis  module,  allows  data  from multiple 
runs  to  be  analyzed  as  a  whole  without 
limitations on the number of samples, genes 
or replicates.  An automated raw data quality 
control is included to prevent bad data being 
used  in  calculations.   qBase  employs  an 
advanced  and  universally  applicable 
quantification  algorithm  that  allows  gene 
specific  amplification  efficiencies  and 
normalization with multiple  reference genes 
to be used (formula 4).  The obtained results 
can easily be exported in tabular format, or 
presented  as  a  single-gene  or  multi-gene 
histogram.
In addition to the functions and automation 
provided  by  qBase,  a  number  of  new 
calculation  methods  were  developed  to 
improve on data analysis (paper 4).  Firstly, 
the  error  on  the  estimated  amplification 
efficiency  is  calculated  and  propagated 
throughout  calculations.   Secondly, 
algorithms  for  inter-run  calibration  were 
developed to allow the comparison between 
samples located on different plates.
No other software packages with comparable 
functionality  are  available  for  the  moment. 
qBase has been recognized as a very useful 
and advanced tool for qPCR data analysis by 
the scientific community.  This is reflected by 
the  fact  that  the  program  has  been 
downloaded by over 2000 users from more 
than 80 countries in 18 months.
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Chapter 5
Discussion
General discussion and future perspectives
1 Background
The  main  goal  of  this  thesis  was  the 
identification  of  the  genetic  and  molecular 
defects responsible for a selection of skeletal 
dysplasias.   To  achieve  this  aim,  a  close 
collaboration  between  molecular  biologists, 
bioinformaticists  and  clinicians  was  often 
necessary.
Clinical background
As  the  understanding  of  bone  disorders 
assumes knowledge about the normal state 
of  the  skeleton,  the  study  of  skeletal 
dysplasias  is  rooted  in  the  description  of 
human anatomy.  One of the most influential 
books  on  human  anatomy  “De  humani 
corporis  fabrica”  (On  the  workings  of  the 
human  body)  was  published  in  1543  and 
written  by  Andreas  Vesalius,  a  Flemish 
anatomist  who  is  often  referred  to  as  the 
founder of modern human anatomy (Vesalius 
1543).   It  took  until  the  end  of  the 
nineteenth  century  before  the  first  skeletal 
dysplasias  were  described.   The  twentieth 
century witnessed a considerable increase in 
the  number  of  recognizable  skeletal 
disorders, resulting in the creation of the first 
'International Nomenclature of Constitutional 
Diseases of Bone' in 1970 (McKusick 1971). 
This nomenclature has been revised several 
times, but the continued identification of new 
disorders and their defects will require future 
updates of this nomenclature.
There is not only an evolution in the clinical, 
radiographic  and  pathologic  description  of 
these disorders,  but,  even  more  so,  in  the 
identification  of  their  underlying  molecular 
defects.  The main driving forces behind the 
progress  in  the  determination  of  causal 
genetic  defects  are  the  advances  made  in 
linkage  mapping  and  DNA  sequencing 
technologies.
Linkage mapping
The concept of mapping genes against a map 
of genetic markers was invented, in 1980, by 
Botstein et al. (Botstein 1980).  It allows the 
localization of genes responsible for inherited 
disorders  in  sufficiently  large,  affected 
families.   The  recognition  in  1989  of 
polymorphic  microsatellites  as  an  abundant 
class  of  genetic  markers  (Weber  1989) 
allowed  easier  and  faster  genotyping  as 
compared  to  the  RFLP  markers  that  were 
proposed by Botstein et al.  The next major 
improvement  was  the  construction  of  large 
genetic maps by institutes such as Généthon 
and  Marshfield  (Weissenbach  1992,  Dib 
1996, Broman 1998).  These maps allowed 
the creation of easy to use commercial sets 
of  genetic  markers  such  as  Applied 
Biosystems' LMS v2.0 which was used in this 
thesis.
My  first  genome-wide  linkage  analysis 
(mapping of the gene for acrocapitofemoral 
dysplasia)  took  about  a  year.   Since  this 
initial effort, the speed by which a genome-
wide  mapping  can  be  performed  in  the 
Center  for  Medical  Genetics  Ghent  has 
increased  considerably.   Due  to  the 
availability  of  better  (i.e.  faster  and  more 
sensitive)  and  automated  capillary 
sequencers,  better  software  and  more 
processing  power,  this  kind of  analysis  can 
currently be performed in just a few weeks 
time.
DNA sequencing
The  second  technology  required  for  the 
identification  of  the  molecular  defects 
responsible  for  genetic  disorders  is  DNA 
sequencing.  Also this technique underwent a 
considerable progress since the publication of 
the  Sanger  method  which  has  currently 
become the most widely applied sequencing 
technology (Sanger 1975).  At the beginning 
of my thesis in 2001, the Center for Medical 
Genetics Ghent had a sequencing capacity of 
about 38,000 bp / day using a ABI377 slab 
gel  sequencer.   By  the  end  of  2005  this 
capacity  had  increased  to  about  1,300,000 
bp  /  day  using  two  capillary  sequencers 
(ABI3130xl  and ABI3730xl).   In fact,  when 
plotted against the initial capacity of 600 bp / 
day in 1990 we have witnessed a doubling of 
sequencing capacity every 18 months.  This 
progress is very similar to Moore's Law that 
predicted  a  doubling  of  the  number  of 
transistors  on  integrated  circuits  (a  rough 
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measure  of  computer  processing  power) 
every 18 months (Moore 1965).
To  cope  with  the  increase  in  sequencing 
capacity,  analysis  and  interpretation  of  its 
results  is  now  facilitated  by  automated 
sequence analysis software packages such as 
SeqScape.  Our latest step in the progress of 
sequencing  technology  is  the  creation  of  a 
facility  that  centralizes  data  management 
and automates all  post-PCR pipetting steps 
required for the preparation of sequences.
In this stimulating environment of increasing 
possibilities, I had the honor to conduct my 
research on the genetic and molecular basis 
of skeletal dysplasias.  This thesis represents 
the  most  relevant  and  successful  results 
obtained during my period as a PhD student. 
They  include  the  identification  of  the  gene 
responsible  for  respectively 
acrocapitofemoral  dysplasia  (IHH)  and 
osteopoikilosis (LEMD3), and the creation of 
a framework and software for improved and 
automated  qPCR  data  analysis  (qBase). 
However,  not  all  of  the  projects  I  was 
engaged in were as successful or relevant as 
these three.
A  genome-wide  linkage  analysis  was 
performed  on  a  family  with  the  RHYNS 
syndrome (acronym for: retinitis pigmentosa 
–  hypopituitarism  –  nephronophtisis  – 
skeletal  dysplasia)  which  resulted  in  the 
localization  of  a  candidate  region  on 
chromosome  3.   Our  candidate  gene 
approach did, however, not reveal the causal 
mutation  for  this  syndrome.   Subsequent 
collaboration  with  the  research  group  of 
Hildebrandt  resulted  in  the  identification  of 
mutations in the NPHP5 gene, the fifth gene 
found to be responsible  for  nephronophtisis 
(Otto  2005).   Genetic  analysis  on  an 
extended  family  with  X-linked  mental 
retardation revealed a candidate region that, 
due to the large size of the linkage interval, 
did not allow pinpointing the affected gene. 
There is also an ongoing effort to identify the 
gene  responsible  for  the  prenatal  form  of 
Caffey disease.  By means of homozygosity 
mapping, a candidate region with suggestive 
linkage has been found on chromosome 16. 
DNA  from  paraffin  embedded  tissue  of  a 
deceased fetus with Caffey is currently used 
to reduce the candidate region in the hope to 
identify the causal gene.
2 The indian hedgehog gene
Acrocapitofemoral  dysplasia,  abbreviated  as 
ACFD, seems to be a very rare,  autosomal 
recessively  inherited  skeletal  dysplasia.   It 
was recently described by Mortier et al. as a 
disorder  characterized  clinically  by  a 
disproportionate  short  stature  with 
brachydactyly, and radiographically by cone-
shaped epiphyses in hands and hips (Mortier 
2003).   Since  the  delineation  of  this 
dysplasia,  no  more  than five  patients  have 
been  identified.   All  patients  live  in  either 
Belgium  or  the  Netherlands,  and  all  were 
involved  in  our  search  for  the  causal  gene 
responsible for this disorder.
Results
A  genome-wide  homozygosity  mapping 
performed  on  the  gDNA  of  three  ACFD 
patients  revealed linkage of  this disease to 
chromosome 2.  With the genetic information 
of all patients and a number of relatives, a 
linkage interval of 5 cM on 2q35-q36 could 
be delineated.   Calculation  of  a  8.02  LOD-
score  demonstrated  that  linkage  of  this 
region  to  the  causal  mutation  was  highly 
significant.  Subsequently,  based  on  their 
known function  and  involvement  in  related 
disorders,  a  selection  of  4  candidate genes 
was  made  out  of  the  75  genes  within  the 
linkage  interval.   Sequencing  of  the  indian 
hedgehog (IHH) gene ultimately revealed the 
presence of homozygous missense mutations 
in  all  patients  (c.137C>T  for  the  Belgian 
family  and c.569T>C for  the Dutch family) 
(Paper  1:  Hellemans  2003).   It  is  quite 
remarkable  that  the clinical  description and 
the identification of the genetic cause of this 
disease were both published within the same 
year.  In addition, ACFD is probably one of 
the  few  mendelian  disorders  for  which  a 
mutation  has  been  found  in  all  known 
patients.
Remaining questions and discussion
Although  the  identification  of  missense 
mutations in the IHH gene has elucidated the 
genetic basis of acrocapitofemoral dysplasia, 
a number of additional questions remain to 
be resolved.  Firstly, we have not yet been 
able to fully explain the differences between 
ACFD  and  brachydactyly  type  A1  (BDA1) 
when considering the nature and position of 
the  IHH mutations.   Both  disorders  are 
caused  by  missense  mutations  in  the  N-
terminal signaling domain of  IHH (Paper 1: 
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Hellemans  2003,  Gao  2001).   BDA1  is  an 
autosomal  dominant  disorder  characterized 
mainly  by  brachydactyly,  whereas  ACFD  is 
recessively  inherited  and,  in  addition  to 
brachydactyly,  characterized  by  a 
disproportionate short stature.  ACFD is not 
merely  the  homozygous  presentation  of 
BDA1  since  the  heterozygous  carriers  of  a 
ACFD  mutation  do  not  show  brachydactyly 
type  A1.   Therefore,  ACFD  and  BDA1 
mutations  are  supposed  to  affect  IHH 
signaling differently.  Mapping of the different 
mutations on the tertiary structure of sonic 
hedgehog,  a  close  homologue  of  indian 
hedgehog,  suggested  differentially  affected 
domains.   The limited  number  of  identified 
mutations (2 and 6 for respectively ACFD and 
BDA1) did, however, not allow drawing any 
reliable  conclusions.   Identification  of 
additional  mutations  would  allow  the  more 
precise delineation of the affected domains, 
and  permit  more  directed  assays  to 
investigate  the  differential  effects  of  the 
recessive  and  dominant  mutations  on  IHH 
signaling.  The second unexplained feature of 
these IHH missense mutations is the fact that 
they do not affect all growth plates equally. 
This  enigma  does  not  only  relate  to  ACFD 
and  BDA1,  but  is  encountered  in  a  large 
number of skeletal dysplasias.
Micromass  culture  data  and  future 
perspectives
Micromass-cultures  (MM-C)  mimic  in-vitro 
the  first  steps  of  endochondral  ossification. 
This  is  achieved  by  culturing  limb  bud 
mesenchymal cells in high density, resulting 
in  the  spontaneous  differentiation  into 
chondrocytes followed by further maturation. 
MM-Cs allow the study of the effect of virally 
induced  transgenes  or  added  molecules  on 
endochondral ossification (Mello 1999).  We 
decided  to  use  this  system  for  the 
investigation of the effects of the ACFD and 
BDA1 mutations on IHH signaling.   I had the 
pleasure  to  receive  an excellent  training in 
the  creation  and  analysis  of  MM-Cs  in  the 
research lab of  Prof  Stephan Mundlos (Max 
Planck  Institute  for  Molecular  Genetics, 
Berlin).   Avian  viruses  responsible  for  the 
transgene expression of wild-type or mutant 
(c.137C>T,  c.298G>A,  c.383G>A  and 
c.569T>C)  chicken  IHH  were  produced. 
Subsequently, a series of micromass-cultures 
were  created  in  parallel  and  either  left 
untreated  or  infected  with  one  of  these 
viruses.  Some interesting observations were 
made  when  comparing  normal  control 
cultures with cultures overexpressing indian 
hedgehog:
• In  contrast  to  wild-type  cultures,  the 
borders  of  the  IHH  cultures  did  not 
attach well to the plate, resulting in the 
detachment  from  their  support.   The 
meaning  or  implications  of  this  finding 
have not yet been clarified.
• IHH  cultures  grew  less  in  height  than 
their  wild-type  counterparts.   Although 
this  seems  contradictory  to  the 
proliferation  inducing  effect  of  IHH,  it 
might  be  explained  by  reduced 
chondrocyte  hypertrophy  resulting  from 
IHH overexpression.
• Nodule  formation  was  significantly 
inhibited in IHH cultures and the typical 
alcian blue staining of these nodules was 
reduced.  This suggests the presence of 
less  sulfated  proteoglycans  in  the 
cartilaginous  matrix  which  indicates 
reduced chondrocyte maturation.
• Alcian  blue  staining  also  revealed  the 
presence  of  a  previously  undescribed 
structure  resembling  a  comet.   It 
consists  of  a  small  intensely  colored 
nodule (core) surrounded by a flat region 
with  lower  than average staining (tail). 
Beyond  this  flat  region  the  culture  is 
again  averagely  stained  and  slightly 
more elevated.
• Alkaline phosphatase (ALP) activity was 
30-40  fold  reduced  in  IHH  cultures, 
confirming  the  less  matured  phenotype 
of IHH overexpressing MM-Cs.
These  findings  largely  correspond  to  the 
known functions of IHH in the growth plate. 
The effects of IHH on cell-plate attachment, 
and the appearance of special  structures in 
MM-Cs overexpressing IHH were unexpected 
and  require  further  investigation.   In  situ 
hybridization with stage specific chondrocyte 
markers  such  as  COL10  could  clarify  the 
composition  of  the  IHH  induced  comet-like 
structures  in  MM-Cs  and  might  provide 
important new insights into the effects of IHH 
on  chondrocyte  differentiation  and  on 
osteoblasts.
Comparison  of  the  cultures  infected  with 
wild-type  IHH,  ACFD-IHH  or  BDA1-IHH  did 
not  reveal  any  differences.   These  data 
indicate  that  ACFD  and  BDA1  missense 
mutations do not result  in complete loss of 
function of IHH.  This finding is in agreement 
with the observation that a complete loss of 
Ihh in mice results in a much more severe 
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phenotype  (St-Jacques  1999).   The 
consequence of the amino acid substitutions 
may  be  explained  by  a)  altered  receptor 
binding  capacities  resulting  in  small 
quantitative effects, b) effects on hedgehog 
modifications or multimerization which could 
affect the signaling range and activity of IHH, 
or  by  c)  changes  in  epitopes  which  are 
involved in the interaction with other proteins 
such as hedgehog interacting protein (HHIP) 
or  matrix  elements  like  heparan  sulfate 
proteoglycans.   Since  micromass-cultures 
now appear unlikely to pinpoint the specific 
effect of BDA1 and ACFD mutations on IHH 
signaling,  alternative  approaches  will  be 
required.
Surface  plasmon  resonance  measurements 
could be used to quantify the effects of the 
amino  acid  substitutions  on  the  affinity  of 
IHH for PTCH (hedgehog receptor) or HHIP 
(inhibitor of hedgehog signaling).  Although it 
might  provide  valuable  information  it  does 
require the purification of  multiple  different 
proteins which constitutes a big obstacle for 
a genetic lab.  The investigation of the effect 
of the ACFD or BDA1 missense mutations on 
the  processing  of  IHH  is  more 
straightforward.   It  can  be  achieved  by 
overexpressing  the  different  forms  (mutant 
and wild-type)  of IHH, followed by Western-
blot analysis.  These blots will allow to verify 
whether IHH is still cleaved to release the N-
terminal signaling domain, whether palmitoyl 
and cholesterol modifications are added and 
whether  free  diffusable  multimers  are 
formed.
It can be anticipated that in vitro models for 
studying the effect of the identified mutations 
on IHH signaling will not be able to solve all 
remaining questions given the fact that ACFD 
and BDA1 only affect a limited set of bones 
and our data indicating that these mutations 
do not result in a complete loss of function. 
The delineation of the mutational spectrum of 
acrocapitofemoral  dysplasia  and 
brachydactyly type A1, and the more precise 
description  of  the  IHH  interaction  domains 
are  expected  to  facilitate  the  study  of  the 
effects of the involved missense mutations in 
the near future.
3 The LEM domain containing 3 
gene
Osteopoikilosis,  the  Buschke-Ollendorff 
syndrome (BOS) and melorheostosis are rare 
skeletal  dysplasias  characterized  by 
increased  bone  density.   In  osteopoikilosis 
and BOS multiple, small sclerotic lesions are 
distributed over the skeleton, whereas only a 
single  or  a  small  number  of  lesions  are 
present  in  melorheostosis.   Osteopoikilosis 
and  BOS  are  usually  asymptomatic 
conditions.  They show autosomal dominant 
inheritance and can co-occur within the same 
family.  Melorheostosis, on the other hand, is 
a more severe disorder which often results in 
contractures  and  chronic  pain.   It  usually 
occurs  as  a  sporadic  anomaly  but  has 
repeatedly  been  reported  in  families  with 
osteopoikilosis or BOS.
Results
Because  these  conditions  can  be  observed 
within  the  same  family,  we  and  others 
assumed  that  osteopoikilosis,  BOS  and 
melorheostosis represent allelic conditions.  A 
genome-wide linkage analysis performed on 
a Belgian family with 7 osteopoikilosis / BOS 
patients  revealed  linkage  of  this  condition 
with  chromosome  12.   Inclusion  of  the 
haplotype  data  obtained  in  two  additional 
osteopoikilosis / BOS families (one with the 
co-occurrence  of  melorheostosis)  confirmed 
this  linkage  (LOD=  6.69)  and  defined  the 
boundaries  of  a  23.55  cM  linkage  interval. 
This  interval  was  quite  large  and  did  not 
reveal  any  obvious  candidate  genes.   The 
identification  of  a  microdeletion,  partially 
overlapping  with  the  linkage  interval,  in  a 
patient  with  the  unusual  association  of 
osteopoikilosis with short stature and mental 
retardation  was  the  breakthrough  in  this 
project.  Together, the microdeletion and the 
linkage  interval  defined  a  smaller  region 
containing  only  23  genes,  of  which  LEMD3 
was selected as the prime suspect gene.  The 
identification of loss-of-function mutations in 
this  gene,  subsequently  demonstrated  the 
causality  of  LEMD3 in  the  etiology  of 
osteopoikilosis  and  its  related  disorders 
(Paper 2: Hellemans 2004).  
For  the  investigation  of  the  spectrum  of 
LEMD3 mutations, a larger series of patients 
was investigated.  A total of 46 patients were 
studied,  including  2  patients  with 
osteopoikilosis,  short  stature  and  mental 
retardation  (group  A),  17  probands  with 
osteopoikilosis or BOS (group B), 4 families 
with the co-occurrence of melorheostosis and 
BOS  (group  C),  and  23  unrelated  patients 
with isolated melorheostosis (group D).  Both 
patients of group A had a microdeletion on 
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12q14 (Menten 2007).  The identification of 
14 loss-of-function mutations in the patients 
of group B confirmed that haploinsufficiency 
for  LEMD3  can  result  in  osteopoikilosis  or 
Buschke-Ollendorff  syndrome.   Although 
LEMD3 mutations  were  found  in  all  4 
melorheostosis  patients  of  group  C,  only  1 
out  of  23  patients  with  sporadic 
melorheostosis  (group  D)  had  a  LEMD3 
mutation.  Based on these data we concluded 
that  the  genetic  defect  in  the  majority  of 
sporadic  and  isolated  melorheostosis  cases 
remains  unknown  (Paper  3:  Hellemans 
2006).
LEMD3 encodes a protein of the inner nuclear 
membrane  whose  function  in  humans  was 
largely  unknown  at  the  beginning  of  our 
study.   The  Xenopus homologue  (Xman1, 
SANE)  was  shown  to  interact  with  BMP 
specific  Smads  leading  to  reduced  BMP 
signaling.   We performed a yeast two hybrid 
screening  to  investigate  similar  interactions 
for  human  LEMD3.   In  addition  to  its 
Xenopus homologue,  human  LEMD3  was 
found  to  interact  with  both BMP and TGFβ 
specific  Smads.   The  effect  of   LEMD3 
overexpression  on  BMP and  TGFβ signaling 
was investigated in two different experiments 
measuring,  respectively,  the  expression  of 
target genes by qPCR and the induction of a 
TGFβ responsive  luciferase.   Both 
experiments  demonstrated  an  antagonistic 
effect of LEMD3 on BMP and TGFβ signaling 
(Paper 2: Hellemans 2004).  Loss of function 
mutations in LEMD3 consequently result in an 
increased  signaling.   Since  BMP  and  TGFβ 
signaling  have  been  found  to  have  a 
stimulatory  effect  on  bone  formation,  the 
sclerosing bone phenotype in osteopoikilosis 
patients  probably  results  from  increased 
signaling of these growth factors.
Remaining questions and discussion
At  least  two  questions  remain  unanswered 
for the moment.  Firstly, what is the genetic 
defect  in  the  majority  of  sporadic  and 
isolated melorheostosis patients?  Secondly, 
why  is  the  sclerosis  not  generalized  in 
osteopoikilosis  but  restricted  to  numerous 
small foci?
Since  melorheostosis  usually  occurs  as  a 
sporadic  condition,  linkage analysis  can not 
be  used  for  the  identification  of  the  major 
genetic defect in this group of patients.  The 
co-occurrence  of  melorheostosis  with 
osteopoikilosis  or  BOS  in  the  same  family, 
and  the  observation  of  two  cases  of 
melorheostosis  in  the  same  family 
(unpublished data) suggest that LEMD3 and 
its pathways are involved in the pathogenesis 
of  melorheostosis  and  LEMD3.   Analysis  of 
these  pathways  may  thus  provide  valuable 
insights in the etiology of melorheostosis.
We  have  tried  to  explain  the  scattered 
appearance of sclerotic lesions by proposing 
a second hit in the affected spots.  Sequence 
analysis of the LEMD3 gene on skin and/or 
bone lesions in a BOS patient and 2 patients 
with  melorheostosis  could,  however,  not 
reveal  such  additional  mutations.   These 
results  can  be  interpreted  in  three  ways. 
Firstly,  somatic  LEMD3 mutations  may  be 
present  but  go  undetected  because  they 
reside in only a subset of cells and culturing 
selects  against  these  cells.   A  similar 
situation is encountered in neurofibromatosis 
type I where special culturing conditions are 
required to prevent counterselection of cells 
with  a  second,  somatic  mutation  (Serra 
2000).  Secondly, the somatic mutation may 
be located outside LEMD3, perhaps in a gene 
within the same signaling pathway.  Finally, 
somatic mutations may not be involved at all 
but  normal  fluctuations  in  gene  expression 
cause the locally reduced LEMD3 levels to be 
insufficient  for  the  maintenance  of  normal 
bone homeostasis.
Future perspectives
Two approaches are currently being prepared 
for  the  further  molecular  analysis  of  the 
effect  of  LEMD3 haploinsufficiency.   These 
are Lemd3 knock-out mice, and an in-vitro 
RNAi system.  Lemd3 knock-out mice were 
obtained  from  BayGenomics 
(http://baygenomics.ucsf.edu/)  and  are 
currently  being  bred  in  the  VIB  mouse 
facility.  Homozygous Lemd3 knock-out mice 
are  reported  to  die  during  embryonic 
development  around  stage  E11  due  to 
defects  in  vascular  remodeling  (Ishimura 
2006).   Lemd3+/- mice,  on the other  hand, 
are normal in terms of growth, fertility and 
lifespan.  In contrast to what we expected for 
Lemd3 haploinsufficiency,  skin  histology 
appeared  normal  and  no  signs  of  bone 
abnormalities  were  found  by  magnetic 
resonance imaging.  Since these data are not 
shown, and no X-ray or CT scans have been 
performed we are still  interested to further 
investigate the bone phenotype of Lemd3+/- 
mice.  In case typical  disseminated sclerotic 
lesions are found by means of X-ray or bone 
histology, genetic and molecular analysis will 
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be  used  to  compare  normal  and  affected 
bone.   This  should,  hopefully,  provide  new 
insights  into  the  development  of  the  bone 
sclerosis  found  in  osteopoikilosis  and  BOS 
patients.
The  second  approach  involves  an  in-vitro 
system in which RNA interference is used to 
reduce  the  expression  of  LEMD3 in  human 
osteoblasts, and thus mimic the effects of an 
osteopoikilosis  mutation.   A  set  of  oligos 
encoding  LEMD3 hairpin RNAs were created 
and  transferred  into  eukaryotic  expression 
vectors which are now ready to be used in 
knock-down  experiments.   6  different 
osteoblast  cultures  will  be  prepared  for 
pairwise  analysis:  control  cells  versus  cells 
with  LEMD3 knock-down,  both  in  basal 
conditions  and  after  BMP  or  TGFβ 
stimulation.   Expression  profiles  for  these 
cultures will be obtained via gene expression 
microarrays and confirmed by means qPCR.
The search for the genetic defect in patients 
with  isolated  melorheostosis  is  another 
important  aspect  of  the  planned  research. 
Since linkage analysis can not be used in this 
group of patients, a candidate gene approach 
is  considered.   Affected tissue,  suitable  for 
the detection of  both germline and somatic 
mutations,  will  be  obtained  via  our 
collaboration  with  the  melorheostosis 
association 
(http://www.melorheostosis.com).   The 
genetic service unit of the Center for Medical 
Genetics Ghent will allow us to perform the 
large  amounts  of  sequencing  and  qPCR 
analyses in a fast and cost efficient manner. 
The selection of candidate genes will initially 
focus  on  the  genes  within  the  LEMD3 
regulated BMP and TGFβ signaling pathways. 
This selection will  later on be updated with 
the data from the experiments on the effect 
of LEMD3 haploinsufficiency, thus integrating 
both  aspects  of  the  planned  research. 
Important  insights  in  the  defects  of 
melorheostosis patients may also be obtained 
from a thorough histological and expression 
analysis of the bone lesions of these patients.
4 qBase
Since its introduction in 1993 (Higuchi 1993) 
and  the  creation  of  the  first  commercial 
instrument  more  than  10  years  ago  (Heid 
1996),  qPCR  has  successfully  become  the 
standard method for quantification of nucleic 
acid  sequences.  The  improvements  in 
detection  chemistry,  protocols  and 
equipment  have  made  qPCR  attainable  for 
most  research  groups.   Accurate 
quantification  with  qPCR  does  not  only 
require reliable measurement of Cq (Ct, Cp 
or  TOP)  values,  but  also  the  correct 
processing of these raw values.  The latter is 
the  major  remaining  hurdle  in  qPCR based 
nucleic  acid quantification.   The problem is 
twofold: on the one hand better algorithms 
are required for reliable quantification (qBase 
framework),  and,  on  the  other  hand, 
automation is desired to improve on the error 
prone  and  time  consuming  spreadsheet 
based calculations (qBase program).
qBase framework
The basic principle of relative quantification is 
the  conversion  of  Cq  values  into  relative 
quantities (RQ).  The ΔΔCq method adjusted 
this basic principle to allow normalization of 
relative quantities based on the results for a 
reference  gene  (Livak  2001).   Accurate 
quantification does however require a more 
complex  set  of  formulas.   With  the  qBase 
framework  we  aimed  to  provide  these 
formulas,  as  well  as  a  description  of 
important  concepts  and  ways  to  perform 
quality control.
We improved on the quantification formula of 
Pfaffl  (Paffl  2001)  in  order  to  allow 
normalization with multiple  reference genes 
and  taking  into  account  the  error  on  the 
amplification  efficiency  (Paper  4).   In  the 
previously  developed  quantification  models, 
the  reference  Cq  value  could  be  chosen 
arbitrarily.   This  choice  does  however 
influence the error on the relative quantities 
as calculated by our new model.  Selection of 
the  average  Cq  value  as  the  reference 
quantification  cycle  does  result  in  a 
minimization  of  the  overall  error  and  is 
therefore  the preferred approach.   We also 
developed an inter-run calibration procedure 
that  works  on  normalized  data.   This 
approach  is  compatible  with  inter-run 
calibrators  (IRC)  using  the  same  cDNA,  or 
even IRCs derived from the same RNA (Paper 
4).   Together  these  formulas  allow  more 
accurate results to be obtained.  In addition, 
proper  error  propagation  provides  a  better 
estimate of the uncertainty on the calculated 
relative quantities.
Another important aspect in qPCR analysis is 
the  experimental  setup.   As  soon  as  the 
number  of  measurements  exceeds  the 
number of available positions in a single run, 
PCR mixes need to be spread over multiple 
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runs.  This can be achieved in several ways, 
but no formal preference for either of these 
possibilities had been published.  We argued 
that  the  sample  maximization  approach, 
putting  as  much  samples  as  possible  in  a 
single run and spreading genes across runs 
as  required,  is  preferable  because  it 
minimizes the nonspecific sample to sample 
variation.   When  using  gene  maximization, 
an  approach  proposed  in  a  number  of 
commercial  kits,  or  in  general  when  the 
samples  for  a  given  gene  are  spread  over 
multiple runs, the variation caused by run-to-
run differences needs to be corrected for by 
means of inter-run calibration.
The  third  important  element  of  the  qBase 
framework  is  the  development  of  quality 
controls.  These include a control on the raw 
Cq values (ΔCq between technical replicates 
and  Cq  value  for  no  template  controls)  as 
well  as  measures  for  the  reliability  of 
normalization  and  inter-run  calibration.   In 
the  geNorm  paper,  Vandesompele  et  al. 
described a method to select the most stable 
reference  genes  out  of  a  set  of  candidate 
reference genes (Vandesompele 2002).  This 
stability  measure  can  also  be  used  to 
evaluate  the  quality  of  normalization  in 
subsequent  experiments,  provided  that 
multiple  reference  genes  have  been  used. 
We  also  realized  that  inter-run  calibration 
and  normalization  are  in  fact  analogues 
procedures: an IRC is for inter-run calibration 
what a reference gene is for normalization. 
Therefore, the stability measure developed to 
asses  reference  genes  quality  during 
normalization can be used for the evaluation 
of  IRCs during inter-run calibration.   These 
quality controls allow easy detection of bad 
data points, low quality reference genes and 
unreliable  IRCs,  thus  avoiding  skewing  of 
qPCR results.
qBase program
All  these  new methods  require  significantly 
more  calculations  to  obtain  results,  thus 
increasing  the  need  for  automation  even 
more.  We developed qBase to facilitate qPCR 
data  processing  (qBase  Analyzer)  and  to 
manage the ever increasing amounts of qPCR 
data  (qBase  Browser)  (Paper  4:  Hellemans 
2007).   This  freely  available  tool 
(http://medgen.ugent.be/qBase) allows 
reliable  results  (normalized  and  calibrated 
relative  quantities)  to  be  calculated  rather 
quickly  and  permits  them to  be  presented 
both graphically and in table format.  It can, 
within the limits posed by Excel, process an 
unlimited  number  of  samples  and  genes 
spread  across  different  runs  and  with 
variable numbers of technical replicates.  The 
calculations  can  deal  with  gene  specific 
amplification  efficiencies,  multiple  reference 
genes and inter-run calibration, and perform 
proper  error  propagation  in  each  of  these 
steps including the error on the amplification 
efficiency.   In  addition,  qBase  contains  a 
number of quality controls analyzing the raw 
Cq  data,  verifying  the  stability  of  the 
reference genes, and testing the reliability of 
inter-run calibration.
Future perspectives
The  current  qBase  framework  addresses 
many shortcomings in the existing calculation 
methods,  but  it  is  as  of  yet  not  complete. 
Firstly,  it  lacks  a  description  of  how  to 
perform absolute quantification and how this 
can  be  combined  with  normalization. 
Secondly, it can only deal with gene specific 
amplification efficiencies.   The possibility  to 
use a single amplification efficiency per gene 
might sometimes be too restricted.   If,  for 
example,  the  expression  of  a  gene  was 
measured  in  two  plates  using  a  different 
master mix, the amplification efficiency might 
differ  between  the  plates  and  a  run-gene 
specific  amplification  efficiency  might  be 
more  appropriate.   Also,  recently  a  large 
interest has grown in the measurement and 
usage  of  sample  specific  amplification 
efficiencies  (e.g.  Rutledge  2003).   This 
concept  is  not  compatible  with  the  current 
qBase framework.  Thirdly, the current inter-
run procedures based on normalized relative 
quantities are not compatible with all possible 
experimental  setups,  or  with  experiments 
with missing data points.  To solve this issue 
we are currently working on complex inter-
run  calibration  procedures  that  allow 
calibration of any kind of setup.  The major 
problem  faced  in  these  algorithms  is  the 
proper error propagation.  We are currently 
collaborating  with  Kristel  Van  Steen  and 
Peter  Konings  to  provide  an  adequate 
solution.  Finally, calculation of quantities is 
not  the  last  step  in  quantification 
experiments.   These  quantities  need  to  be 
processed  statistically  to  allow  funded 
interpretation  of  the  results.   The  required 
statistical methods are usually available, but 
they need to brought closer to the researcher 
to be more easily, and correctly, applied.
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Much  work  can  still  be  done  from  a 
methodological  point  of  view,  but  these 
methods need to be incorporated in software 
to  make them readily  available,  and  easily 
applicable  as  well.   In  the  past  qBase  has 
been written as a free Excel application.  This 
approach  does  however  not  allow  it  to  be 
developed  much  further.   With  the  aid  of 
UGent and funding from the IOF (Industrieel 
Onderzoeksfonds) we will develop qBasePlus 
as  a  commercial  package.   This  software 
should  be  more  user  friendly,  and  work 
platform  independent  (i.e.  not   only  on 
Microsoft but also on Macintosh).  Upcoming 
improvements  or  additions  to  the  qBase 
framework will  only be implemented in this 
commercial  package.   A  well  developed 
framework  and  software  package  for  qPCR 
data  analysis  will  address  the  major 
remaining  problem  in  qPCR  based 
quantification  experiments  and  allow  this 
technology to be applied more easily.
General discussion and future perspectives 105
References
Abad V,  Uyeda JA,  Temple  HT, De Luca F, 
Baron  J.  1999.  Determinants  of  spatial 
polarity  in  the  growth  plate. 
Endocrinology 140(2):958-62.
Akiyama  H,  Chaboissier  MC,  Martin  JF, 
Schedl A, de Crombrugghe B. 2002. The 
transcription  factor  Sox9  has  essential 
roles  in  successive  steps  of  the 
chondrocyte  differentiation  pathway  and 
is  required  for  expression  of  Sox5  and 
Sox6.  Genes  &  development 
16(21):2813-28.
Andersen PE, Jr. 1989. Prevalence of lethal 
osteochondrodysplasias  in  Denmark. 
American  journal  of  medical  genetics 
32(4):484-9.
Ash  P,  Loutit  JF,  Townsend  KM.  1980. 
Osteoclasts  derived  from haematopoietic 
stem cells. Nature 283(5748):669-70.
Benli IT, Akalin S, Boysan E, Mumcu EF, Kis 
M,  Turkoglu  D.  1992.  Epidemiological, 
clinical  and  radiological  aspects  of 
osteopoikilosis.  J  Bone  Joint  Surg  Br 
74(4):504-6.
Bi W, Deng JM, Zhang Z, Behringer RR, de 
Crombrugghe B.  1999.  Sox9 is  required 
for  cartilage  formation.  Nature  genetics 
22(1):85-9.
Botstein D, White RL, Skolnick M, Davis RW. 
1980.  Construction  of  a  genetic  linkage 
map  in  man  using  restriction  fragment 
length polymorphisms. Am J Hum Genet 
32(3):314-31.
Broman KW, Murray JC, Sheffield VC, White 
RL,  Weber  JL.  1998.  Comprehensive 
human genetic maps: individual and sex-
specific  variation  in  recombination. 
American  journal  of  human  genetics 
63(3):861-9.
Brunet  LJ,  McMahon  JA,  McMahon  AP, 
Harland  RM.  1998.  Noggin,  cartilage 
morphogenesis, and joint formation in the 
mammalian  skeleton.  Science 
280(5368):1455-7.
Buschke  A,  Ollendorff  H.  1928. 
Dermatofibrosis  lenticularis  disseminata 
und osteopathia condensans disseminata. 
Derm Wschr 86:257-262.
Camera  G,  Mastroiacovo  P.  1982.  Birth 
prevalence  of  skeletal  dysplasias  in  the 
Italian Multicentric Monitoring System for 
Birth  Defects.  Progress  in  clinical  and 
biological research 104:441-9.
Chen  H,  Johnson  RL.  1999.  Dorsoventral 
patterning  of  the  vertebrate  limb:  a 
process governed by multiple events. Cell 
and tissue research 296(1):67-73.
Connor  JM,  Connor  RA,  Sweet  EM,  Gibson 
AA, Patrick WJ, McNay MB, Redford DH. 
1985.  Lethal  neonatal  chondrodysplasias 
in the West of Scotland 1970-1983 with a 
description  of  a  thanatophoric, 
dysplasialike,  autosomal  recessive 
disorder,  Glasgow  variant.  American 
journal of medical genetics 22(2):243-53.
Debeer P, Pykels E, Lammens J, Devriendt K, 
Fryns JP. 2003. Melorheostosis in a family 
with autosomal dominant osteopoikilosis: 
Report of a third family. Am J Med Genet 
119A(2):188-93.
Dib  C,  Faure  S,  Fizames  C,  Samson  D, 
Drouot N, Vignal A, Millasseau P, Marc S, 
Hazan  J,  Seboun  E  et  al.  1996.  A 
comprehensive genetic map of the human 
genome  based  on  5,264  microsatellites. 
Nature 380(6570):152-4.
Dreyer SD, Zhou G, Baldini A, Winterpacht A, 
Zabel  B,  Cole  W,  Johnson  RL,  Lee  B. 
1998.  Mutations  in  LMX1B  cause 
abnormal  skeletal  patterning  and  renal 
dysplasia in nail patella syndrome. Nature 
genetics 19(1):47-50.
Ducy  P,  Zhang  R,  Geoffroy  V,  Ridall  AL, 
Karsenty  G.  1997.  Osf2/Cbfa1:  a 
transcriptional  activator  of  osteoblast 
differentiation. Cell 89(5):747-54.
Dudley  AT,  Ros  MA,  Tabin  CJ.  2002  A  re-
examination  of  proximodistal  patterning 
during  vertebrate  limb  development. 
Nature 418(6897):539-44.
Eisman JA.  1999.  Genetics  of  osteoporosis. 
Endocrine reviews 20(6):788-804.
106 Chapter 5 - Discussion
Felix  R,  Cecchini  MG,  Fleisch  H.  1990a. 
Macrophage  colony  stimulating  factor 
restores  in  vivo  bone  resorption  in  the 
op/op osteopetrotic mouse. Endocrinology 
127(5):2592-4.
Felix R, Cecchini MG, Hofstetter W, Elford PR, 
Stutzer A, Fleisch H. 1990b. Impairment 
of  macrophage  colony-stimulating  factor 
production  and  lack  of  resident  bone 
marrow macrophages in the osteopetrotic 
op/op mouse. Journal of bone and mineral 
research 5(7):781-9.
Fernandez-Tresguerres-Hernandez-Gil  I, 
Alobera-Gracia  MA,  del-Canto-Pingarron 
M,  Blanco-Jerez  L.  2006.  Physiological 
bases  of  bone  regeneration  II.  The 
remodeling  process.  Medicina  oral, 
patologia oral y cirugia bucal 11(2):E151-
7.
Foster JW, Dominguez-Steglich MA, Guioli S, 
Kowk  G,  Weller  PA,  Stevanovic  M, 
Weissenbach  J,  Mansour  S,  Young  ID, 
Goodfellow  PN et  al.  1994.  Campomelic 
dysplasia  and  autosomal  sex  reversal 
caused  by  mutations  in  an  SRY-related 
gene. Nature 372(6506):525-30.
Gao B, Guo J, She C, Shu A, Yang M, Tan Z, 
Yang  X,  Guo  S,  Feng  G,  He  L.  2001. 
Mutations  in  IHH,  encoding  Indian 
hedgehog, cause brachydactyly type A- 1. 
Nat Genet 28(4):386-8.
Gao YH, Shinki T, Yuasa T, Kataoka-Enomoto 
H, Komori T, Suda T, Yamaguchi A. 1998. 
Potential  role  of  cbfa1,  an  essential 
transcriptional  factor  for  osteoblast 
differentiation,  in  osteoclastogenesis: 
regulation  of  mRNA  expression  of 
osteoclast  differentiation  factor  (ODF). 
Biochemical  and  biophysical  research 
communications 252(3):697-702.
Gori F, Hofbauer LC, Dunstan CR, Spelsberg 
TC,  Khosla  S,  Riggs  BL.  2000.  The 
expression  of  osteoprotegerin  and RANK 
ligand  and  the  support  of  osteoclast 
formation  by  stromal-osteoblast  lineage 
cells  is  developmentally  regulated. 
Endocrinology 141(12):4768-76.
Green AE, Jr., Ellswood WH, Collins JR. 1962. 
Melorheostosis and osteopoikilosis, with a 
review of the literature. Am J Roentgenol 
Radium Ther Nucl Med 87:1096-111.
Gustavson KH, Jorulf H. 1975. Different types 
of osteochondrodysplasia in a consecutive 
series of newborns. Helvetica paediatrica 
acta 30(3):307-14.
Hall  CM.  2002.  International  nosology  and 
classification of constitutional disorders of 
bone (2001). Am J Med Genet 113(1):65-
77.
Hartmann C, Tabin CJ. 2001 Wnt-14 plays a 
pivotal  role  in  inducing  synovial  joint 
formation in the developing appendicular 
skeleton. Cell 104(3):341-51. 
Heaney  RP,  Abrams  S,  Dawson-Hughes  B, 
Looker A, Marcus R, Matkovic V, Weaver 
C.  2000.  Peak  bone  mass.  Osteoporos 
Int. 11(12):985-1009.
Heid CA, Stevens J,  Livak KJ,  Williams PM. 
1996.  Real  time  quantitative  PCR. 
Genome Res 6(10):986-94.
Hellemans  J,  Coucke  PJ,  Giedion  A,  Paepe 
AD,  Kramer  P,  Beemer  F,  Mortier  GR. 
2003.  Homozygous  Mutations  in  IHH 
Cause  Acrocapitofemoral  Dysplasia,  an 
Autosomal Recessive Disorder with Cone-
Shaped Epiphyses in Hands and Hips. Am 
J Hum Genet 72(4):1040-6.
Hellemans J, Debeer P, Wright M, Janecke A, 
Kjaer KW, Verdonk PCM, Savarirayan R, 
Basel  L,  Moss  C,  Roth  J,  David  A,  De 
Paepe  A,  Coucke  P,  Mortier  GR.  2006. 
Germline  LEMD3  mutations  are  rare  in 
sporadic  patients  with  isolated 
melorheostosis. Hum Mutat. 27(3):290
Hellemans J,  Preobrazhenska  O,  Willaert  A, 
Debeer P, Verdonk PC, Costa T, Janssens 
K, Menten B, Van Roy N, Vermeulen SJ, 
Savarirayan R, Van Hul W, Vanhoenacker 
F, Huylebroeck D, De Paepe A, Naeyaert 
JM,  Vandesompele  J,  Speleman  F, 
Verschueren  K,  Coucke  PJ,  Mortier  GR. 
2004.  Loss-of-function  mutations  in 
LEMD3 result in osteopoikilosis, Buschke-
Ollendorff  syndrome and melorheostosis. 
Nat Genet 36(11):1213-8.
Hellemans  J,  Mortier  G,  De  Paepe  A, 
Speleman  F,  Vandesompele  J.  2007. 
qBase  relative  quantification  framework 
and  software  for  management  and 
automated  analysis  of  real-time 
quantitative  PCR  data.  Genome  Biol. 
8(2):R19
Higuchi R, Fockler C, Dollinger G, Watson R. 
1993.  Kinetic  PCR  analysis:  real-time 
monitoring of DNA amplification reactions. 
References 107
Bio/technology  (Nature  Publishing 
Company) 11(9):1026-30.
Hunziker  EB.  1994.  Mechanism  of 
longitudinal  bone  growth  and  its 
regulation by growth plate chondrocytes. 
Microscopy  research  and  technique 
28(6):505-19.
Ishimura A, Ng JK, Taira M, Young SG, Osada 
S.  2006.  Man1,  an  inner  nuclear 
membrane  protein,  regulates  vascular 
remodeling  by  modulating  transforming 
growth  factor  beta  signaling. 
Development  (Cambridge,  England) 
133(19):3919-28.
Janssens  K,  Vanhoenacker  F,  Bonduelle  M, 
Verbruggen L, Van Maldergem L, Ralston 
S, Guanabens N, Migone N, Wientroub S, 
Divizia  MT  et  al.  2006.  Camurati-
Engelmann disease: review of the clinical, 
radiological,  and  molecular  data  of  24 
families and implications for diagnosis and 
treatment. J Med Genet 43(1):1-11.
Jobert  AS,  Zhang  P,  Couvineau  A, 
Bonaventure  J,  Roume  J,  Le  Merrer  M, 
Silve  C.  1998.  Absence  of  functional 
receptors  for  parathyroid  hormone  and 
parathyroid  hormone-related  peptide  in 
Blomstrand chondrodysplasia. The Journal 
of clinical investigation 102(1):34-40.
Kallen  B,  Knudsen  LB,  Mutchinick  O, 
Mastroiacovo  P,  Lancaster  P,  Castilla  E, 
Robert  E.  1993.  Monitoring  dominant 
germ  cell  mutations  using  skeletal 
dysplasias  registered  in  malformation 
registries:  an  international  feasibility 
study.  International  journal  of 
epidemiology 22(1):107-15.
Kang S, Graham JM, Jr., Olney AH, Biesecker 
LG.  1997.  GLI3  frameshift  mutations 
cause  autosomal  dominant  Pallister-Hall 
syndrome. Nature genetics 15(3):266-8.
Karp  SJ,  Schipani  E,  St-Jacques  B, 
Hunzelman  J,  Kronenberg  H,  McMahon 
APBR. 2000. Indian hedgehog coordinates 
endochondral  bone  growth  and 
morphogenesis  via  parathyroid  hormone 
related-protein-dependent  and 
-independent  pathways.  Development 
127(3):543-8.
Komori T, Yagi H, Nomura S, Yamaguchi A, 
Sasaki K, Deguchi K, Shimizu Y, Bronson 
RT,  Gao  YH,  Inada  M  et  al.  1997. 
Targeted disruption of Cbfa1 results in a 
complete lack of bone formation owing to 
maturational  arrest  of  osteoblasts.  Cell 
89(5):755-64.
Kornak  U,  Mundlos  S.  2003.  Genetic 
disorders  of  the  skeleton:  a 
developmental  approach.  Am  J  Hum 
Genet 73(3):447-74.
Krane  SM.  2005.  Identifying  genes  that 
regulate  bone  remodeling  as  potential 
therapeutic  targets.  The  Journal  of 
experimental medicine 201(6):841-3.
Lathrop  GM,  Lalouel  JM.  1984.  Easy 
calculations  of  lod  scores  and  genetic 
risks  on  small  computers.  American 
journal of human genetics 36(2):460-5.
Lefebvre V, Li P, de Crombrugghe B. 1998. A 
new  long  form  of  Sox5  (L-Sox5),  Sox6 
and  Sox9  are  coexpressed  in 
chondrogenesis and cooperatively activate 
the  type  II  collagen  gene.  The  EMBO 
journal 17(19):5718-33.
Léri  A,  Joanny  J.  1922.  Une  affection  non 
décrite  des  os.  Hyperostose  "en coulée" 
sur  toute  la  longueur  d'un  membre  ou 
"mélorhéostose".  Bull  et  Mém  Soc  Méd 
Hôp paris 46:1141-1145.
Li J, Sarosi I, Yan XQ, Morony S, Capparelli 
C, Tan HL, McCabe S, Elliott R, Scully S, 
Van G et al. 2000. RANK is the intrinsic 
hematopoietic  cell  surface  receptor  that 
controls osteoclastogenesis and regulation 
of  bone  mass  and  calcium  metabolism. 
Proceedings  of  the  National  Academy of 
Sciences of the United States of America 
97(4):1566-71.
Livak KJ,  Schmittgen TD. 2001. Analysis of 
relative gene expression data using real-
time  quantitative  PCR  and  the  2(-Delta 
Delta C(T)) Method. Methods 25(4):402-
8.
MacCabe JA, Errick J, Saunders JW, Jr. 1974. 
Ectodermal  control  of  the  dorsoventral 
axis in the leg bud of the chick embryo. 
Developmental biology 39(1):69-82.
Marieb E, Hoehn K. 2006. Human Anatomy & 
Physiology: Benjamin Cummings.
McKusick VA, Scott CI. 1971. A nomenclature 
for  constitutional  disorders  of  bone.  J 
Bone Joint Surg Am 53(5):978-86.
Mello  MA,  Tuan  RS.  1999.  High  density 
micromass cultures of embryonic limb bud 
mesenchymal cells: an in vitro model of 
108 Chapter 5 - Discussion
endochondral  skeletal  development.  In 
Vitro Cell Dev Biol Anim 35(5):262-9.
Menten B, Buysse K,  Zahir F, Hellemans J, 
Hamilton  SJ,  Costa  T,  Fagerstrom  C, 
Anadiotis G, Kingsbury D, McGillivray BC, 
Marra  MA,  Friedman  JM,  Speleman  F, 
Mortier  GR.  2007.  Osteopoikilosis,  short 
stature  and  mental  retardation  as  key 
features of a new microdeletion syndrome 
on 12q14.  J Med Genet. [Epub ahead of 
print].
Minina E, Kreschel C, Naski MC, Ornitz DM, 
Vortkamp  A.  2002.  Interaction  of  FGF, 
Ihh/Pthlh,  and  BMP  signaling  integrates 
chondrocyte  proliferation  and 
hypertrophic  differentiation.  Dev  Cell 
3(3):439-49.
Moore G. 1965. Cramming more components 
onto  integrated  circuits.  Electronics 
38(8):114-117.
Morinobu M,  Nakamoto T,  Hino K,  Tsuji  K, 
Shen  ZJ,  Nakashima  K,  Nifuji  A, 
Yamamoto H, Hirai H, Noda M. 2005. The 
nucleocytoplasmic  shuttling  protein  CIZ 
reduces  adult  bone  mass  by  inhibiting 
bone morphogenetic protein-induced bone 
formation.  The  Journal  of  experimental 
medicine 201(6):961-70.
Mortier GR. 2001. The diagnosis of skeletal 
dysplasias:  a  multidisciplinary  approach. 
European journal of radiology 40(3):161-
7.
Mortier  GR,  Kramer PP,  Giedion  A,  Beemer 
FA. 2003. Acrocapitofemoral dysplasia: an 
autosomal  recessive  skeletal  dysplasia 
with cone shaped epiphyses in the hands 
and hips. J Med Genet 40(3):201-7.
Mundlos S, Otto F, Mundlos C, Mulliken JB, 
Aylsworth  AS,  Albright  S,  Lindhout  D, 
Cole WG, Henn W, Knoll JH et al. 1997. 
Mutations  involving  the  transcription 
factor  CBFA1  cause  cleidocranial 
dysplasia. Cell 89(5):773-9.
Nakashima K, Zhou X, Kunkel  G, Zhang Z, 
Deng JM, Behringer RR, de Crombrugghe 
B. 2002. The novel zinc finger-containing 
transcription factor osterix is required for 
osteoblast  differentiation  and  bone 
formation. Cell 108(1):17-29.
Nilsson  O,  Marino  R,  De  Luca  F,  Phillip  M, 
Baron J. 2005. Endocrine regulation of the 
growth  plate.  Hormone  research 
64(4):157-65.
Nishio  Y,  Dong  Y,  Paris  M,  O'Keefe  RJ, 
Schwarz  EM,  Drissi  H.  2006  Runx2-
mediated  regulation  of  the  zinc  finger 
Osterix/Sp7 gene. Gene. 10;372:62-70.
Niswander  L.  2002.  Interplay  between  the 
molecular signals  that control  vertebrate 
limb  development.  The  International 
journal  of  developmental  biology 
46(7):877-81.
Niswander  L.  2003.  Pattern  formation:  old 
models  out  on  a  limb.  Nature  reviews 
4(2):133-43.
O'Rahilly R, Gardner E. 1975. The timing and 
sequence of events in the development of 
the limbs in the human embryo. Anatomy 
and embryology 148(1):1-23.
Offiah  AC,  Hall  CM.  2003.  Radiological 
diagnosis of the constitutional disorders of 
bone. As easy as A, B, C? Pediatr Radiol 
33(3):153-61.
Orioli IM, Castilla EE, Barbosa-Neto JG. 1986. 
The birth prevalence rates for the skeletal 
dysplasias.  Journal  of  medical  genetics 
23(4):328-32.
Otto  EA,  Loeys  B,  Khanna H,  Hellemans J, 
Sudbrak R, Fan S, Muerb U, O'Toole JF, 
Helou  J,  Attanasio  M  et  al.  2005. 
Nephrocystin-5,  a  ciliary  IQ  domain 
protein,  is  mutated  in  Senior-Loken 
syndrome  and  interacts  with  RPGR  and 
calmodulin. Nature genetics 37(3):282-8.
Otto F, Thornell  AP, Crompton T, Denzel A, 
Gilmour  KC,  Rosewell  IR,  Stamp  GW, 
Beddington RS,  Mundlos S,  Olsen BR et 
al.  1997.  Cbfa1,  a  candidate  gene  for 
cleidocranial  dysplasia  syndrome,  is 
essential for osteoblast differentiation and 
bone development. Cell 89(5):765-71.
Parrot  J.  1886.  Sur  la  malformation 
achondroplasique  et  le  dieu  Phtah.  In: 
Parrot J, editor. La syphilis héréditaire et 
le rachitis. p 280-284.
Pfaffl MW. 2001. A new mathematical model 
for relative quantification in real-time RT-
PCR. Nucleic Acids Res 29(9):e45.
Quinn JM,  Elliott  J,  Gillespie MT, Martin TJ. 
1998.  A  combination  of  osteoclast 
differentiation  factor  and  macrophage-
colony stimulating factor is sufficient for 
both  human  and  mouse  osteoclast 
formation  in  vitro.  Endocrinology 
139(10):4424-7.
References 109
Rasmussen  SA,  Bieber  FR,  Benacerraf  BR, 
Lachman  RS,  Rimoin  DL,  Holmes  LB. 
1996.  Epidemiology  of 
osteochondrodysplasias:  changing  trends 
due to advances in prenatal diagnosis. Am 
J Med Genet 61(1):49-58.
Riddle  RD,  Johnson  RL,  Laufer  E,  Tabin  C. 
1993.  Sonic  hedgehog  mediates  the 
polarizing  activity  of  the  ZPA.  Cell 
75(7):1401-16.
Rockwood C, Wilkins K, King R. Fractures in 
Children: Lippincott.
Rutledge RG, Cote C. 2003. Mathematics of 
quantitative  kinetic  PCR  and  the 
application  of  standard  curves.  Nucleic 
acids research 31(16):e93.
Saiki  RK, Gelfand DH, Stoffel  S,  Scharf  SJ, 
Higuchi R, Horn GT, Mullis KB, Erlich HA. 
1988.  Primer-directed  enzymatic 
amplification of DNA with a thermostable 
DNA  polymerase.  Science 
239(4839):487-91.
Saiki RK, Scharf S, Faloona F, Mullis KB, Horn 
GT,  Erlich  HA,  Arnheim  N.  1985. 
Enzymatic  amplification  of  beta-globin 
genomic  sequences  and  restriction  site 
analysis  for  diagnosis  of  sickle  cell 
anemia. Science 230(4732):1350-4.
Sanger F, Coulson AR. 1975. A rapid method 
for  determining  sequences  in  DNA  by 
primed  synthesis  with  DNA  polymerase. 
Journal of molecular biology 94(3):441-8.
Schipani  E, Lanske B, Hunzelman J, Luz A, 
Kovacs  CS,  Lee  K,  Pirro  A,  Kronenberg 
HM,  Juppner  H.  1997.  Targeted 
expression  of  constitutively  active 
receptors  for  parathyroid  hormone  and 
parathyroid  hormone-related  peptide 
delays endochondral bone formation and 
rescues  mice  that  lack  parathyroid 
hormone-related peptide. Proc Natl  Acad 
Sci U S A 94(25):13689-94.
Seeley R, Stephens T, Tate P. 2006. Anatomy 
and Physiology: McGraw-Hill.
Serra E, Rosenbaum T, Winner U, Aledo R, 
Ars  E,  Estivill  X,  Lenard  HG,  Lazaro  C. 
2000.  Schwann cells  harbor the somatic 
NF1 mutation in neurofibromas: evidence 
of  two  different  Schwann  cell 
subpopulations.  Hum  Mol  Genet 
9(20):3055-64.
Shiang R, Thompson LM, Zhu YZ, Church DM, 
Fielder  TJ,  Bocian  M,  Winokur  ST, 
Wasmuth  JJ.  1994.  Mutations  in  the 
transmembrane  domain  of  FGFR3  cause 
the  most  common  genetic  form  of 
dwarfism, achondroplasia. Cell 78(2):335-
42.
Shier  D,  Butler  JN,  Lewis  R.  1996.  Hole's 
Human  Anatomy  and  Physiology: 
McGraw-Hill.
Simonet WS, Lacey DL, Dunstan CR, Kelley 
M,  Chang  MS,  Luthy  R,  Nguyen  HQ, 
Wooden  S,  Bennett  L,  Boone  T  et  al. 
1997.  Osteoprotegerin:  a novel  secreted 
protein involved in the regulation of bone 
density. Cell 89(2):309-19.
Spranger J, Brill P, Poznanski A. 2002. Bone 
Dysplasia - An Atlas of Genetic Disorders 
of  Skeletal  Development:  Oxford 
University Press.
Stieda  A.  1905.  Über  umschriebene 
Knochenverdichtungen  im  Bereich  der 
Substantia  spongiosa  in  Roentgenbilde. 
Beitr Klin Chir 45:700-703.
St-Jacques B, Hammerschmidt  M, McMahon 
AP.  1999.  Indian  hedgehog  signaling 
regulates proliferation and differentiation 
of chondrocytes and is essential for bone 
formation. Genes Dev 13(16):2072-86.
Stoll  C, Dott B, Roth MP, Alembik Y. 1989. 
Birth  prevalence  rates  of  skeletal 
dysplasias. Clinical genetics 35(2):88-92.
Storm  EE,  Kingsley  DM.  1999.  GDF5 
coordinates  bone  and  joint  formation 
during digit development. Developmental 
biology 209(1):11-27.
Summerbell  D.  1974.  Interaction  between 
the  proximo-distal  and  antero-posterior 
co-ordinates of positional value during the 
specification  of  positional  information  in 
the early development of the chick limb-
bud.  Journal  of  embryology  and 
experimental morphology 32(1):227-37.
Sun  X,  Mariani  FV,  Martin  GR.  2002. 
Functions of FGF signalling from the apical 
ectodermal  ridge  in  limb  development. 
Nature 418(6897):501-8.
Superti-Furga A, Bonafe L, Rimoin DL. 2001. 
Molecular-pathogenetic  classification  of 
genetic  disorders  of  the  skeleton.  Am J 
Med Genet 106(4):282-93.
110 Chapter 5 - Discussion
Superti-Furga  A,  Unger  S.  2007  Nosology 
and  classification  of  genetic  skeletal 
disorders: 2006 revision. Am J Med Genet 
A. 143(1):1-18. 
Takahashi N, Akatsu T, Udagawa N, Sasaki T, 
Yamaguchi  A,  Moseley  JM,  Martin  TJ, 
Suda  T.  1988.  Osteoblastic  cells  are 
involved  in  osteoclast  formation. 
Endocrinology 123(5):2600-2.
Teitelbaum  SL,  Ross  FP.  2003.  Genetic 
regulation of osteoclast development and 
function. Nature reviews 4(8):638-49.
Tickle  C.  1981.  The  number  of  polarizing 
region cells required to specify additional 
digits  in  the  developing  chick  wing. 
Nature 289(5795):295-8.
Trivier E, De Cesare D, Jacquot S, Pannetier 
S, Zackai E, Young I, Mandel JL, Sassone-
Corsi  P,  Hanauer  A.  1996.  Mutations  in 
the kinase Rsk-2 associated with Coffin-
Lowry syndrome. Nature 384(6609):567-
70.
Urist M. 1980. Fundamental and Clinical Bone 
Physiology: Lippincott.
Vandesompele  J,  De  Preter  K,  Pattyn  F, 
Poppe  B,  Van  Roy  N,  De  Paepe  A, 
Speleman  F.  2002.  Accurate 
normalization  of  real-time  quantitative 
RT-PCR  data  by  geometric  averaging  of 
multiple  internal  control  genes.  Genome 
Biol 3(7):RESEARCH0034.
Vesalius  A.  1543.  De  Humani  corporis 
fabrica.
Vortkamp A, Gessler M, Grzeschik KH. 1991. 
GLI3  zinc-finger  gene  interrupted  by 
translocations in Greig syndrome families. 
Nature 352(6335):539-40.
Vortkamp  A,  Lee  K,  Lanske  B,  Segre  GV, 
Kronenberg  HM,  Tabin  CJBR.  1996. 
Regulation  of  rate  of  cartilage 
differentiation  by  Indian  hedgehog  and 
PTH-related  protein.  Science 
273(5275):613-22.
Wagner T, Wirth J, Meyer J, Zabel B, Held M, 
Zimmer J, Pasantes J, Bricarelli FD, Keutel 
J,  Hustert E et  al.  1994.  Autosomal sex 
reversal  and  campomelic  dysplasia  are 
caused by mutations  in  and  around the 
SRY-related gene SOX9. Cell 79(6):1111-
20.
Weber JL, May PE. 1989. Abundant class of 
human DNA polymorphisms which can be 
typed  using  the  polymerase  chain 
reaction. Am J Hum Genet 44(3):388-96.
Weissenbach J, Gyapay G, Dib C, Vignal A, 
Morissette  J,  Millasseau  P,  Vaysseix  G, 
Lathrop  M.  1992.  A  second-generation 
linkage  map  of  the  human  genome. 
Nature 359(6398):794-801.
Yang  X,  Matsuda  K,  Bialek  P,  Jacquot  S, 
Masuoka HC, Schinke T, Li L, Brancorsini 
S,  Sassone-Corsi  P,  Townes  TM  et  al. 
2004. ATF4 is a substrate of RSK2 and an 
essential  regulator of osteoblast biology; 
implication  for  Coffin-Lowry  Syndrome. 
Cell 117(3):387-98.
Yasuda H, Shima N, Nakagawa N, Mochizuki 
SI,  Yano  K,  Fujise  N,  Sato  Y,  Goto  M, 
Yamaguchi  K, Kuriyama M et al.  1998a. 
Identity  of  osteoclastogenesis  inhibitory 
factor (OCIF) and osteoprotegerin (OPG): 
a mechanism by which OPG/OCIF inhibits 
osteoclastogenesis in vitro. Endocrinology 
139(3):1329-37.
Yasuda H, Shima N, Nakagawa N, Yamaguchi 
K, Kinosaki M, Mochizuki S, Tomoyasu A, 
Yano K, Goto M, Murakami A et al. 1998b. 
Osteoclast differentiation factor is a ligand 
for  osteoprotegerin/osteoclastogenesis-
inhibitory  factor  and  is  identical  to 
TRANCE/RANKL. Proc Natl Acad Sci U S A 
95(7):3597-602.
Yoshida H, Hayashi S, Kunisada T, Ogawa M, 
Nishikawa S, Okamura H, Sudo T, Shultz 
LD,  Nishikawa  S.  1990.  The  murine 
mutation  osteopetrosis  is  in  the  coding 
region  of  the  macrophage  colony 
stimulating  factor  gene.  Nature 
345(6274):442-4.
Zhao  M,  Harris  SE,  Horn  D,  Geng  Z, 
Nishimura R, Mundy GR, Chen D. 2002. 
Bone  morphogenetic  protein  receptor 
signaling is necessary for normal murine 
postnatal  bone  formation.  J  Cell  Biol 
157(6):1049-60.
References 111
Summary
Genetic  abnormalities  in  the  development, 
growth,  and  maintenance  of  cartilage  and 
bone can result in the many and varied forms 
of  skeletal  dysplasias 
(osteochondrodysplasias).   Common  clinical 
manifestations  include  short  stature,  early-
onset  osteoartritis,  fractures  due  to 
osteoporosis,  joint  pain  and  even 
extraskeletal malformations.  The phenotypic 
severity  of  this  heterogeneous  group  of 
disorders ranges from asymptomatic to death 
in  the  neonatal  period.   Although  single 
entities had been described in the nineteenth 
century,  considerable  heterogeneity  was 
recognized  by  the  middle  of  last  century 
leading  to  the  current  description  of  about 
300  skeletal  dysplasias.   They  are 
individually  rare,  but  collectively  quite 
common with an estimated prevalence of 2 
to 5 per 10,000 newborns.
The  most  important  aim of  my PhD thesis 
was to identify the genes responsible for  a 
selection  of  skeletal  dysplasias.   In  this 
thesis,  the  results  for  acrocapitofemoral 
dysplasia, osteopoikilosis and melorheostosis 
are presented.
Acrocapitofemoral  dysplasia  (ACFD)  is  a 
recently  described  skeletal  dysplasia  with 
autosomal  recessive  inheritance, 
characterized  clinically  by  a  short  stature 
with  short  limbs,  and  radiographically  by 
cone-shaped epiphyses, mainly in hands and 
feet.   These  cone-shaped  epiphyses  reflect 
an early stage in the premature fusion of the 
growth  plate  that  will  ultimately  result  in 
shortening of the involved skeletal elements.
ACFD  has  so  far  been  identified  in  two 
consanguineous families, both of which were 
included in a homozygosity mapping strategy 
to  identify  the  causal  gene.   Using  400 
microsatellite markers from a commercial kit 
for genome wide linkage analysis, the causal 
mutation could be mapped to an interval of 5 
cM  on  chromosome  2q35-q36.   Based  on 
their  known  function  and  involvement  in 
related disorders,  IGFBP2,  IGFBP5,  IHH and 
STK36 were  selected  as  candidate  genes 
(candidate  gene  approach).   Subsequently, 
sequencing of  IHH revealed the presence of 
homozygous  missense  mutations  in  all 
affected  individuals:  c.137C>T  for  both 
patients of a Belgian family and c.569T>C for 
the three patients of a Dutch family.   Both 
mutations  were  considered  causal  for  the 
phenotype  because  they  segregate  along 
with  the  phenotype  and  affect  completely 
conserved  amino  acids.   These  mutations 
disturb  the  normal  function  of   IHH in  the 
growth  plate  and  probably  cause  an 
increased rate of chondrocyte differentiation 
leading  to  a  premature  epimetaphyseal 
fusion of the involved growth plate.
Osteopoikilosis, Buschke-Ollendorff syndrome 
(BOS) and melorheostosis are rare sclerosing 
dysplasias.   Osteopoikilosis  is  a  benign, 
usually  asymptomatic  condition  with 
autosomal  dominant  inheritance  that  is 
characterized  by  a  symmetric  but  unequal 
distribution of multiple hyperostotic areas in 
different  parts  of  the  skeleton. 
Osteopoikilosis  often  co-occurs  with 
disseminated  connective  tissue  nevi  and  is 
then  known  as  the  Buschke-Ollendorff 
syndrome.   Melorheostosis,  on  the  other 
hand,  is  a  more  severe  disorder  that  is 
radiographically  characterized  by  an 
asymmetric  flowing  hyperostosis  of  the 
cortex  of  tubular  bones  that  is  often 
accompanied  by  abnormalities  of  adjacent 
soft  tissue.   Melorheostosis  usually  causes 
joint contractures, stiffness and chronic pain.
The  occurrence  of  one  or  more  of  these 
conditions  in  the  same individual  or  family 
suggested  that  they  may  represent  allelic 
disorders.   A genome wide linkage analysis 
was  performed  on  three  families  in  which 
affected  individuals  had osteopoikilosis  with 
or  without  manifestations  of  BOS  or 
melorheostosis.   This  resulted  in  a  linkage 
interval  of  24  cM  on  chromosome  12q12-
q14.3.   Subsequently,  a  microdeletion, 
partially  overlapping  this  interval,  was 
identified  in  an  unrelated  patient  with  the 
unusual association of osteopoikilosis,  short 
stature and learning disabilities.  This finding 
reduced  the  candidate  region  to  a  3  Mb 
interval  containing  23  genes.   Using  a 
candidate  gene  approach,  LEMD3 was 
selected for  sequencing which subsequently 
lead  to  the  identification  of  heterozygous 
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loss-of-function mutations in all patients from 
these  3  families.   Mutation  analysis  in  a 
larger set of patients confirmed that almost 
all  individuals  with  osteopoikilosis  or  BOS 
have  an  inactivating  LEMD3 mutation, 
whereas most sporadic patients with isolated 
melorheostosis  have  normal  results  after 
LEMD3 analysis.
By  means  of  a  yeast-two-hybrid  screening, 
LEMD3 was shown to interact with the MH2 
domain  of  both  BMP  and  TGFβ specific 
SMADs.   Two  functional  experiments 
demonstrated an inhibitory effect  of LEMD3 
on SMAD mediated  BMP and TGFβ signaling. 
Increasing  amounts  of  LEMD3  reduced  the 
expression of SMAD target genes after BMP 
stimulation,  and  similarly  LEMD3 
overexpression resulted in reduced luciferase 
activity  in  cells  with  constitutively  active 
TGFβ signaling.
Whereas the first part of this thesis aimed to 
identify the genetic defects for a selection of 
skeletal  dysplasias, the focus in the second 
part was partially shifted to the development 
of  improved  methods  and  a  program  for 
automated qPCR analysis.
Nucleic  acid  quantification  in  general  and 
gene  expression  analysis  more  specifically 
are  becoming  increasingly  important  in 
biological  research  and  clinical  decision 
making,  with  real-time  quantitative  PCR 
(qPCR)  becoming  the  method of  choice  for 
expression  profiling  of  selected  genes. 
Advancements in instruments and detection 
chemistry,  and  improved  assay  design 
guidelines  have  made  the  practical 
performance of qPCR measurements feasible 
for  most  users.  However,  accurate  and 
straightforward processing of the raw data as 
well  as  the  management  of  large  and 
growing data sets remain the major hurdles 
in  this  type  of  PCR based gene  expression 
analysis.
My  dissatisfaction  with  the  available  qPCR 
tools  led  me  to  write  a  program for  qPCR 
data management and analysis: qBase.
This program allows data to be imported in 
any  of  the  numerous  data  formats  being 
used.   These  data  can  be  managed  by 
organizing them into runs, experiments and 
projects,  and  by  annotating  them  in  the 
qBase Browser module.  The Analysis module 
subsequently allows data from multiple runs 
to be analyzed as a whole without limitations 
on  the  number  of  samples,  genes  or 
replicates.   An automated  raw data quality 
control is included to prevent inprecise data 
being used in calculations.   qBase employs 
an  advanced  quantification  algorithm  that 
allows gene specific amplification efficiencies 
and  normalization  with  multiple  reference 
genes to be used.  The obtained results can 
easily  be  exported  in  tabular  format,  or 
visualized  as  a  gene-specific  or  multi-gene 
histogram.
In addition to the functionalities of the qBase 
program  a  number  of  new  calculation 
methods  were  developed  to  improve  data 
analysis.  Firstly, the error on the estimated 
amplification  efficiency  is  calculated  and 
propagated  throughout  calculations. 
Secondly, algorithms for inter-run calibration 
were  developed  to  correct  for  the  often 
underestimated run-to-run variation, and to 
allow comparing results from samples located 
on different plates.  Together, the improved 
calculation methods and the qBase program 
allow  for  faster  and  more  reliable  qPCR 
analysis.
No  other  packages  with  comparable 
functionality  are  available  for  the  moment. 
qBase has been recognized as a very useful 
and advanced tool for qPCR data analysis by 
the scientific community.  This is reflected by 
the  fact  that  the  program  has  been 
downloaded (http://medgen.ugent.be/qBase) 
by  over  2000  users  from  more  than  80 
countries.
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Samenvatting
Genetische  afwijkingen  in  de  ontwikkeling, 
groei en homeostase van kraakbeen en bot 
kunnen resulteren in een van de vele vormen 
van  skeletdysplasieën 
(osteochondrodysplasias).   Klinisch  worden 
deze  aandoeningen  veelal  gekenmerkt  door 
kleine gestalte, osteoartritis op jonge leeftijd, 
botbreuken  ten  gevolge  van  osteoporose, 
gewrichtspijn  en  zelfs  extraskeletale 
afwijkingen.  De ernst van deze heterogene 
groep  aandoeningen  varieert  van 
asymptomatisch tot vroegtijdig overlijden in 
de  neonatale  periode.   De  eerste  types 
werden  reeds  in  de  negentiende  eeuw 
gedefinieerd,  maar  de  herkenning  van 
aanzienlijke heterogeniteit halverwege vorige 
eeuw  leidde  tot  de  beschrijving  van  300 
skeletdysplasieën  op  dit  moment. 
Individueel  zijn  deze  aandoeningen 
zeldzaam,  maar  gezamelijk  zijn  ze  redelijk 
frequent met een geschatte prevalentie van 2 
tot 5 per 10.000 geboortes.
De  hoofddoelstelling  van  mijn 
doctoraatsthesis  was de identificatie van de 
genen verantwoordelijk voor een selectie van 
skeletdysplasieën.  In deze thesis worden de 
resultaten voor acrocapitofemorale dysplasie, 
osteopoikilosis  en  melorheostosis 
voorgesteld.
Acrocapitofemorale  dysplasie  (ACFD)  is  een 
recent  beschreven  skeletdysplasie  met 
autosomaal recessieve overerving die klinisch 
gekarakteriseerd  wordt  door  kleine  gestalte 
met  korte  ledematen,  en  radiologisch  door 
kegelvormige  epiphysen,  voornamelijk  in 
handen  en  voeten.   Deze  kegelvormige 
epiphysen typeren een vroeg stadium van de 
premature  sluiting  van  de  groeischijf  die 
uiteindelijk  resulteert  in een verkorting van 
de getroffen botten.
ACFD werd  tot  op  heden  geïdentificeerd  in 
twee  consanguine  families  die  beiden 
geïncludeerd  werden  in  een 
homozygoziteitsmapping voor de identificatie 
van het causale gen.  Met behulp van de 400 
microsatelliet  merkers  uit  een  commerciële 
kit  voor  genoomwijd  koppelingsonderzoek 
kon de causale mutatie gelokaliseerd worden 
binnen een interval van 5 cM op chromosoom 
2q35-q36.  Op basis van hun gekende functie 
en betrokkendheid in verwante aandoeningen 
werden  IGFBP2,  IGFBP5,  IHH en  STK36 
geselecteerd  als  kandidaat  genen. 
Vervolgens kon door middel van sequeneren 
een  homozygote  IHH mutatie  aangetoond 
worden  in  alle  aangetaste  individuen: 
c.137C>T in de patiënten van de Belgische 
familie en c.569T>C in de drie patiënten van 
de  Nederlandse  familie.   Aangezien  beide 
mutaties  samen  met  het  phenotype 
segregeren  en  volledig  geconserveerde 
aminozuren aantasten werden ze als causaal 
beschouwd.  De premature epimetaphysaire 
sluiting  in  ACFD  patiënten  wordt 
waarschijnlijk  veroorzaakt  door  een 
verhoogde  differentiatiesnelheid  van 
kraakbeencellen  ten  gevolge  van  een 
verstoorde werking van IHH in de groeischijf.
Osteopoikilosis, Buschke-Ollendorff syndrome 
(BOS)  en  melorheostosis  zijn  zeldzame 
scleroserende dysplasieën.  Osteopoikilosis is 
een  goedaardige,  meestal  asymptomatische 
aandoening  met  autosomaal  dominante 
overerving.   Ze  wordt  getypeerd  door  het 
ongelijkmatig maar symmetrisch voorkomen 
van  kleine  hyperostotische  letsels  in 
verschillende  delen  van  het  skelet. 
Osteopoikilosis komt vaak voor in combinatie 
met bindweefseelletsels en staat dan gekend 
als  het  Buschke-Ollendorff  syndroom. 
Melorheostosis is daarentegen een ernstigere 
aandoening  die  radiologisch  gekenmerkt 
wordt  door  een  asymmetrisch  vloeiende 
hyperostose  van  de  cortex  van  de  lange 
beenderen.   Het  zacht  weefsel  rond  deze 
skeletale  letselts  is  ook  vaak  aangetast. 
Melorheostosis  patiënten lijden meestal  aan 
gewrichtscontracturen,  stijfheid  van  de 
aangetaste ledematen en chronische pijn.
Het voorkomen van osteopoikilosis,  BOS en 
melorheostosis in dezelfde patiënt of familie 
suggereerde  dat  ze  allelische  aandoeningen 
zijn.   Een genoomwijd  koppelingsonderzoek 
werd  uitgevoerd  op  3  families  waarin 
osteopoikilosis, al dan niet in combinatie met 
BOS of melorheostosis, voorkomt.  Hiermee 
werd  een  gekoppelde  regio  van  24  cM  op 
chromosoom  12q12-q14.3  geïdentificeerd. 
Vervolgens  werd  in  een  patiënt  met  de 
ongewone combinatie van osteopoikilosis met 
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kleine  gestalte  en  leerproblemen  een 
microdeletie  gevonden  die  de  gekoppelde 
regio  gedeeltelijk  overlapte.   Op  basis 
hiervan  kon de  kandidaatregio  gereduceerd 
worden tot een interval van 3 Mb dat slechts 
23  genen  bevatte.   Met  behulp  van  een 
kandidaat-gen  benadering  werd  LEMD3 
geselecteerd  voor  sequentie  analyse.  Dit 
resulteerde uiteindelijk in de identificatie van 
heterozygote loss-of-function mutaties in alle 
patiënten van de drie onderzochte families. 
Mutatie analyse in een grotere set patiënten 
bevestigde  vervolgens  dat  bijna  alle 
individuen  met  osteopoikilosis  of  BOS  een 
inactiverende  LEMD3 mutatie  draagden, 
terwijl de meeste sporadische patiënten met 
geïsoleerde  melorheostosis  normale 
resultaten hadden voor LEMD3.
Door  middel  van  een  yeast-two-hybrid 
screening kon aangetoond worden dat LEMD3 
interageert met het MH2 domein van BMP en 
TGFβ specifieke SMAD's.  In twee functionele 
experimenten kon een inhibitorisch effect van 
LEMD3 op SMAD gemedieerde BMP en  TGFβ 
signalisatie  aangetoond  worden. 
Toenemende  hoeveelheden  LEMD3 
reduceerden  de  expressie  van  SMAD 
gereguleerde  genen  na  BMP  stimulatie,  en 
LEMD3  overexpressie  resulteerde  in  een 
verlaagde  luciferase  activiteit  in  cellen  met 
een consitutief actieve TGFβ signalisatie.
In  het  eerste  deel  van  deze  thesis  werd 
getracht  de  genetische  defecten 
verantwoordelijk  voor  een  selectie  van 
skeletdysplasieën  te  identificeren.   In  een 
tweede deel  verschoof  de focus gedeeltelijk 
naar  de  ontwikkeling  van  verbeterde 
methodes  en  een  programma  voor 
geautomatiseerde qPCR analyse.
De quantificatie van nucleïnezuren, en in het 
bijzonder  genexpressieanalyse,  worden 
steeds  belangrijker  in  zowel  biologisch 
onderzoek  als  in  de  klinische  diagnostiek. 
Real-time  quantitative  PCR  (qPCR)  is 
momenteel  de  geprefereerde  methode 
geworden  voor  het  bepalen  van  de 
expressieprofielen  voor  een  selectie  van 
genen.   Verbeterde  instrumenten  en 
detectiemethoden,  alsook  geoptimaliseerde 
richtlijnen  voor  het  opstellen  van 
experimenten  hebben  de  praktische 
uitvoering van qPCR experimenten haalbaar 
gemaakt  voor  de  meeste  gebruikers. 
Nochtans blijven de accurate en eenvoudige 
verwerking  van  de  ruwe  data,  alsook  het 
beheer van steeds groter wordende data sets 
grote  hindernissen  voor  dit  type  van  PCR 
gebaseerde gen expressie analyse.
De ontevredenheid over de beschikbare qPCR 
tools zette me ertoe aan om een programma 
te schrijven (qBase) waarmee de qPCR data 
zowel  beheerd  als  geanalyseerd  kunnen 
worden.
De Browser module van dit programma laat 
toe  om  data  te  importeren  vanuit  de 
verschillende  formaten  die  momenteel  in 
omloop  zijn.   Deze  data  kunnen  dan 
vervolgens  beheerd  worden  door  ze  te 
annoteren  en  te  organiseren  in  runs, 
experimenten  en projecten.   In de Analyse 
module kunnen de data van een verzameling 
runs  geanalyzeerd  worden  zonder 
beperkingen op het aantal stalen, genen of 
technische  herhalingen.   Een  automatische 
controle op de ruwe data kan voorkomen dat 
data van lage qualiteit gebruikt worden bij de 
berekeningen.  qBase past een geavanceerd 
quantificatie algoritme toe waarmee rekening 
gehouden  kan  worden  met  genspecifieke 
amplificatie  efficienties  en  normalisatie  op 
basis  van  meerdere  referetiegenen 
uitgevoerd  kan  worden.   De  berekende 
resultaten  kunnen  eenvoudig  in  tabelvorm 
geëxporteerd  worden,  of  gevisualiseerd 
worden in grafiekvorm voor een enkel of voor 
meerdere genen.
Naast  de functionaliteit  die  door  het  qBase 
programma wordt geboden, werden ook een 
aantal  nieuwe  berekeningsmethoden 
ontwikkeld  voor  verbeterde  data  analyse. 
Ten  eerste  werd  de  fout  op  de  geschatte 
amplificatie  efficientie  berekend  en 
gepropageerd  doorheen  alle  berekeningen. 
Ten  tweede  werd  een  algoritme ontwikkeld 
om te corrigeren voor de vaak onderschatte 
variatie tussen runs zodat de resultaten van 
stalen  op  verschillende  platen  met  elkaar 
vergeleken kunnen worden.   De verbeterde 
berekeningsmethoden  en  het  qBase 
programma laten gezamelijk een snellere en 
betere analyse van qPCR experimenten toe.
Op  dit  moment  zijn  geen  paketten 
beschikbaar  met  een  functionaliteit  die 
vergelijkbaar is aan die van qBase.  Het feit 
dat  qBase  reeds  door  meer  dan  2000 
gebruikers  uit  80  landen werd  gedownload 
(http://medgen.ugent.be/qBase)  toont  aan 
dat dit programma erkend wordt als een zeer 
bruikbare  tool  voor  geavanceerde  qPCR 
analyzes.
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Résumé
Des  anomalies  génétiques  dans  le 
développement, la croissance et le maintien 
du cartilage et des os peuvent mener à des 
formes  de  dysplasies  osseuses 
(ostéochondrodysplasies)  nombreuses  et 
variées.  Parmi  les  manifestations  cliniques 
habituelles  l’on  observe:  petite  stature, 
ostéoarthrite  précoce,  fractures  dues  à 
l’ostéoporose,  arthralgie  et  même  des 
malformations extrasquelettiques. La sévérité 
phénotypique  de  ce  groupe  hétérogène 
d’affections  varie  d’asymptomatique  à  la 
mort en période néonatale. Bien que des cas 
particuliers aient été décrits dans le courant 
du dix-neuvième siècle, c’est l’hétérogénéité 
importante, identifiée vers le milieu du siècle 
dernier, qui a mené à la description actuelle 
d’environ  300 dysplasies  osseuses.  Ils  sont 
rares  pris  individuellement,  mais 
collectivement  ils  sont  assez  commun avec 
une prévalence estimée de 2 à 5 par 10.000 
nouveaux-nés.
Le principal  objectif  de ma thèse PhD était 
d’identifier  les  gènes  responsables  d’une 
sélection de dysplasies osseuses. Dans cette 
thèse  sont  présentés  les  résultats  pour  la 
dysplasie  acrocapitofémorale,  l’ostéopoécilie 
et la mélorhéostose.
La  dysplasie  acrocapitofémorale  (ACFD)  est 
une  dysplasie  osseuse  récemment  décrite 
d'hérédité  autosomique  récessive, 
caractérisée  cliniquement  par  une  petite 
stature  avec  des  membres  courts,  et 
radiographiquement  par  des  épiphyses 
coniques,  principalement  aux  mains  et  aux 
pieds.  Ces  épiphyses  coniques  révèlent  un 
stade précoce dans la fusion prématurée du 
cartilage épiphysaire qui aboutira finalement 
à  un  raccourcissement  des  éléments 
squelettiques concernés.
ACFD a jusqu’à présent été identifiée en deux 
familles  consanguines,  qui  toutes  deux  ont 
été  inclues  dans  une  stratégie  de 
cartographie par homozygotie pour identifier 
le  gène causal.  A  l’aide  de 400  marqueurs 
microsatellites  d’un  kit  commercial  pour 
l’analyse  de  liaison  du  génome  entier,  la 
mutation  causale  a  été  localisée  à  un 
intervalle de 5 cM dans le chromosome 2q35-
q36.  Basé  sur  leur  fonction  connue  et 
implication dans des affections apparentées, 
IGFBP2,  IGFBP5,  IHH et  SKT36 ont  été 
sélectionnés  comme  gènes  candidats 
(l'approche du gène candidat). 
Ensuite,  la  détermination  de  la  séquence 
d’IHH a  révélé  la  présence  de  mutations 
faux-sens  homozygote  dans  tous  les 
individus  atteints:  c.137C>T  pour  les  deux 
patients  d’une  famille  belge  et  c.569T>C 
pour  les  trois  patients  d’une  famille 
néerlandaise.  Les  deux  mutations  ont  été 
considérées  causales  pour  le  phénotype  et 
atteignent  des  aminoacides  entièrement 
conservées.  Ces  mutations  perturbent  le 
fonctionnement  normal  d’IHH  dans  le 
cartilage  épiphysaire  et  provoquent 
vraisemblablement  un  plus  haut  degré  de 
différentiation  chondrocyte  causant  une 
fusion  épimetaphyseale  prématurée  du 
cartilage épiphysaire impliqué.
L’ostéopoécilie,  le  syndrome  de  Buschke-
Ollendorff  (BOS)  et  la  mélorhéostose  sont 
des  dysplasies  sclérosantes  rares. 
L’ostéopoécilie  est  une  maladie  bénigne, 
généralement  asymptomatique  d'hérédité 
autosomique  dominante,  qui  se  caractérise 
par une distribution symétrique mais inégale 
de  multiples  zones  hyperostotiques  sur 
différentes  parties  du  squelette.  On entend 
par le syndrome de Buschke-Ollendorff  une 
maladie associant l’ostéopoécilie et des naevi 
conjonctifs  disséminés.  La  mélorhéostose, 
par  contre,  est  une  affection  plus  grave, 
radiographiquement  caractérisée  par  une 
hyperostose en coulée asymétrique du cortex 
des  os  tubulaires  qui  est  souvent 
accompagnée d’anormalités des tissus mous 
adjacentes. La mélorhéostose cause souvent 
des  contractures  des  articulations,  des 
raideurs et des maux chroniques.
Lorsqu’une ou plusieurs de ces maladies se 
produisent  au  sein  d’un  même  individu  ou 
famille  cela  laisse  présumer  qu’il  s’agit 
d’affections alléliques. Une analyse de liaison 
du génome entier a été effectuée chez trois 
familles  ou  des  individus  atteints  avaient 
ostéopoécilie  avec  ou  sans  expressions  de 
BOS ou de mélorhéostose. Ceci a mené à un 
intervalle  de  24  cM  dans  le  chromosome 
12q12-q14.3.  Ensuite  une  microdeletion, 
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recouvrant partiellement cet intervalle, a été 
identifié  dans  un  patient  sans  liens  de 
parenté avec les trois familles précitées, mais 
avec  une  association  inhabituelle 
d’ostéopoécilie,  petite  stature  et  troubles 
d'apprentissage. Cette découverte a réduit la 
région  candidate  à  un  intervalle  de  3  Mb 
contenant  23  gènes.  En  utilisant  une 
approche  du  gène  candidat,  LEMD3 a  été 
sélectionné  pour  la  détermination  de  la 
séquence qui a ensuite mené à l’identification 
des  mutations  hétérozygotes  "perte  de 
fonction"  dans  tous  les  patients  de  ces  3 
familles. Une analyse de mutations dans un 
groupe plus important de patients a confirmé 
que  presque  tous  les  individus  avec 
l’ostéopoécilie  ou  le  BOS ont  une  mutation 
inactivant  LEMD3,  alors  que  la  plupart  des 
patients  ayant  la  mélorhéostose  montrent 
des résultats normaux après analyse LEMD3.
Le  système du  double  hybride  en  levure  a 
révélé  une  interaction  entre  LEMD3  d’une 
part  et  le  domaine  MH2 de  deux  types  de 
SMADs  d’autre  part  (les  uns  réagissant 
spécifiquement  sur  BMP,  les  autres  sur 
TGFβ).  Deux  études  fonctionnelles  ont 
démontré un effet inhibiteur de LEMD3 sur la 
signalisation de BMP et TGFβ qui est mediée 
pat  les  SMADs.  Des  niveaux  croissants  de 
LEMD3  ont  réduit  l’expression  des  gènes 
cibles SMAD après stimulation par BMP, et, 
de  façon  similaire,  une  surexpression  de 
LEMD3 a  conduit  à  une  baisse  de  l’activité 
luciférase  dans  les  cellules  ayant  une 
signalisation TGFβ constitutivement active.
La  première  partie  de  cette  thèse  visait  à 
identifier  les  défauts  génétiques  pour  une 
sélection  de  dysplasies  osseuses.  Dans  la 
seconde  partie  par  contre,  l’accent  a  été 
déplacé partiellement vers le développement 
de méthodes améliorées et d’un programme 
pour des analyses qPCR automatiques.
La  quantification  des  acides  nucléiques  en 
général  et  plus  spécifiquement  l’analyse  de 
l'expression  des  gènes  jouent  un  rôle 
toujours  plus  important  dans  la  recherche 
biologique  et  la  prise  de  décision  clinique, 
avec  la  PCR  quantitative  en  temps  réel 
(qPCR) devenant la méthode de choix pour le 
profilage d'expression de gènes sélectionnés. 
Des  progrès  dans  les  instruments  et  les 
réactifs,  et  de meilleures  directives  pour  la 
conception  de  l’analyse  ont  rendu  les 
performances pratiques des dénombrements 
qPCR  faisables  pour  la  plupart  des 
utilisateurs.  Bien que le traitement fiable et 
sérieux  des  données  brutes,  ainsi  que  la 
gestion  du  grand  –et  toujours  croissant– 
volume  de  données  restent  les  principaux 
obstacles à surmonter dans ce type d’analyse 
de l'expression des gènes basé sur PCR.
Mon  insatisfaction  face  aux  outils  qPCR 
disponibles m’a incité à écrire un programme 
pour  la  gestion  et  l’analyse  des  données 
qPCR: qBase.
Ce  programme  permet  d’importer  des 
données  de n’importe lequel  des nombreux 
formats en usage. Les données peuvent être 
gérées, en les organisant en runs, études et 
projets  et  en  les  annotant  dans  le  module 
qBase  Browser  (Navigateur  qBase).   Le 
module  Analysis  (Analyse)  permet  par  la 
suite  d’analyser  des  données  de  plusieurs 
runs en tant qu’un ensemble, sans limitations 
quant au nombre d’échantillons, de gènes ou 
de  répétitions.  Un  contrôle  automatique  de 
qualité  des  données  brutes  est  inclus  pour 
éviter  que  des  données  imprécises  soient 
utilisées  dans  les  calculs.  qBase  fait  usage 
d’un  algorithme  de  quantification  avancée 
permettant  des  efficacités  de  l’amplification 
spécifique du gène et une normalisation avec 
utilisation  de  multiples  gènes  de  référence. 
Les résultats obtenus peuvent facilement être 
exportés  en  format  tabulaire,  ou  visualisés 
par un histogramme spécifique du gène ou 
multigénique.
En  plus  des  fonctionnalités  du  programme 
qBase un nombre de nouvelles méthodes de 
calcul  a  été  développé  afin  d’améliorer 
l’analyse  des  données.  En  premier  lieu, 
l’erreur  sur  l’efficacité  de  l’amplification 
estimée  est  calculée  et  propagée  dans  les 
calculs. En second lieu, des algorithmes pour 
l’étalonnage  de  différents  runs  ont  été 
développés afin de corriger pour la variation 
entre les runs, souvent sous-estimée, et de 
permettre la comparaison des résultats pour 
des  échantillons  localisés  sur  différents 
cartilages. Les méthodes de calcul améliorées 
combinées au programme qBase permettent 
une analyse qPCR plus rapide et plus fiable.
Pour  le  moment  il  n’y  a  pas  d’autres 
progiciels disponibles avec une fonctionnalité 
comparable.  qBase  a  été  reconnue  par  la 
communauté scientifique comme un outil très 
utile  et  avancé  pour  l’analyse  de  données 
qPCR. Le fait  que plus de 2000 utilisateurs 
dans  plus  de  80  pays  ont  téléchargé 
(http://medgen.ugent.be/qBase)  le 
programme en est la preuve.
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